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MeCP2 was initially identified as an abundant protein in the brain, with an affinity for 
methylated DNA in vitro. Interestingly, both deficiency and excess of the protein leads to 
severe neurological problems, such as Rett syndrome, which is the result of mutations in the 
MECP2 gene. Subsequent transfection experiments showed that MeCP2 can recruit co-
repressor complexes and inhibit gene expression in vivo. MeCP2 was therefore thought to 
repress specific gene targets and the aetiology of Rett syndrome was proposed to result from 
aberrant gene expression in the MeCP2-deficient brain. Although gene expression is 
perturbed in the Mecp2-null mouse brain, few specific targets have been verified and 
alternative hypotheses for MeCP2 function have been put forward. Previous binding studies 
have also failed to clearly identify MeCP2 targets. To shed light on these matters, a novel 
technique was generated to isolate neuronal and glial nuclei and established that the amount 
of MeCP2 is unexpectedly high in neurons, with an abundance approaching that of the 
histone octamer. Chromatin immunoprecipitation experiments on mature mouse brain 
showed widespread binding of MeCP2, consistent with its high abundance, tracking the 
methyl-CpG density of the genome. MeCP2 deficiency results in global changes in neuronal 
chromatin structure, including elevated histone acetylation and a doubling of histone H1. 
The mutant brain also shows elevated transcription of repetitive elements, which are 
distributed throughout the mouse genome. Based on this data, we propose that MeCP2 binds 
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Chapter 1 Introduction 
1.1 Chromatin 
1.1.1 Evolution of the nucleosome 
The transition between prokaryotes and eukaryotes is marked by a significant increase in the 
number of genes and the overall size of the genome, for example, Escherichia coli have 
~4500 genes encoded within 4.5 Mb, whereas Homo sapiens have ~23,000 genes within 
3300 Mb. The number of distinct genes and the ability to regulate their expression can be 
considered as a measure of an organism’s complexity. However, genome expansion cannot 
increase without the ability to control it, namely, to block inappropriate expression of genes 
and of the bulk intervening DNA (Bird and Tweedie, 1995; Bird, 1995). 
 
There are two stark differences in the packaging of the genome between prokaryotes and 
eukaryotes, implying that this may be crucial in the accommodation of a larger genome. 
With the evolution of eukaryotes, the DNA became compartmentalised into the nucleus, with 
the nuclear envelope now separating the DNA from the cytosolic compartment. This had the 
effect of controlling which factors had access to the DNA and thereby limiting inappropriate 
interactions. But importantly, it also spatially uncoupled transcription and translation, 
therefore providing a window of opportunity for quality control before the cell commits to 
the translation of a messenger RNA. Indeed, it appears that a lot of transcripts are degraded 
by the nuclear exosome and never make it to the translation machinery, thereby reducing the 
deleterious effect of any spurious transcripts (Fasken and Corbett, 2009; Lewin, 1980). 
 
Secondly, as opposed to having largely ‘naked’ DNA in prokaryotes, the DNA is packaged 
around proteins to form chromatin. The nucleosome represents the fundamental unit of this 
structure, consisting of 146 bp of DNA wrapped around an octamer of the four core histones 
(H2A, H2B, H3 and H4) (Luger et al., 1997). This repeating structure takes the form of 
‘beads on a string’ and also is known as the 10 nm filament. This core particle can further 
associate with linker histones, such as histone H1. Studies using various nucleosomal 
positioning sequences have proposed different modes of binding for histone H1 (for review 
see (Thomas, 1999)), suggesting that H1 may be able to bind in various configurations 
depending on the local protein and sequence context. The binding of histone H1 to the linker 




thought to promote the formation of higher order structures, such as the 30 nm filament (Sera 
and Wolffe, 1998; Travers, 1999). 
 
This evolution of packaging the DNA into chromatin enables compaction of the large 
eukaryotic genomes by up to 10,000 fold. However, chromatin is more than just a 
compaction tool. Nucleosomes, especially in combination with histone H1, repress spurious 
transcriptional initiation and therefore create a basal level of repression across the entire 
eukaryotic genome (Laybourn and Kadonaga, 1991). This may be due either alteration of 
DNA conformation or the simple occlusion of transcription factor binding sites (Almer et al., 
1986; Luger et al., 1997). They appear to have been particularly adapted for reducing 
transcriptional noise, as they inhibit transcription from inappropriate sites without 
significantly affecting activator-driven initiation from authentic promoters (Laybourn and 
Kadonaga, 1991). 
 
1.1.2  Histone modifications 
Against this backdrop of weak basal genomic repression imposed by chromatin (Laybourn 
and Kadonaga, 1991), the cell needs to identify genes that need to be expressed and also 
those that need to be fully silenced. This is largely achieved through the covalent 
modification of the N-terminal tails of the core histones that protrude from the body of the 
nucleosome, a few specific examples are detailed below. So far numerous modifications 
have been identified including methylation, phosphorylation, acetylation, ADP-ribosylation, 
ubiquitinylation and sumoylation. This is a complex field with the interplay between histone 
modifications still being determined, only a brief summary will be included here (for review 
see (Kouzarides, 2007; Li, 2002)). Generally, histone modifications can be grouped into 
those that are permissive to the transcription of the underlying DNA and those that reinforce 
the basal repression. 
 
There are two characterised mechanisms as to how these modifications alter the 
transcriptional potential. The first is through the intrinsic alteration of the chromatin 
structure. For example, histones can be acetylated on various lysine residues. This has the 
effect of neutralising the basic charge of the amino group. In the case of histone H4 
acetylation this has been shown to directly disrupt inter-nucleosomal electrostatic 
interactions and therefore destabilises higher-order chromatin structures (Luger et al., 1997; 




the recruitment of trans-acting factors that bind via specific domains. For example 
methylation can be recognised by chromo-domains and PHD-domains, whereas acetylation 
can be recognised by bromo-domains. The protein containing these domains often also has 
an associated enzymatic activity, which subsequently determines how the modification is 
interpreted. For example, the repressive mark, H3K27me3, is bound by the WD-40 repeats 
of EED (Margueron et al., 2009). This is one of the core components of the polycomb PRC2 
complex, which also contains EZH2. This protein contains a SET domain which catalyses 
the methylation of H3K27 (Cao et al., 2002). Therefore, the recruitment of EED with the 
associated PRC2 complex to sites of H3K27me3 leads to the self-reinforcing propagation of 
this repressive mark (Margueron et al., 2009). 
 
Generally speaking, chromatin forms two distinct global environments, either “active” 
euchromatin or “silent” heterochromatin, and was originally identified on the basis of 
differential staining (for historical perspective see (Zacharias, 1995)). Heterochromatin is 
typified by low levels of histone acetylation and high levels of H3K9 and H3K27 
methylation, whereas euchromatin is more varied depending on the transcriptional status of 
the surrounding genes (for review see (Kouzarides, 2007)). By creating domains of active or 
repressive histone modifications, this may have enabled a simplification or ‘bar-coding’ of 
the eukaryotic genome (Barski et al., 2007) For example, the majority of mammalian 
promoters are marked H3K4me3, in part at least by virtue of underlying DNA sequence 
((Thomson et al., 2010); also see section 1.3.4). By highlighting promoters with this 
modification and the subsequent recruitment of trans-activators (for review see (Ruthenburg 
et al., 2007)), this may reduce the ‘genomic space’ that the basal transcriptional machinery 
has to search and aid in the fidelity of transcriptional initiation. 
 
The large number of proteins that remove these histone modifications indicate that this is a 
dynamic system, which allows the cell to regulate the accessibility to the underlying DNA. 
For example, to facilitate the passage of RNA polymerase II (RNA PolII) through the gene 
body during transcription, histone acetyltransferases are recruited via the C-terminal domain 
of RNA PolII and result in chromatin destabilisation within gene body. If acetylation was left 
unchecked, it would result in spurious transcription from within the now accessible gene 
body. However, gene bodies are also marked by H3K36me3, which recruits histone 
deacetylases (HDACs) to the coding region in the wake of RNA PolII (Carrozza et al., 




recruitment (Carrozza et al., 2005), indicates how eukaryotes have evolved to use histones to 
suppress parts of their genomes whilst still allowing the genes to be read. 
 
As well as providing a highly dynamic system of genomic accessibility, histone 
modifications are also used to generate stable systems of chromatin silencing. For example, 
in Drosophila melanogaster, HP1 binds to H3K9me3 via its chromodomain (Lachner et al., 
2001) and in turn creates a repressive chromatin environment by recruiting a number of 
proteins including HDACs (Yamada et al., 2005). But importantly, HP1 also recruits 
SU(VAR)3-9, which is the methyltransferase responsible for H3K9 methylation and 
therefore creates a self-reinforcing system of chromatin metabolism (Schotta et al., 2002). 
This propagation of chromatin marks is also exemplified by the polycomb protein EED as 
discussed above. 
 
1.2 DNA methylation 
1.2.1 Methyl-Cytosine 
DNA is composed of four basic deoxyribonucleic acid building blocks (deoxyadenosine, 
deoxythymidine, deoxycytosine, deoxyguanosine) arranged in two anti-parallel helices. 
Through specific base pairing, these helices act as a mirror image of each other (Watson and 
Crick, 1953). The semi-conservative replication of the two DNA strands explains how the 
information encoded in the DNA strands is inherited between cell divisions (Meselson and 
Stahl, 1958) and has subsequently been dubbed the ‘secret of life’ (Watson and Berry, 2003). 
 
Biochemical characterisation of DNA identified the existence of a cytosine variant, which 
has a methyl group on the 5 position of the pyrimidine ring (Johnson, 1925). The methyl 
group is transferred from S-adenosyl methionine in a reaction catalysed by the family of 
DNA methyltransferases (DNMTs; see section 1.3). The structure of these bases is shown in 
figure 1.1. Since the discovery of 5-methylcytosine, it has been found in a wide variety of 
organisms and is intrinsic to the ‘secret of life.’ However, the evolution of 5-methylcytosine 
as component of the hereditary material is somewhat surprising, as this modified base can 
deaminate to thymidine and adds a heavy mutational load on the cell (Figure 1.1; (Bird, 
1980; Cooper and Youssoufian, 1988)). Despite this potential lethal feature of DNA 




selective advantage. One suggestion is that DNA methylation protects the genome in various 

















Figure 1.1 – Cytosine can become methylated on the 5-position of pyrimidine ring in a reaction 
catalysed by DNMT enzymes using S-adenosyl methionine as a substrate. This can spontaneous 
deaminate to produce a thymine and in the absence of a repair will ultimately result in a mutation. The 
structure of these bases is shown. 
 
1.2.2 DNA Methylation in prokaryotes 
In prokaryotes, DNA can be methylated on various bases giving rise to 5-methylcytosine, 
N6-methyladenine and N4-methylcytosine. The production of these bases is catalysed by 
various DNMTs, which bind to specific recognition sequences that contain the base to be 
methylated. The methylation of DNA forms part of the host restriction-modification system 
(for review see (Wilson and Murray, 1991)). Briefly, the bacterium expresses DNMTs that 
methylate its own genome whilst also expressing methyl-sensitive restriction endonucleases, 
which cleaves these sequences but only in the unmodified form. In the event of invasion by 
viruses, the endonucleases digest the unmethylated viral genome, whilst the methylated 
bacterial genome is protected. Other functions of DNA methylation in bacteria have also 
been proposed, including DNA replication initiation, DNA mismatch repair and regulation of 
gene expression (for review see (Palmer and Marinus, 1994)). 
 
In contrast to prokaryotes, DNA methylation in eukaryotes occurs solely in the form of  









modification greatly varies between and within phylogenetic groups. DNA methylation in 
mammals will be discussed in depth, with only a brief description of other eukaryotes. 
1.2.3 DNA Methylation in fungi 
The occurrence of DNA methylation in fungi is sporadic, with no clear evolutionary pattern 
between the species where it can be found. The Saccharomyces cerevisiae genome encodes 
no proteins related to known DNMTs and accordingly, contains no detectable cytosine 
methylation (Proffitt et al., 1984). In Saccharomyces pombe there is also no detectable 
methylation (Antequera et al., 1984) despite the initial identification of a putative 
methyltransferase, pmt1
+
, which contains the 10 conserved domains common to eukaryotic 
DNMTs (Wilkinson et al., 1995). Further analysis of pmt1
+
, identified a key point mutation 
in the catalytic site rendering this enzyme non-functional (Pinarbasi et al., 1996) thereby 
explaining the lack of cytosine methylation observed in fission yeast. 
 
In Neurospora crassa, 2-3% of all cytosines are methylated, which is comparable with 
mammalian levels (Bird, 1980; Selker et al., 2003). However, the role of methylation is 
different, as methyl-cytosine is not found exclusively in a CpG context and the bulk of the 
genome is unmethylated in contrast to mammals. In Neurospora crassa DNA methylation 
forms part of a system known as repeat induced point mutation (RIP). Duplication of 
sequences during the sexual phase of the life cycle activates the RIP pathway leading to 
mutation of these sequences and typically leaves the altered sequences methylated ((Selker et 
al., 2002) and references therein). Whole genome analysis of these mutated sequences 
suggested that they were almost exclusively relics of transposons indicating that RIP is a 
genome defence system (Selker et al., 2003). The loss of DNA methylation by treatment 
with 5-azacytidine results in the reactivation of transposons (Zhou et al., 2001), however, the 
mechanism for this inhibition is currently unknown. The DNA methylation is thought 
propagate through a self-reinforcing system in concert with histone modifications to create 
stable suppression of these transposons (Selker et al., 2002). Therefore, in some fungi, DNA 







1.2.4 DNA methylation in plants 
Plant genomes contain relatively high levels of 5-methylcytosine, ranging from 6% in 
Arabidopsis thalania to 25% in maize, with cytosine methylation content broadly correlating 
positively with genome size and complexity (for review see (Rangwala and Richards, 
2004)). DNA methylation in plant genomes is found in three nucleotide-sequence contexts: 
CpG, CNG and CHH sites (where N is any nucleotide and H is A, C or T). Methylation is 
concentrated at heterochromatic regions such as silenced ribosomal RNA genes, centromeres 
and transposable elements. In Arabidopsis, MET1 was identified as the DNMT responsible 
for replication dependent propagation of CpG methylation (Finnegan and Dennis, 1993). 
Upon deletion of MET1, an increase in pseudogene and transposon expression was observed, 
suggesting a role of DNA methylation in genome suppression within the bulk genome 
(Zhang et al., 2006). 
 
There are a number of mechanisms for targeting DNA methylation. Transcription of 
intergenic regions by RNA PolII and two plant specific polymerases (Pol IV and V) have 
been shown to be involved in the directing DNA methylation through the siRNA machinery 
and the recruitment of the de novo methyltransferase DRM2 ((Wierzbicki et al., 2008; Zheng 
et al., 2009); for review see (Law and Jacobsen, 2010)). In plants, CHG methylation is 
thought to be maintained through a reinforcing loop involving histone and DNA methylation. 
Genome-wide profiling revealed a strong correlation between H3K9 and DNA methylation 
(Bernatavichute et al., 2008). Loss of SUVH4 (also known as KRYPTONITE), which is the 
histone methyltransferase largely responsible for H3K9 dimethylation, resulted in a dramatic 
reduction in DNA methylation (Jackson et al., 2002). Furthermore, the SRA (SET and RING 
associated domain) of SUVH4 can bind directly to methylated domain and suggest a self-
reinforcing system between histone and DNA methylation (Johnson et al., 2007). Recent 
work has identified another factor that can bind to methylated DNA: RDM1, which binds to 
single stranded methylated DNA and associates with RNA PolII and the RNAi machinery, 
through this interaction it has been suggested to link siRNA production with pre-existing 
DNA methylation (Gao et al., 2010). 
 
As in vertebrates, methylation is generally excluded from the promoter regions of genes 
(Cokus et al., 2008; Zilberman et al., 2007). However, only 20% of plant gene bodies are 
typically methylated, compared to the majority of vertebrate gene bodies, (Cokus et al., 
2008; Zilberman et al., 2007). A strong correlation was observed with both high and low 




genes tended to be highly methylated in the gene body (Zilberman et al., 2007). This led to 
the suggestion that DNA methylation within the gene body of these moderately expressed 
genes was preventing spurious transcription in the wake of open chromatin after a transiting 
RNA polymerase 2 (RNA PolII). However, in low and high expressed genes, stable 
nucleosomes or a high density of RNA PolII, respectively, block this spurious transcription 
initiation (Zilberman et al., 2007). This putative use of DNA methylation in suppressing 
spurious transcription was has also been proposed for invertebrates ((Bird and Tweedie, 
1995; Simmen et al., 1999; Suzuki et al., 2007); see section 1.2.5). 
 
1.2.5 DNA methylation in invertebrates 
Invertebrates also contain a highly variable amount of CpG methylation (meCpG), generally 
forming into two categories. Firstly, some show absence or very low levels of methylation, 
such as Caenorhabditis elegans which does not contain any 5-methyl cytosine and contains 
no putative methyltransferase encoding genes (Simpson et al., 1986). Also the Drosophila 
melanogaster genome contains virtually no 5-methylcytosine, with only 0.3%  
5-methylcytosine detected during early embryogenesis (Lyko et al., 2000a; Lyko et al., 
2000b). This low level of methylation has recently been shown to be important in the 
silencing of retrotransposons in somatic cells, with the methylation of retrotransposons 
initiating histone H4K20 trimethylation (Phalke et al., 2009). 
 
Secondly, some invertebrates display a mosaic pattern of methylation but still with overall 
levels lower (10-40% meCpG) than their vertebrate counterparts (60-90% meCpG) (Tweedie 
et al., 1997). Species such as the sea urchin Echinus esculentus (Bird et al., 1979) and the sea 
squirt Ciona intestinalis (Simmen et al., 1999) exhibit long tracts of stably methylated DNA 
and equally long tracts of nonmethylated DNA. Detailed analysis of the sea squirt genome 
indicated that the methylated regions were not specifically enriched for transposable 
elements (Suzuki et al., 2007), suggesting that the key role of DNA methylation was not in 
suppression of transposons as in Neurospora crassa. However, the methylated regions 
showed a strong preference for housekeeping genes, which typically exhibit a moderate 
expression level, in contrast, highly expressed genes were typically found in unmethylated 
domains (Suzuki et al., 2007). This led to the suggestion that methylation was inhibiting 
spurious transcription from within moderately transcribed regions as also suggested in 





1.2.6 DNA methylation in vertebrates 
The invertebrate-vertebrate boundary marks a distinctive evolutionary shift from a fractional 
to a global methylation pattern, with 60-90% of CpG dinucleotides being methylated in 
vertebrates (Tweedie et al., 1997). Whilst invertebrates have limited gene body methylation, 
which is typically restricted to housekeeping genes, almost all gene bodies are methylated in 
vertebrates (Suzuki et al., 2007; Tweedie et al., 1997). Indeed, amphioxus and sea squirts, 
invertebrates close to the evolutionary boundary, have moderate levels of gene body 
methylation in housekeeping genes (Suzuki et al., 2007; Tweedie et al., 1997).  
 
The distribution of methylation is likely to give clues to its function. Methylcytosine is 
broadly distributed throughout the mammalian genome, with ~70% of CpG sites being 
methylated (Ehrlich et al., 1982; Lister et al., 2009). However, the absolute amount of 
methylcytosine is surprisingly low (2-3%), due to CpG sites occurring at one-fifth of the 
expected frequency within the bulk genome, which is largely methylated and forms ~98% of 
the genome (reviewed in (Bird, 1986)). This apparent lack of CpG sites is due to 
spontaneous deamination of methylcytosine to become thymine, resulting in a T:G 
mismatch. If this mismatch is not repaired before replication, it results in a C:G to T:A 
transition mutation in one of the daughter strands. Indeed, a third of all point mutations that 
lead to human disease are the result of a deamination event (Cooper and Youssoufian, 1988), 
with mutations at CpG sites resulting from deamination events occurring at a 10-fold higher 
rate than at other sites (Nachman and Crowell, 2000). Therefore, cytosine methylation drives 
the loss of CpG dinucleotides from the genome, resulting in an average only 1 CpG per 100 
bp within the bulk genome. However, the remaining ~2% of the mammalian genome does 
not typically become methylated and therefore shows little CpG deficiency. These sites were 
first identified by their ability to be cut by methyl-sensitive restriction enzymes, such as 
HpaII and were therefore originally known as ‘HpaII Tiny Fragments’ (Cooper et al., 1983). 
These stretches of nonmethylated DNA are typically 1 kb in length, with a high GC and CpG 
content (>50% and >0.6 o/e
1
 respectively) and are now termed CpG islands (CGIs). CGIs 
have long been associated with promoter regions (Bird, 1986). Recent studies suggest up to 
80% of all CGIs may indeed associate with a promoter (R. Illingworth; manuscript in 
preparation). Despite this clear association, the role and maintenance of CGIs remains 
elusive. Nonmethylated CGIs are generally considered to be non-repressive to transcription 
                                                     
 
1 o/e (observed/expected): is the number of CpG dinucleotides in a given length of DNA divided by 




(Bird et al., 1985). However, CGIs normally remain nonmethylated in somatic tissues where 
the gene is not expressed (Antequera et al., 1990; Illingworth et al., 2008; Weber et al., 
2007). Grossly the dichotomy of mammalian DNA methylation may be summarised as the 
bulk genome exhibiting a low CpG density but methylated, versus CGIs having a high CpG 
density and nonmethylated. This is reminiscent of the formation of chromatin domains with 
histone modifications, and therefore DNA methylation and CGIs may act to simplify the 
large mammalian genome through the highlighting of specific regions (Illingworth and Bird, 
2009; Thomson et al., 2010). 
 
Early work alluded to DNA methylation imposing transcriptional repression, with artificially 
methylated transgenes inserted into mouse cells being transcriptionally silenced compared to 
their nonmethylated counterparts (Stein et al., 1982). It is against the backdrop of repression 
that mammalian DNA methylation will be discussed in detail in the following sections. 
 
Recently it has become clear that there are other forms of cytosine methylation in mammals: 
(1) 5-methylcytosine in a non-CpG context and (2) 5-hydroxymethylcytosine. First, high-
throughput sequencing of bisulphite treated DNA showed that in human ES cells 25% of 5-
methylcytosine was in a non-CpG context, whereas in a somatic cell line (fetal lung 
fibroblasts) only 0.02% of methylcytosine was in a non-CpG context, despite overall 
amounts of CpG methylation being similar (Lister et al., 2009). A study using a similar 
technique reported somewhat higher levels of non-CpG methylation in differentiated cell 
lines (approximately 10-15% of methylcytosine was found in a non-CpG context) (Laurent 
et al., 2010). Cytosine methylation in non-CpG contexts showed enrichment in gene bodies, 
with the level of methylation positively correlating with gene expression level (Lister et al., 
2009). The functional role of non-CpG methylation and how this mark is interpreted are not 
clear, with the abundance in stem cells probably as a result of high levels of de novo 
methyltransferase activity (for discussion see (Laurent et al., 2010; Lister et al., 2009)). 
Second, cytosine has also been recently shown to exist in a 5-hydroxymethylcytosine form 
(Kriaucionis and Heintz, 2009). 5-hydroxymethylcytosine is highly abundant in the brain 
(specifically the purkinje cells where it is present at 0.6% of total nucleotides), suggesting a 
role in epigenetic control of neuronal function (Kriaucionis and Heintz, 2009). The 
production of 5-hydroxymethylcytosine from 5-methylcytosine has been shown to be 
catalysed by the TET1 (Tahiliani et al., 2009). The functional role of 5-
hydroxymethylcytosine is currently unclear, but it should be noted that MeCP2 has been 




alterations in the specificity of DNMT1 (see section 1.3.1 and (Valinluck and Sowers, 
2007)). As such, 5-hydroxymethylcytosine may act to recruit or exclude factors or indeed 
cause passive demethylation by excluding DNMT1 (Tahiliani et al., 2009). 
 
1.3 Mammalian DNA methyltransferases 
Methylation is incorporated into the DNA post-synthetically (Burdon and Adams, 1969; 
Scarano et al., 1965) and is catalysed by a family of enzymes known as DNA 
methyltransferases (DNMTs). So far, five mammalian DNMTs have been identified, with 
their role in establishment and propagation of the methylation signal being largely 
determined by their substrate specificity (for review see (Hermann et al., 2004)). All known 
mammalian DNMTs share a common C-terminal domain structure that contains the catalytic 
domain (Figure 1.2). This domain resembles the prokaryotic counterparts and is 
characterised by the 10 conserved amino acid motifs required for methyltransferase activity 














Figure 1.2 – Domain organisation of the mammalian DNMTs. The C-terminal domain contains the 10 
conserved amino acid motifs (indicated by with red bars), which are required for catalytic activity and 
show homology to the prokaryotic DNMTs. The N-terminal domain contains various motifs which are 
required for localisation and regulation (indicated with grey bars). For details of the regulatory regions 
see (Hermann et al., 2004). Briefly they are as follows: CR: charge-rich region; PCNA: PCNA binding 
site; NLS: nuclear localisation site; CXXC: CXXC type Zinc finger; Polybromo domain containing two 
BAH domains; PWWP: domain containing conserved proline and tryptophan residues; PHD: plant 





The catalytic domain forms a characteristic six-stranded β-sheet flanked by 1 or 2 α-helices 
to create the binding pocket for the substrate S-adenosyl methionine (SAM) and the target 
DNA. The donor methyl group is bound to a sulphonium atom, which increases the 
reactivity of the relatively inert methyl group, leaving it liable to nucleophilic attack. The 
DNMT binds to the DNA and disrupts the C/G base pairing and flips out the cytosine base 
into the catalytic site. The now accessible cytosine undergoes a series of reactions resulting 
in the formation of dihydrocysteine covalently coupled DNA-enzyme intermediate. 
Nucleophilic attack on the activated SAM results in transfer of the methyl group onto the 
carbon 5 position of cytosine and the ultimate release of S-adeonsyl-L-homocysteine as a 
byproduct (for review of catalytic mechanism see (Jeltsch, 2002)). A brief description of 
these enzymes will be given below. 
 
1.3.1 DNMT1 
A regulatory domain in the large N-terminal region ensures that the preferred substrate for 
DNMT1 is hemi-methylated DNA, as deletion of this motif removes this specificity (Bestor, 
1992). Therefore, DNMT1 has the ability to copy the methylation pattern from one strand to 
another and has led to DNMT1 being also known as the maintenance methyltransferase. The 
N-terminus of DNMT1 also mediates an interaction with PCNA (Chuang et al., 1997), 
thereby associating DNMT1 with replication forks (Leonhardt et al., 1992) and was thought 
to allow the faithful replication of the 5-methylcytosine marks onto the newly synthesized 
strand. However, the interaction with PCNA is only transient and only increases the 
methylation efficiency by 2-fold (Schermelleh et al., 2007) suggesting that other factors must 
aid the targeting of DNMT1. Hemi-methylated sites that are missed during the passage of the 
replication fork can ‘picked up’ through the binding of UHRF1 to these sites and the 
subsequent recruitment of DNMT1 (for review see (Jeltsch, 2008)). Mouse cells that are 
ablated for the Uhrf1 gene exhibit mislocalisation of DNMT1 and a resulting loss in 
methylation, indicating that this is an essential backup system for the targeting of Dnmt1 
(Bostick et al., 2007; Sharif et al., 2007). 
 
As such DNMT1 is largely considered to be responsible for the heritable nature of DNA 
methylation and is universally expressed within the nucleus of replicating somatic cells by 
virtue of a nuclear localisation signal. However, during the initial rounds of DNA replication 
in fertilised eggs, DNMT1 is sequestered into the cytoplasm and leads to passive 




1992). During this early phase of development an alternative splice variant maintenance 
methyltransferase, DNMT1o, is expressed within the nucleus and ensures the faithful 
propagation of certain imprinted loci (Ratnam et al., 2002). 
 
The importance of DNA methylation and its maintenance can be inferred from the lethality 
of the Dnmt1 knock-out mouse (Li et al., 1992). Both the knock-out mouse and embryonic 
stem (ES) cells show approximately 70% reduction in 5-methylcytosine. However, despite 
the mutant ES cells being viable, the mouse was embryonic lethal, with the stunted embryos 
terminating at midgestation (Li et al., 1992). This indicates that DNMT1 is essential for the 
completion of development. However, the faithful propagation of methylation is not that 
simple. Early studies using artificially methylated constructs inserted into terminally 
differentiated cell lines suggested that methylation was not maintained indefinitely, with a 
failure rate of ~5% per CpG per cell division (Pollack et al., 1980; Wigler et al., 1981). This 
has also been confirmed for an endogenous locus (Riggs et al., 1998), suggesting that 
maintenance methylation through replication by DNMT1 is not sufficient for the long term 
propagation of these marks and that there must be other factors involved (Bird, 2002). There 
are potential roles of DNMT1 other than cytosine methylation, with DNMT1 been shown to 
interact with HDAC1 (Myant and Stancheva, 2008), raising the possibility that DNMT 
recruit factors to influence the local chromatin state. It has, however, been shown that 
mutation of a key catalytic residue in DNMT1 failed to rescue any of the phenotypes of the 
Dnmt1-null ES cells, suggesting that its key functions are a consequence of its 
methyltransferase activity (Damelin et al., 2007). 
1.3.2 DNMT2 
Analysis of expressed sequence tag (EST) databases for sequences with homology to 
DNMT1 led to the identification of a candidate DNMT, named DNMT2, which was 
expected to be functionally active (Yoder and Bestor, 1998). However, recent work suggests 
that its major role is in the cytosine methylation of a transfer RNA for aspartic acid (Goll et 
al., 2006). This is consistent with its cytoplasmic localisation in zebrafish and the lack of 
change in methylation levels in null mouse ES cells (Okano et al., 1998b; Rai et al., 2007). 
 
1.3.3 DNMT3a and 3b 
Despite the global demethylation observed during pre-implantation development, 




2001)). This coupled with the recorded failure of DNMT1 to maintain methylation (Riggs et 
al., 1998) and the observation that nonmethylated retroviral DNA inserted into Dnmt1-
deficient ES cells can become methylated (Lei et al., 1996) suggested that some de novo 
methyltransferase activity must exist. The differentiation of these Dnmt1-deficient ES cells 
into the embryoid bodies resulted in the loss of methylation from endogenous retroviral 
sequences (Lei et al., 1996). This suggested that the de novo methyltransferase activity was 
most abundant within ES cells and was predicted to be required for the re-setting of the 
methylation patterns during development (Jahner et al., 1982; Stewart et al., 1982). 
 
By searching for human proteins that showed homology to bacterial methyltransferases, two 
putative enzymes were identified and termed DNMT3a and 3b (Okano et al., 1998a). 
Expression analysis indicated that these enzymes were most highly expressed within ES cells 
suggesting that these factors may indeed explain this missing activity (Okano et al., 1998a). 
Furthermore, in vitro methylation studies suggested that these recombinant enzymes could 
act on nonmethylated DNA and showed no preference for hemi-methylated DNA (Okano et 
al., 1998a). The targeted disruption of the genes for Dnmt3a and 3b in mouse ES cells 
indicated that in the absence of both proteins there was a loss of de novo methylation, but 
single gene disruptions maintained de novo activity, suggesting that they may have 
redundant functions (Okano et al., 1999). Analysis of the corresponding mouse phenotypes 
showed that Dnmt3a knockout mice survived to term but then typically died at 4 weeks of 
age, whilst Dnmt3b knockout mice were not viable and failed to develop normally past 
embryonic day 9.5 (Okano et al., 1999). The double knockout mouse, presented with a more 
severe phenotype, indicating that they have partially overlapping functions (Okano et al., 
1999), suggesting that differences in function may lie in the N-terminal regulatory domain 
(Figure 1.2; for review see (Hermann et al., 2004)). Methylation analysis of the genomic 
DNA from these ES cells revealed that loss of Dnmt3a resulted in hypomethylation of major 
satellite repeats and a loss of some maternal imprints, whereas loss of Dnmt3b led to 
hypomethylation of minor satellite repeats (Chen et al., 2003a; Okano et al., 1999), 
suggestive of alternative targeting mechanisms. 
 
Extended culture of ES cells lacking both Dnmt3a and 3b led to a progressive loss of 
methylation to levels approaching that of Dnmt1 knock out ES cells (Chen et al., 2003a). 
Overall, this suggests that both DNMT3a and 3b are required in concert with DNMT1 for the 
faithful propagation of DNA methylation, arguing against the early simplistic labels of 




is some evidence from exogenously expressed proteins indicating that they may interact 
(Kim et al., 2002). A more realistic model is one where all three enzymes work in concert to 
maintain methylation patterns with DNMT3a and 3b helping to fill in gaps left by DNMT1. 
This may go some way to explaining the lack of specific homogeneous methylation patterns 
with respect to individual CpG sites, but instead that the overall methylation content of 
domains is maintained (Bird, 2002; Silva et al., 1993; Stoger et al., 1997). 
 
1.3.4 Targeting DNA methylation: cross-talk with chromatin 
As previously discussed the mammalian genome can largely be divided into (1) the bulk 
genome, which has a low CpG density and is typically methylated, and (2) the CGIs, which 
have a high CpG density and are usually nonmethylated. This leads to three potential models 
for the formation of this methylation pattern. Firstly, methylation is the default and CGIs 
somehow are actively protected from this machinery. Secondly, the CGIs are innocent 
bystanders, whilst the bulk genome is actively targeted. Thirdly, there is some middle ground 
between these models, with active repulsion and recruitment of the DNA methylation 
machinery. There are indeed some special cases for the role of DNA methylation and these 
will be discussed in section 1.4, whereas this section will focus on how this global pattern is 
set up. There is also the potential for active demethylation to occur, with the possibility that 
this could be involved in the maintenance of CGIs as methylation free. In zebrafish, active 
demethylation has been shown to occur through a deamination step followed by the 
subsequent repair by MBD4 (see section 1.7.7; (Rai et al., 2008)). 
 
Recent work provides an intriguing link between chromatin and CGIs to suggest how these 
sequences may be protected from de novo methylation. DNMT3L was identified through 
homology searches with other members of the DNMT3 family (Aapola et al., 2000). The N-
terminal region contains a PHD domain, whilst the truncated C-terminal domain only 
contains 8 of the 10 conserved motifs common to methyltransferases and importantly lacks 
the key catalytic residues. The expression pattern of DNMT3L was shown to be reminiscent 
of DNMT3a and 3b (Hata et al., 2002). Indeed, DNMT3L could interact with both these 
active enzymes (Hata et al., 2002), and in vitro methylation assays suggested that Dnmt3L 
could stimulate their methyltransferase activities (Suetake et al., 2004). However, 
recombinant DNMT3L was shown to be incapable of binding DNA in vitro and was 
therefore assumed to not being involved in the targeting of the de novo methyltransferases 




interaction assays indicated that DNMT3L bound to the N-terminus of histone H3, but that 
this interaction was abolished by the specific methylation of lysine 4 (Ooi et al., 2007). More 
recently CGIs have been shown to recruit Cfp1 (a CXXC CpG binding protein), by virtue of 
their density of nonmethylated CpGs, which in turn recruits a H3K4 methyltransferase, with 
the overall effect of 75% of CGIs being bound by Cfp1 and containing H3K4me3 modified 
chromatin ((Thomson et al., 2010); see Appendix B). Therefore, through specific chromatin 
modification, as directed by the CGI sequence alone, it is proposed that they are maintained 
refractory to DNA methylation. 
 
Other studies have also looked at the maintenance of nonmethylated CGIs. Using a 
transgenic mouse assay, the Aprt CGI became methylated upon removal of binding sites for 
Sp1, a transcriptional transactivator (Macleod et al., 1994). This led to the suggestion that 
active transcription was required for the protection of CGIs. Given the GC-rich consensus 
sequence for Sp1 binding (Letovsky and Dynan, 1989) and the requirement for Sp1 binding 
to maintain the methylation-free status of the Aprt CGI, it was hypothesised that there may 
have been a general requirement for Sp1 for the maintenance of CGIs (for discussion see 
(Marin et al., 1997)). The generation of Sp1-null ES cells, however, showed no gross change 
in the methylation status of CGIs, suggesting that Sp1 is not generally required the 
maintenance of CGIs as methylation-free (Marin et al., 1997). More recently it has been 
shown that another factor, VEZF1, with a similar but distinct GC-rich consensus binding site 
to Sp1, could bind to one of the “Sp1-sites” at the wild-type Aprt promoter (Dickson et al., 
2010). This study went on to show that VEZF1 binding in the absence of Sp1 binding was 
sufficient for the protection of the CGI from methylation (Dickson et al., 2010). It remains 
possible that VEZF1 may play a global role in the maintenance of CGIs as methylation-free.  
 
Given the early suggestion of a role of transcription in the protection of CGIs, it should be 
noted that it has long been known that the majority of CGIs remain unmethylated 
irrespective of their transcriptional activity, such as the human α-globin gene (Bird et al., 
1987) and more recent genome-wide studies (Weber et al., 2007). Perhaps this apparent 
discordance can be explained by a study revealing that H3K4me3 was enriched at both 
active and inactive promoters, but unexpectedly even ‘inactive’ promoters were bound by 
RNA PolII and associated with non-productive transcriptional initiation (Guenther et al., 
2007). This raises questions over what constitutes an active or an inactive promoter, with 
more sensitive techniques required. This may suggest that the Sp1-depleted Aprt promoter in 




promoters. But this does not explain why the Aprt CGI sequence alone did not direct its 
methylation status through the recruitment of Cfp1, as suggested ((Thomson et al., 2010), 
Appendix B). Speculatively, transcriptional initiation and Cfp1 may work synergistically to 
maintain CGIs. 
 
The role of transcription in defining the methylation pattern has also been proposed in the 
context of transcriptional elongation. Using methyl-sensitive restriction of single nucleotide 
polymorphisms, gene bodies were shown to be specifically methylated on the active  
X chromosome (Xa) relative to the inactive X chromosome (Xi) (Hellman and Chess, 2007). 
One hypothesis would be that methylation of gene bodies on the Xa is required to prevent 
spurious initiation within the unfolded chromatin in the wake of transiting RNA PolII, 
reminiscent of the suggestions in Arabidopsis and sea squirt (Suzuki et al., 2007; Zilberman 
et al., 2007). The mechanism of recruiting the methylation machinery to gene bodies is 
currently unknown. In plants, transcription of repetitive elements has been shown to result in 
DNA methylation through the RNAi pathway (for review see (Chan et al., 2005)) and was 
proposed to have a role in plant gene body methylation (Zilberman et al., 2007). However, 
there is no evidence for a similar mechanism in mammals. 
 
Potential targeting mechanisms can be elucidated through studying the interacting partners of 
the DNMTs. A genetic study in Arabidopsis identified a requirement for DDM1, a 
SWI2/SNF2-like chromatin remodeler, in the methylation of heterochromatic loci (Jeddeloh 
et al., 1999). Targeted disruption of LSH, the mammalian homolog, resulted in ~70% loss of 
methylation throughout the genome and is in complex with the DNMTs (Dennis et al., 2001; 
Myant and Stancheva, 2008). Similarly, mutation of ATRX, another SWI2/SNF2-like 
chromatin remodeler, resulted in hypomethylation of ribosomal DNA arrays and specific 
repeats (Gibbons et al., 2000). However, it is not clear if these interacting partners are 
involved in the targeting of DNMTs or in facilitating access to the DNA once targeted. 
Analysis of non-vertebrate species suggests that DNMTs might be recruited by chromatin 
modifications as well as repelled, as already discussed for H3K4me3. In the fungus 
Neurospora crassa, histone H3K9 methylation by a SET-domain containing protein has been 
shown to be required for DNA methylation (Tamaru and Selker, 2001). Similarly, in 
Arabidopsis, the H3K9 methyltransferase, Kryptonite, has been shown to be required for 
CNG methylation, with some suggestion that the DNA methyltransferase CMT3 may be 
directly recruited by this modification (for review see (Chan et al., 2005)). Currently, in 




DNA methylation. A study suggested that H3K27me3 can recruit DNMT activity (Vire et 
al., 2005). A large amount of contention, however, surrounded this study, due to the use of 
image manipulation. Despite this, another study reported the role of polycomb complexes in 
the methylation of the HOXA9 promoter (Reynolds et al., 2006). Further analysis of 
mammalian DNMT interacting partners has shown that HDAC complexes can associate with 
DNMT3a (Fuks et al., 2001). However, it is likely that this interaction is not targeting 
methylation, but providing a link between DNA-based and chromatin-based repressive 
systems, as has been suggested for the interaction between G9a, a H3K9 methyltransferase, 
and DNMT1 (Esteve et al., 2006). This leaves open the question of how, and if, methylation 
is targeted to the bulk genome. 
 
Finally, analysis of the timecourse of methylation may shed light onto its targeting. 
Expression of retroviral elements inserted into carcinoma cells has shown to be silenced ~2 
days after infection, whereas de novo methylation is delayed until ~ 15 days (Gautsch and 
Wilson, 1983). This is consistent with observations that retroviruses can be shutdown in the 
absence of the de novo methyltransferases (Pannell et al., 2000). This is compatible with the 
hypothesis that transcriptional initiation maybe required to maintain the DNA in an 
unmodified state, and in the absence of initiation that the default is to methylate. Potentially 
against this hypothesis is the observation that insertion of multiple copies of a transgene into 
the mammalian genome correlated with gene silencing and DNA methylation, whilst a single 
copy remained active and unmethylated (Garrick et al., 1998), somewhat reminiscent of RIP 
in Neurospora. However, the timecourse of silencing compared to the onset of methylation 
was not evaluated, leaving open the possibility that these transgenes were silenced before the 
default status of methylation encroached. Despite this suggestion that genomic methylation 
is the default status, it may remain that some compartments of the genome are actively 
targeted, for example all gene bodies may be specifically targeted, as suggested for the gene 
bodies on the Xa (see above; (Hellman and Chess, 2007)). Details of these regions and the 
mechanism of targeting are likely to be spurred on by the recent high-throughput bisulphite 
sequencing projects (Laurent et al.; Lister et al., 2009). 
 
1.4 Role of mammalian DNA methylation 
After fertilisation the DNA methylation pattern is generally wiped clean. The male pro-
nucleus is thought to undergo active demethylation, through a currently unknown 




methylation (Monk et al., 1991; Santos et al., 2002). From this point the genome becomes 
largely methylated and this pattern is relatively stably inherited throughout the organism. In 
this manner DNA methylation is unusual compared to histone modifications, as it is largely 
considered to be an irreversible mark. The mouse phenotypes associated with the loss of the 
DNMTs indicates the essential nature of these methylation patterns (Li et al., 1992; Okano et 
al., 1999). This essential requirement is mirrored by mutations in the catalytic domain of 
DNMT3B resulting in the human condition ICF (immunodeficiency, centromere instability 
and facial anomalies), associated with hypomethylation of satellite DNA (Jeanpierre et al., 
1993; Xu et al., 1999). Despite the necessity of DNA methylation for mammalian 
development, the role it plays has however yet to be fully elucidated. Several hypotheses will 
be discussed. 
 
1.4.1 Genome stability and integrity 
Early observations indicated that treatment of human cells with the demethylating agent,  
5-azadeoxcytidine, resulted in an increase in chromosome associations by satellites, 
secondary constrictions, and telomeric regions (Viegas-Pequignot and Dutrillaux, 1976). 
Similar abnormalities were observed with lymphocytes derived from ICF patients. In these 
cells, the juxtacentromeric heterochromatin was abnormally hypomethylated and displayed 
greatly elongated and thread-like structures in metaphase chromosomes, which is associated 
with the formation of complex multiradiate chromosomes (Xu et al., 1999). It is however, 
not clear that a causal relationship exists between the loss of DNA methylation and 
chromosomal abnormalities, as 5-azadeoxcytidine, can also result in the crosslinking of 
proteins to DNA (Juttermann et al., 1994) and the chromosome rearrangements observed in 
these lymphocytes derived from ICF-patients had been cultured for sometime (Xu et al., 
1999). 
 
However, genetic studies have added further weight to a role of DNA methylation in genome 
integrity, with ES cells deficient for Dnmt1 exhibiting an increased mutation rate suggested 
to be the result of increased mitotic recombination and associated chromosomal loss (Chen et 
al., 1998). Furthermore, mice that are hypomorphic for Dnmt1, which express 10% of 
protein compared to wildtype, resulted in a global loss of methylation and developed 
aggressive T-cell lymphomas at 4-8 months. These tumours often displayed trisomy of 
chromosome 15, indicating that demethylation may be linked with carcinogenesis through 





1.4.2 Genome defence 
Another suggestion for the role of mammalian genome-wide methylation is that of silencing 
transposable elements, as previously discussed for the fungus Neurospora crassa (see 
section 1.2.3). However, whether this is true in mammalian organisms is debatable. Mouse 
cells normally repress the transcription of transposable elements, such intracisternal A 
particle (IAP) elements. In mouse embryos lacking DNMT1, the transcription of such sites is 
upregulated 50-fold, suggesting a key role of methylation in their silencing (Walsh et al., 
1998). The purpose of this methylation-dependent silencing is debated, and is thought to be 
either required for the specific suppression of transposition (Yoder et al., 1997) or in the 
general reduction of transcriptional noise imposed by genome-wide methylation (Bird, 
1995). Currently, there no evidence that increased transcription of these elements, resulting 
from demethylation, leads to in increased transposition. Transposition would only display a 
heritable phenotype if it occurred within the germ cell lineage, therefore suggesting that 
transposon methylation at this timepoint would be imperative for in the genome defence 
model. However, at this stage in development, transposons within germ cells are 
hypomethylated (for review see (Reik and Walter, 2001)) and IAP elements are often 
transcriptionally active (for review see (Bird, 1997). It is only later in development where 
these elements become methylated and silenced, and furthermore, methylation has been 
shown to be secondary to transcriptional silencing of inserted retroviral sequences (Pannell 
et al., 2000). Phylogenetic studies may also argue against this model of mammalian genome 
defence, as methylation analysis of the sea squirt Ciona intestinalis showed no indication of 
targeted transposon methylation, with the methylation status determined by the insertion site 
(Suzuki et al., 2007). Indeed, mammalian transposons do not appear to be anymore targeted 
for methylation than the rest of the genome (Rabinowicz et al., 2003). However, despite the 
limited evidence for a role of DNA methylation in genome defence, there is also currently 
little evidence to suggest that there is an increase in transcriptional noise associated with of 
loss of genome-wide methylation. 
 
1.4.3 Transcriptional repression 
One of the best characterised functions of DNA methylation is transcriptional repression and 
this may provide clues as to the reason for the evolution of global DNA methylation in 




increase in the number of genes, which require careful temporal and spatial regulation and 
also an increased bulk genome size. It has been suggested that genomic expansion and 
complexity of expression patterns is limited by the ability of the cell to faithfully repress and 
express genes as required (Bird and Tweedie, 1995). As eukaryotes evolved to use 
nucleosomes to suppress their increased genome size, vertebrates may have evolved to use 
global DNA methylation in concert with chromatin. A study using a variety of transfected 
methylated constructs confirmed the repressive nature of methylation as seen in earlier 
studies, but discovered that the density of meCpG sites correlated with its repressive activity, 
with low density methylation only sufficient to repress weak promoters (Boyes and Bird, 
1992), in a manner reminiscent of chromatin (Laybourn and Kadonaga, 1991). Analysis of 
the average methylation density within the vertebrate bulk genome indicated a density of ~1 
meCpG per 100 bp, which is sufficient to suppress spurious initiation whilst not affecting 
authentic promoters, and therefore has the characteristics of a noise reduction system for the 
bulk genome. In contrast to this portion of the genome, the majority of mammalian 
promoters are embedded within CGIs (Illingworth et al., 2008), and are therefore typically 
devoid of repressive DNA methylation. This stark contrast between promoter regions and the 
surrounding bulk genome may facilitate in faithful transcriptional control by acting as 
landing lights for transcription factors (for review see (Illingworth and Bird, 2009)), whilst 
suppressing spurious activity outside of these key sites.  
 
Potentially contrary to this model of DNA methylation as a noise reduction system are recent 
genome-wide transcription profiling studies, including the ENCODE project. These suggest 
that up to 93% of the human genome is capable of being transcribed (Birney et al., 2007). If 
transcription is everywhere, can mammalian DNA methylation really be suppressing 
transcriptional noise? The relevance of these previously unidentified transcripts is still being 
investigated, but there is increasing evidence that these transcripts are functional, such as 
anti-sense transcripts and inter-gene splice variants (for review see (Kapranov et al., 2007)). 
This suggests that the initial model of transcription units proposed by Jacob and Monod with 
the lac operon is far too simple for higher organisms and what may have been initially taken 
for as noise is actually functional (for review see (Kapranov et al., 2007). 
 
A life-line to this noise reduction model is that global hypomethylation associated with 
human neoplasia has been shown lead to the expression of certain transposable elements 
(Rodriguez et al., 2006). In line with the increased expression of IAP elements in Dnmt1 




the mammalian bulk genome has a suppressive effect. However, the mechanism by which 
this low density of methylation of ~1 meCpG per 100 bp leads to transcriptional suppression 
is not clear. 
 
Whilst the mammalian genome is highly methylated, the actual density of methylation is 
low, due to the depleted CpG content of the bulk genome (Bird, 1980). However, there are 
some specific cases where the typically nonmethylated CGIs become methylated and are 
associated with transcriptional silencing of the gene. It seems likely that these particular sites 
evolved to harness the repressive ability of DNA methylation that already existed within the 
bulk genome. The best understood examples of CGI methylation are involved in the 
inactivation of the X chromosome and in imprinting, as discussed below. However, recent 
advances in microarrays and high-throughput sequencing have suggested that methylated 
CGIs are more prevalent than initially expected. A microarray study focusing on the majority 
of human promoters indicated that 3% of CGI-containing promoters were methylated in 
somatic tissues and primary cell lines (Weber et al., 2007). Subsequently, a study focusing 
on all CGIs, irrespective of their association with annotated promoters, suggested that 6%-
8% of CGIs were methylated in primary tissues (Illingworth et al., 2008). Furthermore, the 
CGIs that displayed tissue-specific methylation were over-represented at numerous genetic 
loci that are essential for development, including HOX and PAX family members 
(Illingworth et al., 2008). The role and targeting of methylation to these CGIs is still being 
investigated. Recently, the chromatin state and the level of RNA PolII association were 
shown to correlate with the propensity for methylation of CGIs in cancer (Takeshima et al., 
2009), suggesting that transcriptional inactivity could lead to methylation.  
 
1.4.4 X inactivation 
In mammals, sex determination is mediated by a pair of heteromorphic sex chromosomes, 
with females harbouring two X chromosomes, compared to males with only one. In order to 
equalise the expression levels of X-linked genes between the genders, females silence one 
copy of the X chromosome in each cell during early development (for review see (Heard et 
al., 2004)). Interestingly, during the first five cell divisions of the cell divisions of female 
embryogenesis, the paternal X chromosome is inactivated. Subsequently, the marks of this 
early allele-specific inactivation are removed in the cells of the inner cell mass and then 





The mechanism of random X inactivation is complex and will only briefly be discussed. 
There is an initially a reversible phase which ultimately leads to the irreversible repression of 
a single X chromosome (Wutz and Jaenisch, 2000). The expression of Xist, a large non-
coding RNA, from the Xi initiates chromosome-wide repression in cis (Wutz and Jaenisch, 
2000). In humans, Xi heterochromatin appears to relatively distinct forms: (1) the Xist RNA 
physically coats the Xi and associates with polycomb complexes and macro H2A; (2) the 
chromatin is marked with H3K9me3 and bound by HP1 (for review see (Valley and Willard, 
2006)). 
 
DNA methylation has been shown to have a central role in X inactivation. Treatment with  
5-azadeoxcytidine of hybrid mammalian cells resulted in transient demethylation and 
reactivation of the PGK-1 gene located on the inactive X chromosome (Xi), with the 
heritability of the reactivation dependent on the length of the demethylated region (Hansen 
and Gartler, 1990). CGIs on the Xi have been shown to specifically acquire methylation 
during development, consistent with a role of methylation in X inactivation (Heard et al., 
2004; Lock et al., 1986). This link is enhanced with the observation that CGIs of genes that 
escape X-inactivation are infrequently methylated when compared to those that are silenced 
(Carrel and Willard, 2005; Illingworth et al., 2008). 
 
The role of DNA methylation seems to be in the maintenance rather than in establishment of 
silencing. The targeted disruption of Dnmt1 in mouse ES cells led to aberrant X inactivation 
upon differentiation, with silencing of both X chromosomes thought to be the result of 
aberrant expression on Xist from Xa, indicating a role of methylation in the maintenance of 
silencing rather than the initiation (Panning and Jaenisch, 1996). Furthermore, methylation 
of the Hprt CGI has shown to occur after the gene has been silenced (Lock et al., 1987), 
consistent with DNA methylation acting to maintain silencing. 
 
Surprisingly, an early study using methyl-sensitive restriction of human metaphase 
chromosomes followed by labelling with biotinylated nucleotide and visualisation by 
immunofluorescence indicated that the Xi was actually overall hypomethylated compared to 
the Xa (Viegas-Pequignot et al., 1988). More recent studies have indicated that the 
distribution of this increased Xa methylation is within the intergenic DNA (Weber et al., 
2005) and within exons (Hellman and Chess, 2007). The role of Xa specific methylation has 
yet to be determined, but speculatively may be to suppress spurious transcription of the Xa, 






Genomic imprinting is where a particular gene is only expressed from a single allele 
determined by the parental origin and is controlled by ‘imprints’ that are laid down in the 
parental germ cells. Imprinting was first discovered in the 1980s where nuclear 
transplantation of uniparental embryos, which contain only one set of the parental 
chromosomes, resulted in differing phenotypes dependent on whether the maternal or 
paternal chromosomes were used (for review see (Reik and Walter, 2001)). Furthermore, 
loss of control of these imprinted sites often results in human disease, highlighting their 
importance. There are in region of 100 imprinted genes identified in humans, with the 
majority appearing within clusters in the genome, with each cluster typically containing 
several protein coding genes and at least one non-coding RNA (ncRNA). Each cluster is 
under the control of a single major cis-acting element, the imprinting control region (ICR) 
(for review see (Edwards and Ferguson-Smith, 2007)). The paradigm for this phenomenon 
comes from the first imprinted site to be identified: the H19 and Igf-2 genes, which are 
transcribed from the maternal and paternal alleles respectively, regulated by an ICR situated 
between these two genes. In Igf2 -/+ mice, passage of the null allele through the maternal 
line resulted in normal offspring, but passage of this allele through the male line resulted in 
growth deficiency (DeChiara et al., 1990; DeChiara et al., 1991). 
 
DNA methylation has been shown to have a determining role in genomic imprinting. The 
H19 locus has been shown to be specifically methylated on the paternal allele (Ferguson-
Smith et al., 1993); sites that shown parent-specific methylation are now known are 
differentially methylated regions (DMRs). Mouse embryos null for Dnmt1 exhibited a loss of 
methylation at DMRs and resulted in the loss of imprinting of this locus, with the normally 
paternally silent H19 gene now showing activation and the paternal activated Igf-2 gene 
showing repression (Li et al., 1993). The reciprocal regulation of the H19/Igf-2 locus is 
controlled by the binding of CTCF (CCCTC-binding factor) to four CpG-rich repeats 
specifically to the nonmethylated maternal H19 DMR, which is located 2 kb upstream of the 
H19 transcriptional start site (TSS). The binding of CTCF on the maternal allele acts as an 
insulator and blocks the enhancers from driving the Igf-2 promoters (Arney, 2003; Bell and 






The prefix Epi- describes an event which occurs ‘upon’ and therefore epigenetic literally 
translates into ‘upon the gene’. The term epigenetics has evolved since its introduction by 
Conrad Waddington, where epigenesis was the study of how genotypes give rise to 
phenotypes during development (Waddington, 1957).Through the work of Arthur Riggs and 
colleagues, epigenetics was defined as “the study of mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA sequence (Russo, 
1996).” More recently, however, the term epigenetics has been used to describe a wide array 
of chromatin modifications and metabolism with a reduced emphasis on the inheritability of 
this mark (for discussion see (Bird, 2007)). Overall, this has given rise to a recent definition 
stating: “the structural adaptation of chromosomal regions so as to register, signal or 
perpetuate altered activity states” (Bird, 2007). This includes various contemporary features 
of cell biology such as the Polycomb and Trithorax system, histone modifications and DNA 
methylation. By having this system of epigenetic memory it allows the cell to maintain or 
perpetuate the transcriptional status as determined by sequence specific transcription factor 
binding events, for example in the recruitment of histone acetyltransferases to promoter 
following transcription and therefore priming the promoter for continued activity (for review 
see (Clayton et al., 2006) and references therein). 
 
The recent advances in sequencing technology have given rise to a huge amount of genome-
wide data regarding the positions of these epigenetic marks. A full review of this field is out 
of the scope of this discussion. Briefly, an analysis of promoters marked by H3K4me3 and 
H3K27me3 revealed a strong correlation with the expression level of the associated gene 
(Mikkelsen et al., 2007). The so-called bivalent genes, those with promoters marked by both 
H3K4me3 and H3K27me3 and are thought to represent genes that are developmentally 
poised for activation, typically showed lineage specific resolution of these marks to give 
either activation or silencing (Bernstein et al., 2006; Mikkelsen et al., 2007). DNA 
methylation patterns have also been examined using these high throughput sequencing 
techniques. An initial reduced representation DNA methylation analysis based on an Msp1 
digest coupled with bisulphite sequencing indicated that as expected the CpG sites within 
CGIs were predominantly non-methylated and CpG sites within the bulk genome were 
mainly methylated (Meissner et al., 2008). However, this study identified that this pattern of 
CpG methylation was not universally true and that histone methylation was a better predictor 
of the CpG methylation status, with H3K4me3 and H3K4me2 being associated with non-




et al., 2008). The pattern of DNA methylation at CGIs and the bulk genome was shown to 
change upon differentiation of ES cells into neuronal progenitor cells, with corresponding 
changes in histone methylation (Meissner et al., 2008). The impact of changes in DNA 
methylation during development on gene expression and the involvement of proteins that 
bind meCpG sites, such as MeCP2, is likely to be further elucidated by high-throughput 
techniques to identify changes in this epigenetic mark. 
 
1.6 DNA methylation and chromatin controlling landscape of 
the genome  
Although eukaryotes and more specifically vertebrates may have evolved to use chromatin 
and global DNA methylation as apparently distinct means of compartmentalising their larger 
genomes, there are a number of parallels that can be drawn between these two mechanisms 
and it is clear that this evolution has been of cost to the organism. Firstly, it appears that 
chromatin and DNA methylation has impacted the very DNA sequence that they are trying 
to package. Recent nucleosomal modelling has shown that the entire genome has evolved its 
sequence to allow the positioning of nucleosomes, due to the manner of tightly wrapping the 
DNA around the histone octamer leading to sequence constraints (Segal et al., 2006). This is 
paralleled with DNA methylation altering the DNA sequence through deamination leading to 
a deficit of CpG sites in the genome. In sea squirt this has occurred to such an extent that it is 
possible to accurately predict the methylation status solely by looking at the CpG density 
(Suzuki et al., 2007). How these chromatin and DNA methylation dependent changes in 
DNA sequence have affected the genes is still being elucidated. Studies have shown that 
exons exhibit codon bias against sequences that results in the formation of overly stable 
chromatin, as this would impede transcription (Cohanim and Haran, 2009), whether this 
effect has been harnessed for the regulation of gene expression is unknown. The effect of 
DNA methylation on codon bias is currently unknown. From the suggestions of gene body 
methylation as a mechanism of preventing spurious initiation (Simmen et al., 1999; Suzuki et 
al., 2007; Zilberman et al., 2007), it may be hypothesised that exons from these methylated 
genes may preferentially include CpG-containing codons. Chromatin and DNA methylation 
have both impacted all levels of genomic metabolism. Through CGIs and H3K4me3 
domains, promoters become conspicuous within the genome and may act to attract the 
transcriptional machinery by highlighting key regions of the genome. There are suggestions 
that gene body chromatin and methylation have reduced the efficiency of transcriptional 




nevertheless been tolerated, perhaps through a need to reduce spurious transcription in wake 
of transiting RNA PolII (Carrozza et al., 2005; Suzuki et al., 2007; Zilberman et al., 2007). 
Limited analysis of recent high throughput sequencing of bisulphite treated human DNA 
suggested that highly transcribed genes show increased gene body methylation (Laurent et 
al., 2010), potentially providing evidence that this suppression of spurious intragenic 
transcription also exists in mammals. Indeed, this slowing of transcriptional elongation 
within the methylated gene body may have resulted in genes having to become longer in 
plants to avoid stalling of the polymerase early in the transcription cycle at promoter 
proximal regions (Zilberman et al., 2007). This slowing of elongation may have been 
harnessed to increase the fidelity of exon definition, with a marked increase in the DNA 
methylation density being observed at the 5’ splice site (Laurent et al., 2010). Splicing also 
seems to be effected by the surrounding chromatin environment, with specific histone 
modifications associated with splice sites (Sims et al., 2007). The role of these systems 
within the bulk genome seems to be create a transcriptionally inert environment, with 
suggestions that this may be a noise reduction system (Bird, 1995; Boyes and Bird, 1992; 
Laybourn and Kadonaga, 1991). Overall, it appears that both chromatin and DNA 
methylation have become highly entrenched within the cell affecting how the genome is 
utilised at almost every level. 
 
1.7 Interpreting DNA methylation 
1.7.1 Identification of methyl-CpG binding proteins 
The previous discussion has highlighted the key roles of mammalian DNA methylation. 
However, the mechanism by which DNA methylation is interpreted to exert these functions 
is still somewhat enigmatic. The increased level and dependence of DNA methylation in 
vertebrates may have necessitated an increased ability of the cell to interpret this signal 
(Hendrich and Tweedie, 2003). There are three potential mechanisms by which DNA 
methylation could be read by the cell. First, the meCpG moiety could intrinsically alter the 
chromatin or DNA structure and thereby alter its metabolism and accessibility. Currently, 
there is no evidence for this as a potential mechanism, with early experiments involving 
microinjection of the herpes simplex thymidine kinase gene showing that initially the 
methylated form was equally as active as the non-methylated form, with the methylated copy 
only becoming silenced after 100 hours, suggesting an indirect mechanism of methylation 




could actively prevent the binding of transcription factors and this has been shown for 
several proteins including CTCF (see section 1.4.5; (Arney, 2003)), Cfp1 (see Appendix B; 
(Thomson et al., 2010)), Sp1 (Clark et al., 1997; Mancini et al., 1999), CREB (Mancini et 
al., 1999). A recent study using high-throughput bisulphite sequencing demonstrated the use 
of CpG methylation as a mechanism for controlling transcription factor accessibility during 
development for p300, which binds to enhancer regions outside of CGIs (Lister et al., 2009). 
Third and the focus of this discussion is that meCpG could directly recruit factors which in 
turn interpret the DNA methylation signal. One of the first studies suggesting the existence 
of meCpG binding factors came from restriction digest of mammalian nuclei. Digestion of 
naked DNA with Msp1 (cut site: CCGG) resulted in extensive cleavage, however, digestion 
of intact nuclei only resulted in cleavage at CGIs, suggested that the meCpG sites were 
somehow specifically protected (Antequera et al., 1989). Two meCpG binding activities 
were subsequently observed. An activity termed MeCP1 (methyl-CpG binding protein 1) 
was initially identified by bandshift experiments of a methylated probe using nuclear extracts 
(Meehan et al., 1989). The protein responsible for this activity was not indentified until later 
as MBD2 (see section 1.6.6;(Feng and Zhang, 2001)). MeCP2 (methyl-CpG binding protein 
2) was subsequently shown to possess meCpG binding activity by south-western assay and 
to be distinct from MeCP1 by virtue of different chromatographic properties (Lewis et al., 
1992). Purification of this protein and sequencing by Edman degradation allowed 
identification of the MeCP2 gene (Lewis et al., 1992). 
 
1.7.2 The MBD protein family 
Deletion analysis of MeCP2 in combination with a south western assay identified a sequence 
85 amino acids long as the minimal fragment required for methyl-specific DNA binding and 
was termed the methyl-CpG binding domain (MBD) (Nan et al., 1993). The sequence of the 
MBD was used to search cDNA databases and led to the identification of PCM1 (protein 
containing methyl-CpG binding domain 1) (Cross et al., 1997). Further bioinformatic based 
approaches led to the identification of three more mammalian MBD-containing proteins 
named MBD2, MBD3 and MBD4 (Hendrich and Bird, 1998). These MBD-containing 
proteins were shown in vitro to specifically bind a methylated probe with the exception of 
MBD3, which was later shown to contain amino acid substitutions that prevent binding to 
methyl-CpG (Hendrich and Bird, 1998). In line with the repressive nature of DNA 




genetic studies have indicated that they have non-overlapping roles (Martin Caballero et al., 









Figure 1.3 – Schematic representation of the MBD protein family, all of which bind meCpG through the 
methyl binding domain (MBD), with the exception of MBD3. In addition, MBD1 has three zinc finger 
domains (CXXC), one of which specifically binds non-methylated DNA. The transcriptional repression 
domain (TRD) interacts with various co-repressors. The GR repeats of MBD2 have been reported to 
interact with RNA (Jeffery and Nakielny, 2004).  The C-terminal glycosylase domain of MBD4 functions 
in DNA repair. Adapted from (Klose and Bird, 2006). 
1.7.3 The structure of the MBD domain 
Solution structures of unliganded MBDs of MBD1 (Ohki et al., 1999) and MeCP2 
(Wakefield et al., 1999) have been determined. The structure of the MBD domain of MeCP2 
indicated the presence of numerous arginine and lysine side chains on the DNA binding 
surface, suggested to provide non-sequence specific binding to aid association with a methyl-
CpG moiety irrespective of sequence context (Wakefield et al., 1999). These structural 
studies suggested that specificity for methylated DNA was due to a conserved hydrophobic 
patch on the MBD interacting directly with the methyl group (Ohki et al., 2001; Wakefield et 
al., 1999). However, a more recent high resolution structure of the MBD domain of MeCP2 
bound to methylated DNA indicated that methyl-specific binding was largely through a 
hydrophilic surface, which included co-ordinated water molecules in the major groove of the 































Figure 1.4 – Structure of the MBD domain of MeCP2 bound to a methylated DNA ligand. A polypeptide 
corresponding to amino acids 77-167 of the human MeCP2 MBD domain was expressed and co-
crystallised with a 20 bp DNA fragment from a promoter of the mouse brain derived neurotrophic factor 
gene. (A) The overall structure is composed of a four stranded anti-parallel beta sheet linked to a single 
short alpha helix, which is similar to the unliganded structure as determined by NMR (Wakefield et al., 
1999). The methyl groups of the meCpG are shown as spheres (B) The methyl group of DNA (shown 
in yellow) is contacted by co-ordinated water molecules (shown in purple) and hydrophilic interactions 
with the protein. Adapted from (Ho et al., 2008). 
 
 
1.7.4 The ancestral MBD protein 
Bioinformatic analysis has successfully mapped the evolution of MBD containing proteins 
with the aid of available genome sequence information (Hendrich and Tweedie, 2003). 
MBD2 and MBD3 are likely the ancestral MBD proteins as they are the only vertebrate for 
which homologues can be identified in invertebrate genomes (Hendrich and Tweedie, 2003). 





two similar proteins in vertebrate genomes (Hendrich and Tweedie, 2003). It has been 
suggested that the increase in DNA methylation at the invertebrate-vertebrate transition and 
the increased dependence on DNA methylation as a means of controlling the genome, 
possibly by acting to reduce transcriptional noise, would have required an increased number 
of proteins that could interpret this DNA mark (Hendrich and Tweedie, 2003). Accordingly, 
vertebrates have evolved a number of other MBD proteins: MeCP2, MBD1 and MeCP2 
(Hendrich and Tweedie, 2003). 
1.7.5 MeCP2 
MeCP2 will be discussed in detail in section 1.7. 
 
1.7.6 MBD1 
The MBD domain of MBD1 can bind to symmetrically methylated DNA and more weakly 
to hemi-methylated DNA in vitro (Hendrich and Bird, 1998). MBD1 has been shown to bind 
to the densely methylated heterochromatic foci in vivo, but perhaps surprisingly, this 
localisation remains in methylation deficient cells (Hendrich and Bird, 1998; Jorgensen et 
al., 2004). As well as containing a functional MBD domain, MBD1 contains a transcriptional 
repressor domain (TRD) and three cysteine rich CXXC domains. Transfection studies 
suggested that the CXXC-3 domain selectively binds nonmethylated DNA in vitro and in 
vivo and may explain the methylation independent localisation (Jorgensen et al., 2004). The 
explanation for the protein having the ability to bind both methylated and nonmethylated 
DNA is currently not understood. However, accordingly MBD1 has been shown to be able to 
repress transcription form both methylated and nonmethylated DNA, with this repression 
dependent on the TRD (Jorgensen et al., 2004). The role and targets of MBD1 in vivo is 
currently unknown with the null mice exhibiting a mild neurological phenotype (Zhao et al., 
2003). MBD1 was originally known as PCM1 (Protein containing methyl-CpG-binding 
domain 1) (Cross et al., 1997). 
 
1.7.7 MBD2 and MBD3 
Initially, the methyl binding activity of the MeCP1 complex was thought to be due to the 
MBD1 protein (Hendrich and Bird, 1998), but it has been later shown that MBD2 is the 
protein responsible and forms part of the MBD2/NURD chromatin remodelling and histone 




closely related MBD proteins (~70% amino acid identity), MBD3 cannot specifically bind 
methylated DNA due to tyrosine to phenylalanine substitution (Fraga et al., 2003; Hendrich 
and Bird, 1998). The core mammalian NURD co-repressor complex is thought to contain: 
MBD2, MBD3, HDAC 1/2, MTA2, Mi-2, RbAP46/48 and p66/68; consistent with the 
repressive nature of DNA methylation. Genetic analysis indicated that MBD2 and MBD3 are 
not functionally redundant (Hendrich et al., 2001), which led to the biochemical purification 
of MBD2 and MBD3 specific NURD complexes (Le Guezennec et al., 2006). 
 
The role of MBD2 and MBD3 in this complex is unclear. Mbd2-deficient mice are viable, 
fertile and present only a mild maternal nurturing phenotype (Hendrich et al., 2001). MBD2 
has been shown to be required in the colon for the repression of pancreas and duodenum 
specific genes (Berger et al., 2007). A gene candidate based approach rationalised that genes 
with methylated CGIs were likely to be targets for MBD proteins. This led to the observation 
that MBD2 is involved in the repression of the methylated Xist promoter, with loss of MBD2 
resulting in a low-level reactivation of Xist in an HDAC dependent manner (Barr et al., 
2007). In contrast, loss of MBD1 and MeCP2 did not show the same effect, suggesting that 
the MBD proteins do not have overlapping functions (Barr et al., 2007). However, evidence 
of a generalised role of MBD2 in the repression of methylated promoters has not been 
forthcoming. 
1.7.8 MBD4 
The MBD of MBD4 is most similar to that of MeCP2 in primary sequence and was shown to 
bind to both symmetrically and hemi-methylated DNA in vitro, consistent with the 
observation that a GFP fusion protein was shown to be localised to the pericentromeric 
heterochromatin in a methylation dependent manner (Hendrich and Bird, 1998). Further 
work identified that MBD4 preferentially binds to m
5
CpG x TpG mismatches, the primary 
product of deamination of methyl-CpG (Hendrich et al., 1999). MBD4 was shown to 
efficiently remove thymine or uracil from a mismatched CpG site in vitro (Hendrich et al., 
1999). In humans, the mutation rate from 5-methylcytosine to thymine is 10-50-fold higher 
than other transitions, with the consequence that the methylated CpG sequence is under-
represented in the genome. Over one-third of germline point mutations associated with 
human genetic disease and many somatic mutations leading to cancer involve loss of CpG 
(Cooper and Youssoufian, 1988). Genetic studies using Mbd4-/- mice found that the 
frequency of C > T transitions at CpG sites was increased by a factor of three (Millar et al., 




showed accelerated tumour formation with CpG > TpG mutations in the wildtype Apc allele 
(Millar et al., 2002). Therefore, MBD4 suppresses CpG mutability and tumorigenesis in vivo. 
MBD4 has also been shown to act as a transcriptional repressor through the recruitment of 
HDAC complexes and be present at the hypermethylated promoters of the p16(INK4a) and 
hMLH1 genes (Kondo et al., 2005). However, the siRNA knockdown of MBD4 did result in 
an upregulation of these genes, therefore the role of MBD4 in gene regulation at these sites 
and elsewhere is currently unknown. 
 
1.7.9 Kaiso and Kaiso-like proteins 
Aside from the MBD family there is a second group of proteins that specifically bind to 
methylated CpGs. The founder member of this group, Kaiso, has an N-terminal POZ domain 
and C-terminal zinc fingers; it was originally purified from K652 cells as an activity that 
could bind specifically to methylated DNA (Prokhortchouk et al., 2001). As well as having 
affinity for methylated DNA, the zinc fingers of Kaiso can bind to a consensus sequence that 
lacks CpG dinucleotides (Daniel et al., 2002). However, in reporter assays, transfected Kaiso 
can still repress transcription in a methylation dependent manner (Prokhortchouk et al., 
2001). There is also evidence that Kaiso can function to silence endogenous genes by 
recruiting histone deacetylase activity to methylated promoters (Yoon et al., 2003). In 
Xenopus, Kaiso deficiency allows zygotic transcription to commence before the mid blastula 
transition with subsequent phenotypes including developmental arrest and apoptosis (Ruzov 
et al., 2004). However, Kaiso-null mice show no developmental abnormalities or changes in 
gene expression profiles (Prokhortchouk et al., 2006). 
 
Two more proteins, ZBTB4 and ZBTB38, were identified on the basis of homology with 
Kaiso (Filion et al., 2006). These proteins were also shown to be able to bind to methylated 
CpGs via their zinc finger domains and to repress transcription in reporter assays. The 
localization of these proteins to pericentromeric heterochromatin is also consistent with their 
binding to methyl-CpG (Filion et al., 2006). Furthermore, ZBTB4 and ZBTB38, as well as 
Kaiso, were shown by chromatin immunoprecipitation to be present exclusively at the 
methylated paternal allele of the H19/Igf2 differentially methylated region (Filion et al., 






1.8.1 The structure of the Mecp2 gene 
The MeCP2 gene was initially identified from the results of Edman degradation probing a 
cDNA library (Lewis et al., 1992). The mouse gene was mapped to Xq28 and was shown to 
be subject to X inactivation (Quaderi et al., 1994). Examination of EST libraries identified 
alternative polyadenylation sites giving rise to multiple mRNAs with different 3’ 
untranslated regions (UTRs): 2 kb and 10 kb, amongst others (Coy et al., 1999). The 
sequence of the 10 kb 3’UTR in mouse and human shows only 52% homology, but the 
distribution of free energy along the length of the 3’UTR is very similar (Coy et al., 1999). 
Coy et al. speculated that the 3’UTR of MeCP2 has key regulatory roles in the expression of 
MeCP2, with differential expression of the two isoforms between tissues and during 
development, with the 10 kb isoform prevalent in the mature brain. The exact role of the 
3’UTR has, however, remained mysterious. Recent studies have increased interest, with the 
identification of a binding site within the long 3’UTR for a brain-enriched microRNA: 
miR132 (Klein et al., 2007). Using cultured cortical neurons, miR132 was shown to be 
induced upon neuronal depolarisation via the CREB pathway and resulted in a decrease in 
MeCP2 protein levels through post-transcriptional regulation, thereby allowing immediate 
response of MeCP2 protein levels to neuronal activity (Klein et al., 2007). 
 
A bioinformatic search for conserved elements throughout the human MECP2 gene and its 
neighboring regions identified four enhancer elements, two silencer elements and a 
conserved ~1 kb region immediately upstream of exon 1 with multiple regulatory elements 
(Liu and Francke, 2006). Some of these elements have recently been shown to exhibit 
DNase1 hypersensitivity and be marked by various histone modifications, implying a role in 
the regulation of the gene (Singh et al., 2008). Additionally, a study taking advantage of the 
recent explosion of high-throughput data from the ENCODE project, identified that the 
second intron in the human MECP2 gene, which is atypically long at almost 60 kb, contains 
several conserved regions (Singh et al., 2008), suggesting that the regulation of this gene 
may be highly complicated. 
 
1.8.2 The MeCP2 protein and expression pattern 
Initially, the MeCP2 protein was purified from rat brain as a single 84 kDa protein (Lewis et 




exons contributing to the protein (Coy et al., 1999). More detailed bioinformatic analysis 
revealed an additional upstream non-coding exon embedded in a CGI (Reichwald et al., 
2000). MeCP2 was recently shown to be subject to alternative splicing giving rise to two 
isoforms (α and β), generating different N-termini with the α isoform containing a 
polyalanine and polyglycine tract (Figure 1.5A;(Kriaucionis and Bird, 2004)). MeCP2α was 
shown to be the significantly more abundant isoform in the mouse brain and alignment 
suggested that MeCP2α more closely resembled the ancestral form of MeCP2 (Kriaucionis 
and Bird, 2004). The functional differences between these proteins are currently unknown, 
with both isoforms showing localisation to methylated pericentromeric heterochromatin 
(Kriaucionis and Bird, 2004). Note, however, that in human brain, both isoforms are more 
equally expressed, with this study observing that the previously unidentified N-terminus 
containing the polyA/polyG tract is also present in the signaling protein ERK1, but there is 
no indication of a functional relationship (Mnatzakanian et al., 2004). Therefore it remains 
possible that these isoforms have distinct functions. 
 
The distribution of MeCP2 may be key to understanding its role in cells. MeCP2 is 
ubiquitously expressed throughout human and mouse tissues (Su et al., 2002), but was 
immediately shown to be particularly abundant within the brain (Figure 1.5B; (Lewis et al., 
1992)). The brain is broadly composed of two cell types: neuronal and glial cells. 
Immunofluorescence based experiments using mouse brain suggested that MeCP2 was 
primarily expressed within the neuronal nuclei but not in the glial nuclei (Kishi and Macklis, 
2004). MeCP2 expression within development has also been examined with the finding that 
levels increased with neuronal maturation (Balmer et al., 2003; Kishi and Macklis, 2004; 
Shahbazian et al., 2002b). Despite this being somewhat reminiscent of the increase in DNA 










































Figure 1.5 – Mecp2 gene structure and expression pattern (A) Exon structure of MeCP2 indicating the 
alternative splice forms. Shaded boxes are protein coding and open boxes represent untranslated 
regions. The large second intron spans ~60 kb and ~43 kb in human and mouse respectively; the 
intron is cropped in this schematic. The β isoform is thought to be subject to translational interference 
due to the presence of a AUG codon within exon 1 and is therefore inefficiently translated (Kriaucionis 
and Bird, 2004). The red bar indicates the position of the probe used in the expression analysis shown 
in the panel below. (B) MeCP2 gene expression profiling across a wide range of mouse tissues, 
sourced from BioGPS (Su et al., 2002). Brain regions are highlighted within a red box. Expression 








1.8.3 MeCP2 and Rett Syndrome 
Rett syndrome is a relatively frequent form of mental retardation and occurs sporadically 
once every 10,000-22,000 female births (Kriaucionis and Bird, 2003). In Rett patients, 
apparently normal development gives way to regression after 6-12 months, with loss of 
acquired skills, including speech and mobility (Armstrong, 2002). Many patients survive into 
adulthood, but few procreate. Rare familial cases of Rett syndrome allowed the mapping of 
the disease region to Xq28, with mutations in the X-linked MECP2 gene shown to be the 
primary cause of the disease (Amir et al., 1999). Studies have shown that after the initial 
crisis, there is no further neurodegeneration and therefore Rett syndrome is classed as a 
neurodevelopmental disorder. The neurological phenotype resulting from loss MeCP2 is in 
line with the highest expression of MeCP2 being observed in the brain. 
 
Comprehensive databases of disease-causing MECP2 mutations have been compiled. Most 
missense mutations that cause Rett syndrome are tightly clustered within the MBD domain, 
suggesting the key importance of this domain (Figure 1.6; see section 1.6.5 for discussion). 
Non-sense and frame shift mutations are distributed throughout the protein (for review see 
(Kriaucionis and Bird, 2003)). With almost some sense of cruel irony, approximately half of 
the missense mutations affect an arginine residue, which contains a CpG dinucleotide in its 
codon. It is likely that these gene body CpG sites are methylated and that the Rett syndrome 














Figure 1.6 – Map indicating the position of the missense mutations that result in Rett syndrome 




































Rett syndrome is almost exclusively a disease of females, as the MECP2 gene is X linked 
and patients are heterozygous for the mutated allele. Following random X-inactivation, the 
MeCP2 expression forms a mosaic pattern with typically half of the cells expressing the 
wildtype allele and half expressing the mutated form. Various studies have tried to correlate 
Rett symptoms with the causative mutation, with the hope of attributing specific functions of 
the protein to the various protein domains ((Temudo et al., 2010) and references therein). 
However, there have been no clear links. This may result from a number of reasons, 
including the possibility of skewed X inactivation, which could lead to some regions of the 
brain being over-represented in mutant cells and the overall proportion of mutant cells in the 
whole brain varying. Therefore this heterogeneity may prevent clear genotype-phenotype 
correlations. 
 
1.8.4 Mouse models of Rett syndrome 
Two groups independently produced Mecp2 null animals (Guy et al., 2001) (Chen et al., 
2001). The null mice showed no phenotype until 3-8 weeks of age, at which point they 
developed a stiff uncoordinated gait, hind limb clasping, irregular breathing and on average 
died at 54 days after birth (Guy et al., 2001) (Chen et al., 2001). In line with the human 
condition, the female heterozygote mice do not die prematurely, but display a similar 
neurological phenotype as the null males, but with onset of symptoms occurring between 
three and nine months (Guy et al., 2001) (Chen et al., 2001). The parallels between Rett 
patients and these mice, with the late onset neurological phenotype, suggest that this is a 
reasonable model for the study of Rett syndrome. 
 
Brain specific knockout of MeCP2 produced mice indistinguishable from that of the null 
animals (Guy et al., 2001), suggesting that the key function of MeCP2 is within the brain, 
where it is most abundant. As discussed, immunofluorescence has shown that MeCP2 is 
expressed primarily from neurons and is absent from the glia (Kishi and Macklis, 2004). 
This is also mirrored in the mouse genetic studies where neuron specific expression of 
MeCP2 rescues the null phenotype (Luikenhuis et al., 2004). This suggests the major 
function of MeCP2 is in the brain and more specifically the neurons. However, this has 
recently been contested from cell line based experiments, which suggests that MeCP2 
expression in the neurons alone is not sufficient for wildtype growth patterns, with the 




morphology of co-cultured neurons (Ballas et al., 2009). These assertions as to the pivotal 
role of MeCP2 within glia will likely be elucidated from the phonotype a glial-specific 
knockout mouse. 
 
As well as absence of MeCP2 resulting in a severe neurological phenotype, surprisingly only 
a mild overexpression of the protein also results in a neurological symptoms. Overexpression 
of MeCP2 via the Tau promoter in mouse post-mitotic neurons led to neurological phenotype 
distinct from those caused by the loss of MeCP2 (Luikenhuis et al., 2004). This 
overexpression was only ~2-4 fold and did not result in an alteration in protein localisation 
as measured by immunofluorescence (Luikenhuis et al., 2004), suggesting that the levels had 
not reached a saturation point where localisation becomes uniform. This observation has 
been recapitulated with a transgenic mouse that also expresses the human form of MeCP2 
from a large human genomic clone, resulting in two-fold overexpression of MeCP2 and an 
associated neurological phenotype (Collins et al., 2004). Symptoms associated with the 
overexpression of MeCP2 in mice have also been observed in humans, with MECP2 gene 
duplications events giving rise to developmental delay and mental retardation in a manner 
distinct from Rett syndrome (Lubs et al., 1999). Overall, these mouse models suggest that 
too much MeCP2 is just as bad as too little. 
 
1.8.5 MeCP2 as a methyl-binding activity 
MeCP2 was originally identified form rat brain extract on the basis of methyl-DNA specific 
binding as determined by a south-western assay using a probe containing multiple 
methylated CpG sites (Lewis et al., 1992). Subsequent deletion analysis identified the amino 
acid sequence between 89 and 162 as the minimal region required for binding to methylated 
DNA: the MBD domain (Nan et al., 1993). Using a band shift assay with bacterially 
expressed recombinant proteins, the MBD was shown to interact with a single symmetrically 
methylated CpG site with a dissociation constant in the order of 1 x 10
-9
 M (Nan et al., 
1993). The in vivo binding characteristics have been further analysed. In mouse cells, the 
predominant DNA sequence in the pericentromeric heterochromatin is the major satellite 
repeat, which accounts for ~7% of the total genomic DNA but ~40% of the 5-methylcytosine 
content of the cell. A lacZ fusion protein with full length rat MeCP2 was transiently 
expressed in mouse cells, with microscopy indicating a characteristic punctate pattern co-
localising with the pericentromeric heterochromatin (Nan et al., 1996). The methyl-




which contain approximately 5% of the wildtype levels of DNA methylation. Here, the 
fusion MeCP2 protein did not largely display a punctate distribution, but instead was mostly 
diffuse throughout the nucleus (Nan et al., 1996). More recent work addressed the question 
of whether the different MBD proteins have different targets due to a requirement for 
additional DNA sequences at the CpG site (Klose et al., 2005). A methyl-SELEX 
(Systematic Evolution of Ligands by Exponential Enrichment) assay using the MBD of 
MeCP2 alone, indicated that MeCP2 binding was enhanced by the presence of a [A/T}≥4 run 
situated one to three base pairs or six to nine base pairs form the meCpG site, whereas the 
MBD of MBD2 showed no such requirement (Klose et al., 2005). 
 
The validity of MeCP2 as a methyl-specific binding protein has recently been questioned in 
numerous studies; this will be discussed in section 1.8.8 
 
1.8.6 Transcriptional repression and binding partners 
Early experiments involving the introduction of methylated reporter constructs into cells 
suggested that DNA was a repressive mark (Stein et al., 1982). However, initial experiments 
did not show that MeCP2 repressed transcription in a methylation specific manner; this was 
thought to be due to impurities (Meehan et al., 1992). Using cleaner preparations of MeCP2, 
it was shown to repress in vitro in a methylation specific manner and deletion analysis 
identified the transcriptional repressor domain (TRD) (Nan et al., 1997). The nature of this 
repression had several interesting features. Firstly, a targeted Gal4-TRD fusion was capable 
of effectively repressing transcription of a reporter from a distance of at least ~2 kb in vivo 
(Nan et al., 1997). This may suggest that MeCP2 is more suited to setting up repressive 
domains, rather than targeting key sites or simply working through steric occlusion of 
promoter bound transcriptional activators. Secondly, the impact of methylation density on 
repression was determined by using various bacterial methyltransferases. The data clearly 
showed that repression was non-linear with the methylation density of the construct, but 
repression appeared suddenly at ~1 meCpG/100 bp, with no further increase in repression 
with increasing methylation (Nan et al., 1997). This coincides with the methylation density 
of the bulk mammalian genome with the observation that low density methylation of ~1 
meCpG/100 bp is only sufficient to repress weak promoter activity (Laybourn and 
Kadonaga, 1991). Overall this may suggest that the repressive activity of MeCP2 has been 






Much work has focussed on which interacting factors are responsible for this  
methyl-dependent repression. By co-immunoprecipitation, the TRD was shown to interact 
with a co-repressor complex containing mSin3a and HDACs (Nan et al., 1998). Accordingly, 
transfection studies using a Gal4-targeted TRD indicated that repression could be partially 
alleviated using the HDAC inhibitor, trichostatin A (TSA), thereby confirming the role of 
histone deacetylation in MeCP2 dependent repression (Nan et al., 1998). This has been 
further corroborated by the observation of increased histone acetylation in mice expressing a 
truncated form of MeCP2 lacking the TRD (Shahbazian et al., 2002a). This study 
hypothesised that the increase in acetylation would result in the altered expression of specific 
genes in the brain (Shahbazian et al., 2002a). 
 
The only partial relief of repression with TSA treatment was suggestive of other mechanisms 
of repression. MeCP2 was shown to associate with a H3K9 methyltransferase activity (Fuks 
et al., 2003). However the factor involved is unknown, with no clear evidence of a change in 
H3K9 methylation levels in the various null mouse models. Deletion analysis showed this 
activity associated with a region overlapping with the MBD of MeCP2 (Fuks et al., 2003). 
 
Recently the N terminus of MeCP2 has been shown to associate with HP1 in an in vitro 
myogenesis system (Agarwal et al., 2007). This study showed localisation of HP1 to the 
pericentromeric heterochromatin, but only in MeCP2 positive nuclei and went on to show a 
physical association using tagged constructs in co-immunoprecipitation experiments. 
However, the co-immunoprecipitation of endogenous proteins only gave a very weak signal, 
questioning the validity of this interaction (Agarwal et al., 2007). 
 
Using in vitro transcription assays, MeCP2 binding was shown to prevent the assembly of 
pre-initiation complexes due to interaction of the TRD with the basal transcription factor 
TFIIB (Kaludov and Wolffe, 2000). However, the in vivo significance of this interaction has 
not been investigated. 
 
MeCP2 has also been shown to interact with DNMT1 through the TRD in a complex that is 
mutually exclusive with the complex formed between MeCP2 and HDAC1 (Kimura and 
Shiota, 2003). This study postulated that this interaction had a role in the faithful replication 
of DNA methylation marks, with MeCP2 recruiting DNMT1 to hemi-methylated sites 




bandshift experiments did not support the observation of MeCP2 binding to hemi-methylated 
DNA (Nan et al., 1993). 
 
MeCP2 has been shown to interact with various other protein factors including; ATRX,  c-
Ski, PU.1, RNA splicing factors (Nan et al., 2007), (Kokura et al., 2001) (Suzuki et al., 
2003) (Young et al., 2005). However, the functional nature of these interactions remains 
poorly understood. The identification of key interacting partners has likely been hampered 
by the observation that MeCP2 does not form stable complexes (Klose and Bird, 2004). 
 
1.8.7 MeCP2 gene targets 
MeCP2 was quickly identified as a transcriptional repressor and considering the global 
distribution of methyl-cytosine, it was therefore expected that MeCP2 would regulate the 
activity of a large number of genes. Indeed, misregulation of gene expression was identified 
in lymphoblast cell lines derived from Rett patients (Ballestar et al., 2005; Traynor et al., 
2002). However, cell lines are known to have aberrant high levels of CGI methylation not 
seen in primary tissues (Antequera et al., 1990), suggesting that cell lines may not be the 
appropriate model system for identifying target genes. Numerous studies have utilised the 
Mecp2-null mouse to look for changes in gene expression using microarray based 
experiments, with these changes typically verified by quantitative PCR analysis (Ben-
Shachar et al., 2009; Chahrour et al., 2008; Jordan et al., 2007; Nuber et al., 2005; Tudor et 
al., 2002). Despite several genes being identified as misregulated in the Mecp2-null mouse, 
there is no clear consensus on what are the ‘Rett genes.’ Furthermore, one study showed that 
the number of misregulated genes was 30% lower in the mice with exon 3 deletion 
(Mecp2
tm1.1Jae
) than in mice with the larger deletion (Mecp2
tm1.1Bird
) suggesting that the 
manner of the genetic disruption may have an effect, however, this also may be due to the 
difference in the genetic background between the lines (Jordan et al., 2007). Additionally, 
these studies may be complicated by the onset of Rett-like symptoms and therefore 
questioning what can be considered as a true target, as opposed to a secondary change. 
 
Perhaps more success has resulted from using a candidate gene approach for genes known to 
show activity-dependent neuronal transcription. Brain derived neurotrophic factor (Bdnf) has 
been identified as a direct target for MeCP2 using cultured cortical neurons taken from 
embryonic animals (Chen et al., 2003b; Martinowich et al., 2003). Bdnf plays important roles 




controlled by at least 8 alternative promoters, which show activity dependent and cell-type 
specific expression. MeCP2 was shown to bind to the exon IV and modestly silence basal 
gene expression (Chen et al., 2003b; Martinowich et al., 2003). Upon membrane 
depolarisation, MeCP2 was shown to be phosphorylated and dissociated from the promoter, 
accordingly no effect on the expression in the excited state was detected. It was therefore 
expected that Bdnf expression would be up regulated in the MeCP2 null mouse, however, in 
whole brain lysates of symptomatic animals Bdnf mRNA levels were shown to be down at 
70% of wild type (Chang et al., 2006). This apparent conflict was suggested to be as a result 
of different neuronal activities between wild type and null mice (Chang et al., 2006). It may 
also reflect differences between cultured embryonic neurons and the mature mice, as MeCP2 
is known to show a developmental increase in expression (Balmer et al., 2003; Kishi and 
Macklis, 2004; Shahbazian et al., 2002b). 
 
Horike et al. used ChIP-and-clone of 1 day old mice to identify MeCP2 target genes. They 
identified a putative imprinted gene cluster containing Dlx5/6 as a MeCP2 target (Horike et 
al., 2005). They claimed that in wild type mice that Dlx5/6 was monoallelically expressed, 
whereas in the Mecp2-nulls, biallelic expression was observed. However this work has more 
recently been refuted, showing that Dlx5/6 is not imprinted and there was no significant 
difference in expression between wild type and null mice (Schule et al., 2007). Overall, 
currently there is no clear consensus as to which genes, if any, MeCP2 specifically regulates. 
 
Work on Xenopus laevis embryos showed that MeCP2 interacted with the SMRT co-
repressor complex and is involved in the regulation of expression of a neuronal repressor 
xHairy2a in the differentiating neuroectoderm (Stancheva et al., 2003). The MeCP2/SMRT 
complex was shown to dissociate from the promoter upon Notch/Delta signalling (Stancheva 
et al., 2003). 
 
1.8.8 Current models for MeCP2 function 
i Classical methyl-dependent transcriptional repressor 
The identification of mutations MeCP2 as primary cause of Rett syndrome led to the 
expectation that the disorder was the result of aberrant upregulation of genes due to the loss 
of a methyl-dependent transcriptional repressor. However, the failure to identify clear 




does not in fact act as a classical transcriptional repressor by binding to a discrete set of 
targets. 
 
ii Transcriptional activator 
Perhaps the two most surprising MeCP2-related papers in the last few years have suggested 
that MeCP2 predominantly activates a large number of genes (Ben-Shachar et al., 2009; 
Chahrour et al., 2008). The first study compared the expression profile of wildtype 
hypothalamus with that of the Mecp2-null hypothalamus and found ~3000 genes whose 
expression was altered using a modest cut-off of 1.2-fold (Chahrour et al., 2008). 
Surprisingly, ~85% of these genes were downregulated in the absence of MeCP2, suggesting 
that they were activated by MeCP2 (Chahrour et al., 2008). The strength of this study came 
from the use of the MECP2-Tg mouse, which over-expresses MeCP2 by two-fold (Collins et 
al., 2004) and showed upregulation of the majority of these same genes (Chahrour et al., 
2008). A closer inspection of the microarray data has questioned the statistical significance 
of these reciprocal changes (personal communication with J. Guy). ChIP analysis was 
performed in order to implicate MeCP2 in direct regulation of these genes. The data was 
however not conclusive, in part due to very poor immunoprecipitation specificity, but 
moreover due to the limited analysis performed, with only a single primer pair used to 
investigate MeCP2 binding at the target genes and the lack of MeCP2 binding to non-target 
genes was not confirmed. Using co-immunoprecipitation experiments, the study went further 
to suggest that MeCP2 recruits the activator protein CREB to target sites (Chahrour et al., 
2008). Further work will be required to test the significance of this interaction, which 
appears sub-stoichiometric. The methyl-dependence in binding to these sites and acting as a 
transcriptional activator was not studied in detail, but found that five out of the six genes 
examined had nonmethylated promoters (Chahrour et al., 2008). 
 
This study was one of the first to use a distinct brain region (Chahrour et al., 2008), which 
may have gone some way to explain the inconsistency with previous studies that used whole 
brain and identified very few changes (Nuber et al., 2005; Tudor et al., 2002), suggesting 
brain region-specific differences in the function of MeCP2. However, a very similar study 
from the same laboratory indicated that MeCP2 largely activated the same set of genes in the 
cerebellum (Ben-Shachar et al., 2009). Therefore, suggesting that this role as an activator 





iii Control of alternative splicing 
Through co-immunoprecipitation and mass spectrometry analysis, MeCP2 was shown to 
interact with Y-box binding protein (YB-1) (Young et al., 2005).This interaction was 
abolished on the treatment of nuclear extracts with RNaseA, suggesting that it was RNA-
mediated binding. Comparison of splicing patterns between brains from wildtype and 
Mecp2
308/Y
, which expresses a truncated form of MeCP2, suggested a modest number of 
genes showed altered splicing patterns (Young et al., 2005). However, the interaction 
between MeCP2 and YB-1 was not abolished on using MeCP2-R106W, a common Rett 
mutant form of MeCP2, suggesting that the loss of this interaction is not key in causing Rett 
syndrome (Young et al., 2005). Further work will be required to examine the role of MeCP2 
in controlling splicing. 
 
iv Nonmethyl-dependent functions 
In contrast to the early studies identifying MeCP2 as a methyl binding activity, there has 
been a large number of recent studies suggesting that MeCP2 can bind to naked DNA and to 
chromatin irrespective of the methylation status (Ben-Shachar et al., 2009; Chahrour et al., 
2008; Georgel et al., 2003; Nikitina et al., 2006; Yasui et al., 2007). These in vitro studies 
investigated the interaction between recombinant MeCP2 and DNA containing strong 
nucleosomal positioning sequences. MeCP2 was suggested to bind to nonmethylated 
nucleosomal arrays and cause extensive compaction of the arrays into a heterogeneous 
population of structures as visualised by shadowed electron microscopy (Georgel et al., 
2003). The second study built upon these findings and used truncated forms of MeCP2 to 
suggest that the C-terminal domain was responsible for the methylation independent 
interaction, whilst the MBD maintained a partial methyl-specific interaction (Nikitina et al., 
2006). Further electron microscopy suggested that MeCP2 was capable of modulating the 
structure of nucleosomal arrays by in cis compaction of an array and in trans association of 
multiple arrays (Nikitina et al., 2006). However, there have been some concerns that the low 
salt conditions used in the band shift assays may allow spurious interactions between a 
positively charged protein such as MeCP2 and DNA. There are no clear in vivo examples 
confirming this structural role for MeCP2 in compacting chromatin. The only indication 
coming from a limited chromatin conformation capture study suggesting that MeCP2 
mediated chromatin looping at the Dlx5/6 locus (Horike et al., 2005), with this work being 
subsequently refuted (Schule et al., 2007). Additional support for methylation independent 




implicated MeCP2 in transcriptional repression through the binding to nonmethylated DNA 
(Harikrishnan et al., 2010; Kernohan et al., 2010) and expression arrays indicating MeCP2 
regulating nonmethylated genes (Chahrour et al., 2008). The validity of these ChIP-based 
studies has, however, been of question, with only limited analysis using a single primer pair 
being used to identify MeCP2 binding sites {Harikrishnan, 2010 #454}{Kernohan, 2010 
#455}{Chahrour, 2008 #235}. 
 
1.9 Aims of this thesis 
There has been a recent flurry of interest in MeCP2, much of which has provided some 
controversy and intrigue into the role of MeCP2. This study started with a re-analysis of the 
phenotypes associated with the loss and overexpression of MeCP2. This has led to several 
key objectives to shed light on the function of MeCP2: (1) determination of the distribution 
and abundance of MeCP2 in the mature mouse brain; (2) the characterisation of the binding 





Chapter 2 Materials and Methods 
 
All methods were carried out at room temperature (RT) unless otherwise stated. Some 
standard techniques will not be outlined in detail. 
 
2.1 Common solutions and reagents 
All material and reagents were stored at room temperature (RT) unless otherwise stated 
 
Coomassie blue stain:  
 
40% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.25% 
(w/v) Coomassie Brilliant Blue R-250. Filtered through a 
Whatmann number 1 filter. 
Coomassie destain solution: 
 
40% (v/v) methanol and 10% (v/v) glacial acetic acid 
DNA sequencing buffer (2.5x): 
 
20 mM Tris HCl (pH 8.0) and 5 mM MgCl2 
Orange G loading buffer (6x): 0.198% (w/v) orange G, 12% (w/v) Ficoll,  
120mM EDTA (pH8.0), 4.2% (w/v) SDS 
Phenol for DNA extraction Phenol: Chloroform: Isoamyl Alcohol (25:24:1). Saturated 
with 10 mM Tris, (pH 8.0), 1 mM EDTA (Sigma-Aldrich). 
Stored at 4 °C 
Phenol for RNA extraction Phenol: Chloroform: Isoamyl Alcohol (125:24:1). 
Saturated with 2 M NaOAc (pH 4.0) (Fluka). 
Stored at 4 °C 
Phosphate buffered saline  
(PBS): 
 
140 mM NaCl, 3 mM KCl, 2 mM KH2PO4,  
10 mM Na2HPO4 
Protein loading buffer (2x): 
 
125 mM Tris-HCl (pH 6.8), 4% (w/v) SDS, 20% (v/v) 
Glycerol, 300 mM β-Mercaptoethanol, 0.2% (w/v) 
bromophenol blue. Aliquoted and stored at -20 °C 
Proteinase K stock solution: 
 
20mg/ml proteinase K, 100mM EDTA pH 7.5, 2% (w/v) 
SDS. Stored at −20°C 
RNaseA stock solution:  
 




Tris buffered saline (TBS): 
 
50 mM Tris-HCl (pH 8.0), 150 mM NaCl 
Tris-acetate EDTA (TAE) 
(1x): 
 
40 mM Tris-acetate, 1 mM EDTA 
Tris-borate EDTA (TBE) (1x): 
 
45 mM Tris-borate, 1mM EDTA 
Tris-EDTA (TE) buffer (1x):  
 
10 mM Tris-HCl (pH 7.5), 1 mM EDTA 
Tris-glycine SDS (1x): 
 
25 mM Tris, 250 mM Glycine, 0.1% (w/v) SDS 
Transfer buffer (1x):  
 
25 mM Tris, 192 mM Glyine (supplemented with 20% 
(v/v) methanol when using PVDF membrane) 








2.2 List of antibodies  
Antibody Source; Cat no. Application Immunogen/Notes 
Anti-MeCP2 Sigma-Aldrich; 
Mec-168 










Peptide from rat MeCP2; amino acids 
1-392 (Nan et al., 1998) 
Anti-H4 Abcam; ab7311 WB (1:500) Proprietary peptide derived from 
human H4; amino acids 1- 100 
Anti-H3 Abcam; ab1791 WB (1:10000) Proprietary peptide derived from 











amino acids 1-20 of Tetrahymena 
histone H3 (ARTKQTAR[K*]STGG 
[K*]APRKQLC) where K* is 
acetylated 
Anti-Histone H1 Abcam; ab1938 WB (1:1000) Calf thymus intact Histone H1 (MW 
23 kDa) complexed to rRNA. No 
information was available regarding 
the primary structure of the 
immunogen, it is however, expected to 
recognise all H1 isoforms (personal 
communication with Abcam) 
Infra-red anti-
rabbit 680 IgGs 
Licor; 32223 WB (1:7000)  
Infra-red anti-
mouse 680 IgGs 
Licor; 32212 WB (1:7000)  
Infra-red anti-
goat 680 IgGs 



































Table 2.1 – List of Antibodies 
WB: Western blotting (typical dilutions are indicated) 
FACS: Fluorescence activated cell sorting 





2.3 Mouse strains and sample preparation 
2.3.1 Mouse strains 
C57BL6 Mecp2
tm1.1Bird
 mice were used with wildtype littermates as controls. Unless 
otherwise stated all mice were 6-8 weeks of age. Mice were typically euthanized by CO2 
asphyxiation, tissues dissected and either frozen in liquid nitrogen for ChIP or used directly 
for nuclei preparation. Assistance was kindly received from Dr Jim Selfridge and Dina De 
Sousa in the organisation of the mouse lines and in the setting up of timed matings for the 
harvesting of embryonic tissues. 
 
2.3.2 Dissection of the striatum granulosum of the dentate 
 gyrus 
Assistance in the dissection was gratefully received from Dr S Cobb. Briefly, the whole 
brain was first removed and rinsed in 1 x PBS at 4 °C. Subsequently, 500 µm sections were 
cut and the slices corresponding to the hippocampus retained. Using a dissection microscope, 
the striatum granulosum of the dentate gyrus was conspicuous by virtue of the density of 
cells. This region was carefully dissected and stored on ice before continuing with further 
experiments. Typically, from the dissection of a single mouse brain in the order of 1 x 10
6
 
cells were recovered. 
2.3.3 Isolation of nuclei from mouse tissues 
Typically nuclei from up to 5 brains or 3 livers were prepared at one time. Freshly taken 
mouse tissues were placed in a 15 ml dounce (Braun) to which 9 ml (equivalent to 
approximately 5 volumes of mouse tissue) of ice-cold buffer A was added (10 mM Hepes 
(pH 7.9), 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 0.5 mM 
EGTA, 2 M sucrose, 10 % glycerol, 10 mM sodium butyrate and complete protease 
inhibitors (Roche)). Tissues were homogenised using a Potter S (Braun) motorized 
homogenizer (7strokes at 1100 rpm). The homogenate was layered onto a 3 ml cushion of 
buffer A and centrifuged in pre-chilled SW40 rotor (24000 rpm, 40 min, 3 °C) to recover the 






After centrifugation, the ‘fatty plug’ was removed and the tube inverted to allow the buffer 
to drain. The pelleted nuclei were then resuspended gently in typically 1 ml of resuspension 
buffer (1 x PBS, 20% (v/v) Glycerol, 10 mM sodium butyrate and complete protease 
inhibitors (Roche)). Nuclei were observed by phase contrast microscopy to ensure they were 
of good quality. Serial dilutions of nuclei were counted using a haemocytometer to 
determine concentration. Nuclei were aliquoted as required and flash frozen in liquid 
nitrogen then stored at -80 °C. For the analysis of nuclear RNA, the resuspension buffer was 
supplemented with 40 U/ml of RNasin (Promega). 
 
 
2.3.4 Fluorescence activated cell sorting (FACS) 
In order to focus on neurons, a procedure was developed to sort neuronal from glial nuclei 
using FACS on the basis of expression of the neuronal nuclear marker (NeuN). Frozen total 
brain nuclei were thawed, pelleted (600 g, 5 min, 4 °C) and resuspended in 1 ml of blocking 
solution (1 x PBS supplemented with 1.5% (v/v) fetal calf serum (Hyclone), 10 mM sodium 
butyrate and complete protease inhibitors (Roche)) and incubated for 15 min at RT. At this 
stage 20 µl was removed and kept at 4 °C as an ‘unsorted’ population. NeuN antibody was 
added at 1:500 dilution and MeCP2 antibody (Upstate 07-013) was added at 1:200 dilution. 
Nuclei were incubated at 4 °C for 2 h rotating on a wheel. Nuclei were washed with 3 x 1 ml 
blocking solution for 5 min and then incubated with secondary antibodies at 1:1000 dilution 
for 1 h at 4 °C rotating on a wheel. Nuclei were washed as before and then used for FACS. 
Recovered nuclei were pelleted as before and then used for future experiments. 
 
This protocol was also modified to include a crosslinking step. Before staining, the pelleted 
nuclei were resuspended in 1ml 1 x PBS supplemented with 1% formaldehyde and incubated 
at RT for 10 min. The formaldehyde was quenched by adding glycine to a final 
concentration of 125 mM. The nuclei were pelleted and resuspended in 1 ml blocking 
solution and the staining procedure continued as above. 
 
2.3.5 Preparation of mouse samples for protein analysis 
For western blot analysis of mouse samples either intact tissues or isolated nuclei were used. 
In the case of intact tissues, three mouse brains were dissected, pooled and then 




MgCl2, 0.1% (v/v) Triton-X-100, 1 mM DTT, 20% (v/v) Glycerol and complete protease 
inhibitors (Roche)) using a 5 ml dounce (Braun). The homogenate was added directly to 
protein loading buffer then mixed vigorously and boiled for 7 min. This was then used 
directly for gel electrophoresis. 
 
Isolated nuclei in resuspension buffer were added directly to protein loading buffer then 
mixed vigorously and boiled for 3 min. This was then used for gel electrophoresis. 
 
2.4 DNA manipulation and cloning 
2.4.1 Genomic DNA extraction 
Nuclei were prepared from the mammalian tissue (see section 2.3.3). Typically 10 x 10
6
 
nuclei were used per DNA preparation, resulting in approximately 60 µg of DNA. Nuclei 
were pelleted by centrifugation (330 g, 5 min, 4 °C) and then gently resuspended in a buffer 
containing 50 mM Hepes (pH 7.9), 10 mM EDTA, 5 mM EGTA, 0.5 µg/µl proteinase K,  
0.5 µg/µl RNaseA. After resuspension, NaCl and SDS were added to a concentration of  
300 mM and 1% respectively, in a total volume of 300 µl. The extraction was allowed to 
proceed for 6 h at 55 °C with occasional gentle agitation. To extract the proteins an equal 
volume of phenol: chloroform: isoamyl alcohol (25:24:1) was added and mixed by shaking. 
The upper aqueous layer was removed and DNA precipitated by the addition of 3 volumes of 
ethanol, with the addition of 20 µg of glycogen (Roche) as a carrier. The DNA pellet was 
subsequently washed in 70% (v/v) ethanol. The DNA pellet was air dried and resuspended in 
typically 100 µl TE buffer. 
 
2.4.2 Measurement of DNA concentration 
DNA solutions were measured at OD260nm and OD280nm using a Nanodrop-1000 
spectrophotometer. An automated reading of DNA concentration was calculated using 
Beer’s law (Concentration ng/ul = (Absorbance_OD260nm x Extinction coefficient dsDNA  
50 ng/µl/cm) / pathlength cm). DNA purity was determined using OD260nm:OD280nm ratio, 





2.4.3 Restriction digestion 
DNA digest was carried out as per manufacturer’s instructions (New England Biolabs). 
Briefly, DNA was diluted in the appropriate buffer, with 100 µg/ml of bovine serum albumin 
(BSA) as required and digested with 6 units of enzyme per µg of DNA. Reactions were 
typically allowed to proceed for 1-2 h at 37 °C. 
2.4.4 DNA electrophoresis 
DNA was resolved by agarose gel electrophoresis using the Sub-cell system (Bio-Rad). 0.8-
2% (w/v) agarose gels were used depending on the DNA fragment(s) size to be resolved. 
Agarose gels were prepared with TAE or TBE containing 0.5µg/ml ethidium bromide. DNA 
samples and an appropriate DNA size ladder (New England Biolabs/Fermentas) were 
prepared in orange G loading buffer and were loaded. Agarose gels were run at constant 
voltage (75-110V) in electrophoresis buffer and visualised under UV light. Where 
electrophoresed DNA was to be further manipulated, UV exposure was kept to a minimum 
to prevent damage. 
 
2.4.5 Gel extraction of DNA 
Gel extraction was used to purify a homogeneous population of DNA fragments for cloning. 
Fragments were resolved by agarose gel electrophoresis in 1 x TAE buffer, visualised under 
UV and precisely cut out using a scalpel. The gel slice was placed on dry ice for 20 min and 
then centrifuged (16000 g, 20 min, RT). The resulting liquid was subsequently used for 
further applications. 
 
2.4.6 Standard polymerase chain reaction (PCR) 
The conditions of the PCR were determined for each primer pair and also depended on the 
aim of the experiment. Typically, reactions were performed in a volume of 20 µl containing 
~50 ng of genomic DNA as a template, 250 nM of both forward and reverse primer, 1 x Red 
Hot PCR buffer (Abgene), 400 nM dNTPs (Abgene) and 1 unit Red Hot Taq (Abgene). 
Exact composition of the PCR and cycling parameter depended on the primer pair and aim of 
the experiment. For example, in the testing of primer pairs for real-time PCR, 3 mM MgCl2 
was added and typical cycling conditions were as follows: an initial denaturation at 96 °C for 
2 min followed by 35 cycles of (1) 96 °C for 30 s; (2) 60 °C for 30 s; (3) 72 °C for 30 s. In 




each primer pair, however, as a starting point these typical conditions were employed: 2.5 
mM MgCl2, 3% (v/v) DMSO and cycling parameters were as follows: an initial denaturation 
at 94°C for 2min followed by 40 cycles of (1) 94°C for 50 s; (2) annealing temperature for  
50 s; (3) 72°C for 50 and then an additional 72°C extension phase for 5 min. 
 
Depending on the purpose of the experiment, some or all of the PCR was resolved by 
agarose gel electrophoresis and visualised under UV. 
 
2.4.7 Real-time PCR 
Each PCR was performed in a 20 µl reaction volume containing (1) 250 nM of both forward 
and reverse primers; (2) 5 µl of the template diluted in 0.1 x TE; (3) 10 µl of 2 x Quantace 
Sensimix Plus. Real time PCR was carried out using with a Roche Lightcycler according to 
manufacturer’s instructions with the following cycling parameters: an initial denaturation at 
96 °C for 10 min followed by 45 cycles of (1) 96 °C for 10 s; (2) 60 °C for 10 s; (3) 72°C for 
15 s (with a single acquisition at 522 nm taken at the end of the extension phase); (4) melt 
curve analysis by increasing the temperature from 60 °C to 95 °C at a rate of 0.29 °C/s with 
continuous acquisitions). 
 
Cycle threshold (Ct) values were determined by the second differential maximum method as 
calculated by the Roche Lightcycler software. An arbitrary measure of DNA quantity (Q) 




2.4.8 Bisulphite sequencing of DNA 
This technique was employed to determine the DNA methylation status in two main 
applications: (1) analysis of genomic DNA and (2) analysis of immunoprecipitated DNA. In 
the case of genomic DNA analysis, 2-5 µg of DNA was either digested with a restriction 
enzyme that cleaved outside the region of interest (typically EcoR1) and then subsequently 
ethanol precipitated. DNA was resuspended in 25µl TE buffer. Otherwise the genomic DNA 
was lightly sonicated in using a Diagenode Bioruptor (10 s, maximum power) and 2-5 µg of 





In the analysis of immunoprecipitated DNA, the DNA was fragmented during the chromatin 
immunoprecipitation protocol. Typically, 1-2 µg of input DNA and an entire 
immunoprecipitation was used in a volume of 25 µl 0.1 x TE buffer for bisulphite treatment. 
 
The DNA and denatured at 100 °C for 5 min and then snap cooled on ice. To aid 
denaturation, 2.5 µl of freshly prepared 3 M NaOH was added to the DNA and incubated at 
37 °C for 20 min. Bisulfite modification solution was freshly prepared as follows: 3.8 g 
sodium hydrogen sulphite (NaHSO3) was mixed gently in 5 ml H2O and 1.5 ml 2 M NaOH 
(protected from light). 110 mg hydroquinone was dissolved in 1 ml H2O at 55 °C for ten 
minutes. The sodium bisulphite and the hydroquinone solutions were then mixed. 270µl of 
bisulfite modification solution was added to the denatured DNA and then overlayed with 
200µl of mineral oil. The bisulphite treatment was incubated at 55 °C for 5 h in the dark 
prior to isopropanol precipitation supplemented with 50 µg glycogen (Roche) as carrier. 
DNA was resuspended in 25 µl and desulphonated by the addition of 2.5 µl of freshly 
prepared 3 M NaOH and incubation at 37 °C for 15 min. The DNA was ethanol precipitated 
in the presence of ammonium acetate and resuspended in 30µl of TE. 
 
Typically 2µl bisulfite-treated DNA was used in a standard Red Hot PCR reaction. 
Bisulphite-specific primers were designed with the aid of Methprimer 
(www.urogene.org/methprimer/index1.html). 
 
PCRs were resolved by agarose gel electrophoresis (TAE), gel extracted and PCR cloned. 
The cloning reaction was transformed into StrataClone Solo Pack Competent Cells 
(Stratagene) according to the manufacturer’s instructions. Transformed cells were spread 
onto blue/white selection ampicillin LB agar plates. 
 
Colonies harbouring plasmids containing inserts were identified by blue/white screening 
(insertion into the cloning site disrupts the α-fragment of β-galactosidase). Inserts were PCR 
amplified from single colonies by transferring some cells with a pipette tip into a 20 µl Red 
Hot PCR reaction containing M13-phage primers flanking the vector insert site. 5µl of each 
PCR was resolved by agarose gel electrophoresis to confirm that cloned fragments were of 
the correct size. The remaining 15 µl of the PCRs were incubated with 5 units of 
Exonuclease I and 5 units of Antartic Phosphatase (New England Biolabs) for 15 min at  




Sequencing reactions contained 3.5 ul of the treated PCR product, 4 µl 2.5 x DNA 
sequencing buffer, 5 pmol M13 sequencing primer (forward) and 2 µl BigDye Terminator 
v3.1. The reactions were incubated under the following conditions: initial DNA denaturation 
at 96°C for 10secs, then 24 cycles (1) 96 °C for 30 s; (2) 50 °C for 20 s; (3) 60°C for 4min. 
Sequencing reactions were cleaned up and were run on an ABI 3730 capillary sequencer by 
the School of Biological Sciences Sequencing Service. Sequence data was quality controlled 
and analysed using Chromas Lite and Lasergene software respectively.  
 
Bisulfite genomic sequencing data was analysed using the BiQ_Analyzer software package 
(Bock et al., 2005). 
 
2.5 Protein manipulation 
2.5.1 SDS-Polyacrylamide gel electrophoresis (PAGE) 
Samples were diluted in protein loading buffer and boiled for 3 min at 100 °C. 0.75 mm 
thick gels were assembled in a Bio-rad Mini Protean-3 apparatus according to the 
manufacturer’s instructions. Stacking gels (pH 6.8) contained 4.3% (w/v) acylamide:bis-
acrylamide (29:1; Bio-rad) and separating gels (pH 8.8) contained 7-20% (w/v) 
acylamide:bis-acrylamide (29:1; Bio-rad) depending on the size of the proteins of interest. 
Both gels contained 0.1 (w/v) SDS and the acrylamide was polymerised with the addition of 
ammonium persulphate and TEMED as a catalyst. Samples were loaded along with 
Fermentas pre-stained markers. Electrophoresis was carried out at 120 V in Tris-glycine 
buffer. 
2.5.2 Coomassie blue staining of proteins 
For direct visualisation of proteins the SDS-PAGE gel was incubated with fresh Coomassie 
blue stain for 1 h with gentle mixing. Excess stain was removed with H20 and then incubated 
in Coomassie destain solution with mixing until the protein bands were revealed. The gel 
was then rinsed in water. Quantification of protein bands was performed using the Licor 






2.5.3 Recombinant proteins as standards 
Protein Source; Cat no. Notes 
MeCP2 Gift from R. J. Klose Full length untagged wildtype MeCP2 
(NM_004992.3) was expressed and 
purified using a baculovirus expression 
system. 
Histone H4 New England 
Biolabs; M2504S 
 
Table 2.2 – List of recombinant proteins used as standards 
 
Recombinant MeCP2 and histone H4 was used to quantify the absolute abundance of these 
proteins in isolated nuclei. SDS-PAGE with coomassie staining was used to determine the 
concentration of recombinant MeCP2 by comparison to a known concentration of BSA 
(New England Biolabs). 
 
2.5.4 Wet transfer of proteins to a membrane 
Wet transfer was carried out using a Bio-rad Mini trans-blot cell according to the 
manufacturer’s recommendations. Briefly, the transfer cassette was assembled in transfer 
buffer with 2 layers of 0.3 mm Whatman paper underneath the gel. A single layer of 
membrane (pre-soaked in transfer buffer) was placed on top of the gel followed by two 
further layers of Whatman paper. A constant current of 0.3 A for 1.5 h was used. After 
transfer the membrane was rinsed in H20 and then subjected to Ponceau S staining  
(2% Ponceau S (w/v), 30% (w/v) trichloroacetic acid, 30% (w/v) sulfosalicyclic acid) and 
then washed in PBS. 
 
Both nitrocellulose (0.4 µm pore size, Bio-rad) and PVDF (0.2 µm pore size, Bio-rad) 
membranes were used. Where PVDF was used, the membrane was first wetted in methanol 
and the transfer buffer was supplemented with 20% (v/v) methanol. 
2.5.5 Western blotting 
For most antibodies the following western blot procedure was used. After a 1 hour block in a 
5 % milk (w/v), 1 x TBS solution at RT, fresh blocking solution containing a dilution of the 
primary antibody was applied. The primary antibody was incubated overnight at 4 °C 
followed by four consecutive 15 min washes in a PBST solution (1 x PBS, 0.1% (v/v) 
Tween-20). The membrane was then incubated in the blocking solution for 20 min after 




a 5 % milk, 1 x TBS solution for one hour at RT. Four consecutive 15 min washes in a PBST 
solution were followed by four quick rinses in 1 x PBS. For HRP-conjugated secondary 
antibodies the membrane was then placed in a freshly prepared equal volume mixture of 
ECL solution 1 (2.5 mM luminol, 0.396 mM p-coumeric acid, and 100 mM Tris-HCl pH 
8.5) and solution 2 (5.6 mM H2O2, 100 mM Tris-HCl pH 8.5) for one minute. The blot was 
wrapped in a single layer of saran wrap and exposed to ECL Hyper-film (Amersham 
Biosciences). For IR-dye conjugated secondary antibodies, the bands were visualised using 
the Licor Odyssey imaging system. Quantification was performed using NIH ImageJ or 
Licor Odyssey software. The Kolmogorov-Smirnov (KS) test was used to test for statistical 
significance between samples, with the statistical software R (version 2.9.1) being used for 
the analysis. The KS test is a non-parametric test of equality of one-dimensional probability 
distributions used to compare two samples. Assistance in statistical analysis was provided 
from Dr A. Kerr. 
 
For typical dilutions of antibodies used in western blotting see section 2.2 
 
2.6 Analysis of chromatin 
2.6.1 Standard chromatin immunoprecipitation (ChIP) 
Throughout the protocol buffers were supplemented with complete protease inhibitors 
(Roche Applied Science) and 10 mM sodium butyrate. Frozen mouse tissues were thawed 
quickly in 2.5 ml 1 x PBS and homogenised using a 5 ml dounce (Braun; 5 strokes). 
Homogenate was pelleted (1000 g, 3 min, 4 °C) and then crosslinked in 10 ml PBS 
containing 1% formaldehyde for 10 min at room temperature. Crosslinking was quenched by 
adding glycine to a final concentration of 125 mM. The homogenate was pelleted as before 
and then washed in ice-cold PBS. The homogenate was then pelleted and resuspended in  
1.4 ml lysis buffer (50 mM Tris-HCl (pH 8.1), 1% (w/v) SDS, 10 mM EDTA) and incubated 
on ice for 10 min. For each immunoprecipitation, 140 µl (~10 x 10
6
 cells) was taken, and 
1260 µl dilution buffer added (20 mM Tris-HCl (pH 8.1), 150 mM NaCl, 2 mM EDTA,  
1% (v/v) Triton X-100, 3 mM CaCl2, 10 mM MgCl2). Chromatin was incubated with 3 U 
Micrococcal nuclease (Fermentas) at room temperature for 17 min and stopped by adding 
EDTA and EGTA to a final concentration of 10 mM and 20 mM respectively. Chromatin 
was further fragmented by sonication for 3 min (Branson digital sonifier). Overall, chromatin 




centrifugation (16000 g, 10 min, 4 °C) and the chromatin pre-cleared with 50 µl protein A 
sepharose (GE Healthcare) that had been previously washed and blocked with 1 mg/ml 
tRNA and BSA. 
 
The beads were pelleted gently and the supernatant was used for immunoprecipitations 
(1200 µl) and input (200 µl). Antibodies were added to the supernatant (7 µl MeCP2 674 
antibody; 5 µl H3Ac Millipore) and rotated at 4 °C overnight. Precipitated debris was 
pelleted and the supernatant incubated with 25 µl blocked protein A sepharose for 1 h at 4 C. 
The beads were then washed for 4 min at room temperature using 1 ml of ice-cold buffers as 
follows: once in buffer 1 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 
mM Tris-HCl pH 8.1); four times in buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 
500 mM NaCl, 20 mM Tris-HCl pH 8.1); once in buffer 3 (250 mM LiCl, 1% NP-40, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1); and three times in TE buffer (10 mM 
Tris-HCl pH 7.5, 1 mM EDTA). Between washes the beads were pelleted by centrifugation 
for 1 min at 3000 g. Immunocomplexes were then eluted with 200 µl of extraction buffer 
(1% SDS, 100 mM NaHCO3), by incubation at 55 °C for 20 min and placed on a shaking 
platform for 20 min. The eluate was collected by passing the slurry through a QIAShredder 
column (Qiagen) and cross-links were reversed by adding 5 M NaCl to a final concentration 
of 300 mM, followed by incubation at 65 °C overnight.  
 
DNA was extracted by the supplementing the extraction buffer with 50 mM Tris-HCl (pH 
7.5), 8 mM EDTA, 40 µg proteinase K and 40 µg RNaseA. This was further incubated at  
55 °C for 1 h. Proteins were removed by the phenol extraction and the DNA precipitated by 
the addition of 3 columns of ethanol with 20 µg of glycogen as a carrier. DNA pellets were 
washed in 70% ethanol. Isolated DNA from both immunoprecipitations and inputs were 
either resuspended in 300 µl 0.1 x TE for real time PCR analysis (5 µl / PCR) or 25 µl for 
bisulfite treatment. 
 
Real time PCR was carried out as described in section 2.4.7. % IP / Input was calculated 




) and factoring in the 6-fold difference in 
volume of sheared chromatin supernatant used for input and immunoprecipitation and 





2.6.2 Salt wash ChIP protocol 
A modified version of the standard ChIP protocol where isolated nuclei were incubated in a 
salt solution prior to crosslinking was used in order to liberate bound proteins. An aliquot of 
approximately 60 x 10
6
 isolated nuclei was and thawed on ice, split into four tubes and then 
pelleted by centrifugation (400 g, 5 min, 4 °C). The aliquots of pelleted nuclei were then 
resuspended in 500 µl extraction buffer (20 mM Hepes (pH 7.9), 0.1 mM EDTA, 1 mM DTT 
and complete protease inhibitors (Roche)) supplemented with either 150 mM NaCl or 300 
mM NaCl. A 30 µl sample was taken and kept for protein analysis. The extraction was 
allowed to proceed for an various durations at RT. At the end of the allotted time, 500 µl of 
crosslinking buffer was added (1 x PBS, 2% formaldehyde) and incubated for 10 min at RT. 
Glycine was added to a concentration of 125 mM to quench the formaldehyde. Nuclei were 
pelleted by centrifugation (700 g, 5 min, 4 °C) and then resuspended in 470 µl 1 x PBS with 
complete protease inhibitors (Roche). At this point a second 30 µl sample was taken for 
protein analysis. The nuclei were pelleted again (700 g, 5 min, 4 °C) and resuspended in  
140 µl ChIP lysis buffer and the protocol continued as before (see section 2.6.1). 
 
2.6.3 Micrococcal nuclease laddering 
The striatum granulosum of the dentate gyrus was dissected as previously described in 
section 2.3.2. Tissues were homogenised in 150 µl of ice-cold NE1 buffer (20 mM HEPES-
KOH (pH 7.9), 10 mM KCl, 1 mM MgCl2, 0.1% (v/v) Triton-X-100, 1 mM DTT, 20% (v/v) 
Glycerol and complete protease inhibitors (Roche)) using a polypropylene pestle (Sigma-
Aldrich Z359947) directly within the eppendorf. Nuclei were isolated by centrifugation  
(500 g, 5 min, 4 °C) and resuspended in 500 µl MNase buffer (5 mM Tris-HCl (pH 7.5), 80 
mM NaCl, 1 mM CaCl2, 0.2 M sucrose and complete protease inhibitors (Roche)). Limited 
MNase treatment was performed by the addition of 8 units of MNase (Fermentas). A 
timecourse of digestion was performed by taking 40 µl of the reaction and stopping the 
reaction with the addition of 260 µl Stop buffer (11 mM Tris-HCl (pH7.5), 11 mM EDTA, 
22 mM EGTA, 333 mM NaCl, 1.1% SDS (w/v), 0.5 µg/µl proteinase K, 0.5 µg/µl RNaseA). 
DNA was phenol extracted and ethanol precipitated. Isolated DNA was resuspended in 20 µl 
of water. DNA was treated with Antartic phosphatise (NEB) and then subsequently end-
labelled with γ-
32
P-ATP by the addition of T4 polynucleotide Kinase (NEB). Unincorporated 
ATP was removed by passing the sample through a G-50 column (GE Healthcare). DNA 
was resolved by agarose gel electrophoresis (1.3% (w/v) in Tris-glycine buffer) and 




2.7 High-throughput sequencing 
Assistance in high-throughput sequencing and bioinformatic analysis was gratefully received 
from Dr Rob Illingworth, Shaun Webb, Dr Alastair Kerr. Sequencing was performed in 
collaboration with the Wellcome Trust Sanger Institute, United Kingdom 
 
2.7.1 Preparation of ChIP DNA for Solexa sequencing 
For high-throughput sequencing of MeCP2 bound chromatin (MeCP2 ChIP-seq)  
six independent MeCP2 immunoprecipitations were performed from a single mouse brain 
then subsequently pooled. The DNA was end repaired by incubation at 20 °C for 30 min 
with 3 units of T4 DNA Polymerase (New England Biolabs (NEB)), 10 units of 
Polynucleotide Kinase (NEB), 2 units DNA Polymerase I Large (Klenow) fragment (NEB), 
1x T4 DNA ligase reaction buffer (NEB) and 400 nM dNTPs. The enzymes were then heat 
inactivated at 75 °C for 20 min, after which the DNA was ethanol precipitated. A tail of 'A' 
bases was added to the 3’ ends of the DNA by incubation with 5 units Klenow Fragment (3’-
5’ exo-; NEB), 200 nM dATP and 1x buffer 2 (NEB) at 37 °C for 30 min. The enzymes were 
heat inactivated and cleaned up as before. Illumina paired end adaptors were then ligated to 
the processed ChIP DNA by incubation with 300 units of T4 DNA ligase (NEB), 1x T4 
DNA ligase buffer (NEB), 7.5% PEG-6000 and 2 pmol of annealed Illumina adaptors for 3 h 
at room temperature. Ligated DNA was purified using MinElute PCR columns (Qiagen) and 
eluted in 10 µl water. This protocol was gratefully developed by Dr Rob Illingworth. 
 
2.7.2 Methyl-DNA specific chromatography 
Dr Rob Illingworth gratefully donated data indicating the genome-wide distribution of 
meCpG in mouse cerebellum. Only a brief description of the protocol will be described here, 
for more detailed information see ((Illingworth et al., 2008) and Illingworth et al., 
manuscript in preparation). 
 
75 µg of mouse cerebellum genomic DNA (C57Bl6) was sonicated to an average length of 
400 bp (Branson digital sonifier). The fragmented DNA was end repaired and Illumina 
paired end adaptors were ligated. The ligated DNA was separated into two 35 µg aliquots 
and purified independently to enrich for sequences containing methylated CpGs as 
previously described (Illingworth et al., 2008). Briefly, the ligated DNA was fractionated 




MeCP2. DNA tightly retained by the methyl-affinity matrix (NaCl >700 mM) was passed 
over the affinity column for a second time increase binding specificity. The volume of 
purified DNA was reduced to 200 µl using an Amicon Ultra 30 kDa centrifugal filter (30,000 
NMWL columns; Millipore) and subsequently ethanol precipitated. 
 
2.7.3 Library preparation and Illumina Solexa sequencing 
Illumina Solexa sequencing was used as a technique to produce high-throughput sequence 
data for the DNA recovered from MeCP2-ChIP and methyl-DNA specific chromatography. 
Briefly, specific adaptors are ligated on to the ends of the recovered DNA. The ligated DNA 
is bound to complementary immobilised adaptors on a flow cell, after which amplification 
results in the generation of clusters of DNA molecules with the same sequence. These 
clusters are then sequenced. 
 
Ligated DNA was amplified by 10-12 cycles of PCR with primers complementary to the 
adaptor sequences and Phusion 2x premix (Finnzymes). The DNA was purified using 
QIAquick PCR Purification columns (Qiagen) and library fragments of >200 bp (insert plus 
adaptor and PCR primer sequences) were isolated by gel extraction. The purified DNA was 
captured on an Illumina flow cell for cluster generation. Libraries were sequenced on the 
Genome Analyzer following the standard Illumina protocol to generate 37 bp reads using a 
Solexa sequencer. Single-end sequence reads were mapped to the mouse genome 
(NCBIm37) using MAQ (http://maq.sourceforge.net/). Reads with a mapping score greater 
or equal to 30 where retained. For MeCP2 ChIP-seq seven independent lanes of sequence 
were generated and the results from these were combined. For high-throughput sequencing 
of methylated sequences (MBD-seq) 2 lanes of sequence were generated and the results from 
these were combined (R. Illingworth, manuscript in preparation). 
 
2.7.4 Analysis of high-throughput sequencing 
Assistance in high-throughput sequencing and bioinformatic analysis was gratefully received 
from Dr Rob Illingworth, Shaun Webb, Dr Alastair Kerr. Sequencing was performed in 
collaboration with the Wellcome Trust Sanger Institute, United Kingdom. CpG density 
calculations were performed on the ensEMBL repeat masked version of the mouse NCBI 
build 37 genome. Sliding window analysis was employed to count observed CpGs, ignoring 




parameters have been used to produce a measure of MeCP2 hits per window across the 
mouse genome, according to mapped Solexa sequenced reads. Genome wide levels of 
methylation have been traced by further applying the sliding window to mouse cerebellum 
MBD-seq data. An inner join, on relative sets of data, pairs windows with identical co-
ordinates to form a relationship between observed CpG, MeCP2 reads and MBD reads 
across the mappable genome. For visualisation genomic intervals and values have been 
translated in to wiggle files and displayed via the Integrated Genome Browser. 
 
To determine the level of MeCP2 binding to methylated CpG islands the methylated CpG 
rich fraction of the mouse genome was defined using MBD-seq data for cerebellum as 
outlined above. Methylated CGIs were identified by intersecting a repeat masked NCBI 
CGI-strict dataset with regions of high MBD-seq enrichment (>4 reads per base that span at 
least 90 bp and with a maximum gap of 250 bp). Sliding window analysis was employed to 
count MeCP2 reads across 5 kb domains centred upon the midpoint of each methylated CGI 
(500 bp window with a 100 bp slide). 
 
2.8 RNA manipulation and expression analysis 
2.8.1 RNA extraction from whole tissues 
Brains were dissected and snap frozen in liquid nitrogen then stored at -80 °C until use.  
Tri-Reagent (Sigma-Aldrich) was used according to the manufacturer’s instructions. Briefly, 
a single frozen brain was homogenised in 5 ml Tri-Reagent using a Polytron (15 s, maximum 
power; Janke and Kunkel). The homogenate was spun centrifuged (15 min, 1800 g, RT). The 
upper fatty layer was removed and the remaining homogenate was incubated at RT  
for 5 min. 1 ml of chloroform was added, mixed vigourously and incubated for 10 min  
at RT. The aqueous phase (RNA) was resolved from the organic phase (DNA and proteins) 
by centrifugation as above. To precipitate the RNA, the aqueous phase was transferred to a 
tube containing 2.5 ml isopropanol, mixed and allowed to stand for 10min at RT. RNA was 
pelleted by centrifugation as above, washed with 5 ml 70% (v/v) ethanol, air dried and 
resuspended in 500 µl of nuclease free water (Ambion). 10 µg RNA was DNase1 treated 
using RNase-free DNase1 (RQ1 Promega) according to the manufacturer’s 
recommendations with the addition of 40 units RNasin (Promega). RNA was phenol 





2.8.2 RNA extraction from isolated nuclei 
Typically 6 x 10
6
 isolated nuclei were used per RNA preparation. Nuclei were lysed in 
extraction buffer (30 mM Tris-HCl (Ph 7.5), 300 mM NaCl, 10 mM EDTA, 1% SDS,  
0.5 mg/ml proteinase K, 0.2 units/µl RNAsin). The extraction was allowed to continue for 40 
min whilst being incubated at 37 °C, after which RNA was extracted using 500 µl acid 
phenol (pH ) and precipitated using iso-propanol. The isolated RNA was resuspended in 100 
µl nuclease free water (Ambion) supplemented with 40 units of RNasin (Promega). The 
RNA was DNase1 treated using the Ambion DNA-free system according to the 
manufacturer’s recommendations. 
 
2.8.3 RNA electrophoresis 
In a crude assessment of RNA integrity, the purified RNA was resolved by gel 
electrophoresis to confirm the presence of sharp bands corresponding to the ribosomal 
RNAs. RNA was resolved by agarose gel electrophoresis using the Sub-cell system (Bio-
Rad). In an attempt to reduce the presence of ribonucleases the apparatus was cleaned using 
RNase-Zap (Ambion). 1.8% (w/v) agarose gels were prepared with 1 x TBE containing 
0.5µg/ml ethidium bromide. RNA samples and an appropriate size ladder (New England 
Biolabs/Fermentas) were prepared in orange G loading buffer and were loaded. Agarose gels 
were run at 80 V voltage in electrophoresis buffer and visualised under UV light 
 
2.8.4 cDNA synthesis 
Typcially 2 µg of the RNA was synthesized into cDNA in a total volume of 50 µl. Initially 
the purified RNA was incubated with 5 nM random hexamers (Roche) at 70 °C for 5 min. 
The RNA was then snap cooled on ice and 13.5 µl of RT-mix added (RT buffer (Promega),  
1.25 mM dNTPs (Abgene), 40 units RNAsin (Promega)) and then incubated at RT for 5 min. 
Subsequently, 200 units of m-Moloney murine leukemia virus reverse transcriptase 
(Promega) were added. In addition a minus (-)RT reaction was set up in parallel containing 
all the components except for the reverse transcriptase to control for DNA contamination by 
PCR. The reactions were incubated as follows: (1) 25 °C, 10 min; (2) 37 °C, 60 min;  
(3) 70 °C, 10 min. The 50 µl reactions were then typically diluted 4-fold in H20 and stored  





Chapter 3 MeCP2 Abundance and Distribution 
3.1 Introduction 
To my mind, research into the function of MeCP2 has to be guided by the disease 
phenotypes associated with alteration in the expression of MeCP2. In humans, a large range 
of mutations in the MECP2 gene are associated with the neurodevelopmental disorder Rett 
syndrome, which is generally considered to be the result of loss of function of MeCP2 (Amir 
et al., 1999). However, chromosomal rearrangements which result in the duplication of the 
region encoding the MECP2 gene also result in a distinct neurological phenotype (Lubs et 
al., 1999). These observations have been closely mirrored in mouse models, where loss of 
Mecp2 expression or indeed expression of a truncated form, result in a neurological 
phenotype resembling Rett syndrome (Chen et al., 2001; Guy et al., 2001; Shahbazian et al., 
2002a). Additionally, only mild two-fold overexpression of MeCP2 results in a neurological 
condition (Collins et al., 2004; Luikenhuis et al., 2004). These experiments suggest that the 
precise expression level of MeCP2 is critical to its function. This is born out by recent 
studies suggesting that the regulation of the MECP2 gene is under the control of a great 
number of factors (for review see (Singh et al., 2008). Additionally, the levels of MeCP2 
protein appear to be also modulated through post-transcriptional control via microRNAs in 
response to neuronal activity (Klein et al., 2007). 
 
From these observations, a greater understanding of the expression pattern of MeCP2 may 
provide insight into its function. The neurological phenotypes associated with the 
perturbation of both the human and mouse genes is consistent with the early observations 
that MeCP2 is particularly abundant in the brain (Lewis et al., 1992; Nan et al., 1997). This 
is again indicated by mouse genetic studies that revealed a brain-specific knockout of 
MeCP2 was equivalent to the null animals (Chen et al., 2001; Guy et al., 2001). The late 
onset of these phenotypes is paralleled with a developmental increase in MeCP2 expression 
in the brain (Balmer et al., 2003; Kishi and Macklis, 2004; Shahbazian et al., 2002b), 
suggesting that failure to express MeCP2 to the high levels later in development is key to the 
symptoms. Immunofluorescence experiments performed on mature mice suggested that 
MeCP2 was primarily expressed within the nucleus of neuronal cells and absent from glial 
nuclei (Kishi and Macklis, 2004). Accordingly, a mouse model expressing MeCP2 under the 
Tau promoter, which is primarily neuron-specific, rescued the null animals (Luikenhuis et 





These observations highlight that the precise high abundant level of expression within 
mature neurons is key to the function of MeCP2, correspondingly, failure of this results in 
late-onset neurological symptoms. From this standpoint, a precise understanding the absolute 
abundance of MeCP2 in neurons of mature mice was required. 
 
3.2 Timecourse of MeCP2 expression 
Numerous studies have reported a developmental increase in MeCP2 expression in the 
mouse at both the RNA level (Shahbazian et al., 2002b) and the protein level as measured by 
immunofluorescence (Kishi and Macklis, 2004) and also in humans as measured by laser 
scanning ctyometry (Balmer et al., 2003). Despite these studies and the importance of 
MeCP2 expression in these associated late onset phenotypes, there is no clear quantitative 
data revealing a timecourse analysis of MeCP2 expression. Therefore, quantitative western 
blotting analysis was used to determine when during postnatal mouse development MeCP2 
reaches its maximal expression (Figure 3.1). Licor Odyssey near-infrared imaging was used, 
whereby the secondary antibody is conjugated to a proprietary fluorophore. This reportedly 
allows more accurate quantitation over a wider range than chemiluminescence based 
westerns (for more information please see company website). The majority of western blots 
were initially performed using chemiluminescence based detection, ensuring that the scope 
of intensities measured was within a small range and extrapolation was not required. Similar 






























Figure 3.1 – MeCP2 expression in the mouse brain increases dramatically after birth, reaching maximal 
protein levels at ~5 weeks of age. For each timepoint, three mouse brains were pooled and 
homogenised. The homogenate was added directly to Laemmli buffer and boiled for 7 min and used 
directly for gel electrophoresis. Samples were separated by SDS-PAGE and quantitative western 
blotting was performed for MeCP2 (Sigma Aldrich, Mec-168) and histone H3 as a loading control using 
infra-red imaging (Licor Odyssey). Molecular weight markers (kDa) are arrowed. Westerns were 
quantified and the data represented as % of maximal MeCP2 expression, normalised for differences in 
loading based on H3 quantification; error bars indicate +/- standard error of the mean (SEM). 
 
MeCP2 was weakly detectable in neonatal brain, but increased rapidly to reach a maximum 
at ~5 weeks of age, after which the total levels remained approximately constant. This is 
consistent with the mouse phenotypes associated with loss of MeCP2 expression displaying 
symptoms at 5-6 weeks, which ultimately leads to death between 6 and 12 weeks (Chen et 
al., 2001; Guy et al., 2001). From this analysis, an understanding of the function of MeCP2 
would more likely be gained by the use of mature mice, therefore for all subsequent 
experiments 6- to 8-week-old mice were used unless otherwise indicated. The developmental 
expression pattern of other MBD proteins was not investigated. 
 
3.3 FACS purification of neuronal nuclei 
Immunofluorescence experiments have indicated that MeCP2 is expressed predominantly in 
the neuronal nuclei, with much less present in glial nuclei (Kishi and Macklis, 2004). This is 
consistent with a mouse genetic model suggesting that the primary function is within neurons 
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developed to sort neurons from glia using fluorescence-activated cell sorting (FACS). It is 
imperative for FACS that a single particle suspension is produced. However, the ability to 
disaggregate all the cells from a mature mouse brain was questionable, as this is one of the 
reasons embryonic or neonatal mice are used for neuronal culture (Eide and McMurray, 
2005). As a result, the use of purified nuclei, of which a single particle suspension is easily 
obtainable, was investigated. Despite the use of nuclei limiting the number of available 
markers, the vast majority of neuronal nuclei are fortunately positive for staining by the 
neuronal nuclear marker NeuN, whereas glial nuclei are invariably negative (Mullen et al., 
1992). Due to the absence of a degenerate marker for glial nuclei, they can only identified by 
the absence of NeuN staining and therefore can not be formally identified as glia. As 
expected, NeuN staining of total brain nuclei gave a bimodal distribution comprising of 50% 
NeuN-positive nuclei (neurons) and 50% negative nuclei (predominantly glia) (Figure 3.2A). 
Staining of total brain nuclei for MeCP2 gave a similar bimodal distribution: 56% high and 
44% low MeCP2 staining, with an approximately 6-fold difference in staining intensity 
(Figure 3.2B). Sorting of nuclei on the basis of the NeuN staining purified a neuronal 
population and a predominantly glial population of nuclei (Figure 3.2C). As expected from 
published immunofluorescence experiments (Kishi and Macklis, 2004), NeuN-positive 
nuclei co-sorted with the population of nuclei expressing high levels of MeCP2 (Figure 
3.2C). This protocol was successfully used with both non-crosslinked and crosslinked nuclei 



































Figure 3.2 – FACS purification of isolated brain nuclei can be used to purify neuronal nuclei from glial 
nuclei on the basis of NeuN. Nuclei were isolated from wildtype whole mouse brain by homogenisation 
followed by centrifugation through a sucrose cushion. The single particle suspension of nuclei was 
FACS-stained for (A) NeuN and (B) MeCP2. C) Nuclei sorted for NeuN-negative and NeuN-positive 
staining co-sorted with low-MeCP2 and high-MeCP2 stained nuclei, respectively. The NeuN-negative 
nuclei are marked as “glial” nuclei, as no positive identification was used. Assistance in FACS was 
gratefully received from Andrew Sanderson and Martin Waterfall. 
 
FACS analysis also allows an analysis of size, as measured by forward scatter, and internal 
complexity, as measured by side scatter. Isolated total brain nuclei displayed a diverse range 
of both size and internal complexity (Figure 3.3). Sorting of nuclei on the basis of NeuN 
staining identified that whilst the neuronal nuclei maintained this heterogeneous range in 
nuclear morphology they were on average larger and more complex than the predominantly 




























Figure 3.3 – Neuronal nuclei display a heterogeneous morphology, whereas the glial nuclei had a 
homogenous morphology. FACS staining of isolated brain nuclei and purification was performed as 
described in Figure 3.2. The morphology of the nuclei populations was investigated for size, as 
indicated by forward scatter (y-axis) and internal complexity side scatter (x-axis). Assistance in FACS 
was gratefully received from Andrew Sanderson and Martin Waterfall. 
 
The FACS sorted nuclei were isolated and the purification verified by quantitative infra-red 
western blotting (Figure 3.4A). Analysis of NeuN levels confirmed that the neuronal nuclei 
were greatly enriched for this marker, whilst it was almost absent in the “glial” population. 
Analysis of MeCP2 levels indicated 7-fold more MeCP2 in the neuronal population than in 
the predominantly glial population (Figure 3.4A and B), similar to the difference in staining 










Figure 3.4 – Neuronal nuclei are enriched for both NeuN and MeCP2 relative to glial nuclei. Nuclei 
isolated from total brain were FACS sorted on the basis of NeuN staining (A) Infra-red western blotting 
for NeuN, MeCP2 (Sigma Aldrich, Mec-168) and histone H3 (as a loading control) was performed on 
unsorted nuclei and nuclei recovered from FACS sorting. (B) The graph indicates quantification of 
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As a further verification of the FACS based purification technique and its further potential 
uses, sorted crosslinked nuclei were used for MeCP2 ChIP analysis. However, the choice of 
a known binding target was limited, due to the lack a of clear consensus within the literature 
(for example (Horike et al., 2005; Schule et al., 2007)). The major satellite repeat can be 
considered as a known binding target as localisation studies have indicated the methylation 
dependent binding of MeCP2 to the pericentromeric heterochromatin (Nan et al., 1996). As a 
result, the unsorted and sorted populations were investigated for MeCP2 binding to this 
repeat (Figure 3.5). Consistent with the western blot analysis, neuronal nuclei showed 
elevated levels of MeCP2 binding relative to unsorted nuclei, whilst the predominantly glial 
fraction was depleted for binding. The magnitude of the difference did not however strictly 
correlate between techniques, with the ChIP data indicating ~20-fold greater binding in 
neurons and than glia (Figure 3.5), compared to a 7-fold difference in MeCP2 protein levels 
(Figure 3.4). This may suggest that the distribution of MeCP2 does not strictly correlate with 












Figure 3.5 – FACS sorted neuronal nuclei show increased binding of MeCP2 to the major satellite 
repeat compared to glial nuclei. (A) Total wildtype brain nuclei were crosslinked using formaldehyde 
and then FACS sorted on the basis of NeuN staining into neuronal and predominantly glial fractions. 
Unsorted and sorted populations were used for ChIP with an antibody against MeCP2 (674) or with 
pre-immune serum as a negative control (see section 4.2 for verification of the antibody and discussion 
of the protocol). Immunoprecipitated DNA was analysed by real-time PCR using primers against the 
major satellite repeat. ChIP data is represented as % immunoprecipitation (IP) / Input. Error bars 
indicate mean ± SEM. Primers were designed by Xinsheng Nan. (B) A schematic of the 234 bp mouse 
major satellite repeat is indicated: the blue vertical lines mark the position of CpG sites; black arrows 
mark the position of the primers used for real-time PCR analysis; a scale bar is indicated. A melting 













































3.4 Quantification of absolute MeCP2 levels 
The precise abundance of MeCP2 seems to be tightly regulated and key to its function (see 
section 3.1 for discussion). As a result, the absolute abundance of MeCP2 was determined. 
The concentration of recombinant MeCP2 was determined by titration against a bovine 













Figure 3.6 – The concentration of recombinant MeCP2 was determined by quantification against a BSA 
standard. A titration of a known concentration of BSA was compared to recombinant MeCP2 protein by 
SDS-PAGE and subsequent coomassie staining. The graph depicts densitometry analysis using Licor 
Odyssey imaging. The positions of molecular weight markers (kDa) are indicated. The recombinant 
MeCP2 was a kind gift from R. J. Klose. Error bars indicate mean +/- SEM from two SDS-PAGE 
experiments. Linear co-efficients (R
2
) for BSA and recombinant MeCP2 standard curves were 
calculated as 0.99 and 0.96 respectively. 
 
Quantitative western blotting allowed the determination of the absolute abundance of 
MeCP2 in unsorted nuclei isolated from mature mouse brain as 6 x 10
6
 molecules per 
nucleus (Figure 3.7A and see Table 3.1 for details of the calculations). A similar analysis 
was used to calculate the amount of MeCP2 in sorted neuronal nuclei (NeuN positive) as  
16 x 10
6
 molecules per nucleus, compared with ~2 x 10
6
 molecules per nucleus in the 
predominantly glial nuclear fraction (NeuN negative) (Figure 3.7B and Table 3.1). The level 
of MeCP2 within the glial nuclei is likely to represent an overestimate due to a proportion of 
neuronal nuclei staining negative for NeuN, such as cerebellar purkinje cells, olfactory bulb 
mitral cells, and retinal photoreceptor cells (Mullen et al., 1992). FACS staining suggested 
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suggested (LaSalle et al., 2001), indicating that these average values may not apply to each 
cell. A previous preliminary analysis of MeCP2 levels in whole brain performed by 
Xinsheng Nan indicated that there were 6 x 10
6
 molecules per nucleus, in agreement with the 










Figure 3.7 – The abundance of MeCP2 in purified neuronal nuclei approaches that of the histone 
octamer. (A) Nuclei were isolated from mature mouse brain, the concentration of which was 
determined by counting multiple dilutions with a haemocytometer. The level of MeCP2 in unsorted 
brain nuclei was quantified against recombinant MeCP2 by infra-red western blotting. The graph below 
indicates densitometric analysis using Licor Odyssey software. (B) Densitometric analysis of western 
blots to determine absolute abundance of MeCP2 in the different nuclei populations. The positions of 
molecular weight markers (kDa) are indicated. Error bars indicate the mean +/- SEM from at least 3 
experiments. 
 
Due to the fact that MeCP2 diseases are associated with neurological symptoms, consistent 
with its neuronal abundance, the absolute abundance of MeCP2 was examined in a known 
low expressing tissue. The abundance of MeCP2 in liver nuclei was calculated as 0.5 x 10
6
 
molecules per nucleus (Figure 3.8 and Table 3.1). To relate MeCP2 levels to the core 
components of chromatin, the abundance of histone H4 was determined using an equivalent 
technique as 64 x 10
6
 molecules per brain nucleus (Figure 3.9 and Table 3.1), which 
corresponds to 32 x 10
6
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Figure 3.8 – MeCP2 is expressed at much lower amounts in liver nuclei. A titration of a known 
concentration of recombinant MeCP2 was compared to nuclei isolated from mouse liver by infra-red 
western blotting. The graph below indicates densitometric analysis using Licor Odyssey. The positions 










Figure 3.9 – Quantification of the absolute abundance of histone H4 in total brain nuclei. A titration of a 
known concentration of recombinant H4 and unsorted brain nuclei were compared using quantitative 
infra-red western blotting. The graph to the left indicates densitometric analysis of the western blot 
using Licor Odyssey software. This shows that in total brain nuclei i that there are 64 x 10
6
 molecules 




















































Table 3.1 – Summary of the quantification of (A) MeCP2 and (B) Histone H4 absolute abundance in 
brain and liver nuclei. Using infra-red western blotting (Licor Odyssey), a titration of a known 
concentration of recombinant protein was compared to isolated nuclei and used to calculate the 
abundance (expressed as ng / 1000 nuclei). The number of mols per nucleus was determined from the 
molecular weight of the protein (MeCP2: 52.3 kDa; H4: 11.4 kDa). From this value the absolute number 
of molecules per nucleus was calculated using Avogadro’s number (6 x 10
23
 molecules / mol). 
 
3.5 Discussion 
This work provides a method for the isolation of nuclei corresponding to a neuronal and a 
predominantly glial population. Due to heterogeneous distribution of MeCP2 between these 
populations, this technique allows purification of the neuronal fraction for the study of 
MeCP2 in the relevant cell type. There are however, a significant number of limitations to 
this technique as presented here. Firstly, despite NeuN often being considered to be a 
degenerate neuronal marker and sufficient for their identification (Herculano-Houzel and 
Lent, 2005), not all neuronal subtypes are positive for this marker (Mullen et al., 1992). 
Therefore, the purified neuronal nuclei will not truly represent an average of all neuronal 
subtypes, and correspondingly the glial population will be contaminated with NeuN-negative 
neuronal nuclei. The exact level of contamination within the glial population is difficult to 
quantify, due to lack of knowledge of the absolute numbers of neuronal subtypes. However, 
studies looking at isolated cerebellar purkinje neurons, which are NeuN-negative, suggest 
that they are sufficiently low in abundance to not significantly contaminate the glial 
population (Kriaucionis and Heintz, 2009). The second limitation is related to the 
requirement to isolate nuclei prior to FACS, as this reduces the number of available markers 
for sorting. Therefore the future possibilities to sort specific neuronal subtypes would be 
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greatly limited, as the majority of characterised cell markers are cytoplasmic or cell 
membrane-associated. Thirdly, again due to the loss of the cytoplasmic component, the 
ability to investigate this cellular compartment, for example its RNA levels, is lost. Fourthly, 
the overall purification efficiency is very low, with the protocol typically starting with 50-
100 x 10
6
 nuclei but a final recovery of only 1-2 x 10
6
 nuclei, limiting the use of the protocol 
in downstream applications. This final issue is the greatest problem from a practical point of 
view. The protocol for the isolation of neuronal nuclei would likely be improved by the 
physical separation of nuclei based NeuN staining, as opposed to the FACS based procedure 
as it stands. This could possibly be achieved, through the labelling of NeuN antibody with 
biotin, followed by the physical purification using streptavidin magnetic beads. However, 
current bead sizes are significantly above that of the nuclear pore complex. 
 
The use of FACS purified neuronal nuclei allowed the absolute abundance of neuronal 
MeCP2 to be determined as 16 x 10
6
 molecules of MeCP2 per neuronal nucleus. Through 
the quantification of the histone H4, the number of nucleosomes was calculated as 32 x 10
6
 
per nucleus, which corresponds to one nucleosome per 165 base pairs of genomic DNA. The 
estimated number of methyl CpGs per diploid nucleus is 40 x 10
6
 methylated CpG sites 
(based on 1 meCpG every 125 bp). Therefore, the number of MeCP2 molecules in the 
nucleus of a mature neuron approaches the number of histone octamers and methyl-CpG 
sites and may be sufficient to almost “saturate” the genome. This huge abundance of 
MeCP2, which the associated phenotypes indciate is imperative for its function, suggests that 




Chapter 4 Analysis of MeCP2 Binding 
4.1 Introduction 
The general view amongst the majority of reports is that MeCP2 binds to discrete sites 
within the genome and regulates the gene at that specific locus, with the methylation 
dependence of the binding varying between studies (for example see (Ben-Shachar et al., 
2009; Chahrour et al., 2008; Chen et al., 2003b; Jordan et al., 2007; Klose et al., 2005; 
Shahbazian et al., 2002a)). Multiple studies have identified putative target genes through 
expression analysis of wildtype and Mecp2-null brain. To further indicate the role of MeCP2 
in the direct regulation of these genes, ChIP analysis at these loci was performed (Ben-
Shachar et al., 2009; Chahrour et al., 2008; Jordan et al., 2007; Nuber et al., 2005; Urdinguio 
et al., 2008). However, these studies have typically looked at single site which confirmed the 
presence of MeCP2 binding, but did not confirm that genes unaffected by the loss of MeCP2 
were negative for MeCP2 binding, as would be predicted by this simple causal mechanism. 
 
Potentially the most characterised MeCP2 target gene is Bdnf (Chen et al., 2003b; 
Martinowich et al., 2003). These studies used cultured neurons taken from immature 
embryonic day 14 mouse brains (Martinowich et al., 2003) and from embryonic day 18 rat 
brains (Chen et al., 2003b). ChIP analysis revealed enriched binding of MeCP2 to exon 4 
(Chen et al., 2003b; Martinowich et al., 2003). Note a change in the nomenclature of the 
alternative promoters (Aid et al., 2007). However, MeCP2 binding, albeit at a reduced level, 
was also observed at the other alternative promoters (Chen et al., 2003b). In the Mecp2-null 
neuronal cultures, the basal level of Bdnf expression was moderately elevated by two-fold, 
but no effect was observed on the stimulated activity, which was 100-fold higher than basal 
(Chen et al., 2003b). This lack of an effect on the stimulated state was suggested to be the 
result of a loss of MeCP2 binding upon neuronal stimulation following the phosphorylation 
of serine 421 on MeCP2 (Chen et al., 2003b). The relevance of Bdnf as a target gene in the 
mature mouse has since been questioned (Chang et al., 2006). This apparent contradiction 
could be the result of a change in function associated with the developmental increase in 
MeCP2 levels, as only 20% of MeCP2 is expressed in neonatal mice compared to the mature 
mouse (Figure 3.1). An independent study cloned 100 DNA fragments isolated by MeCP2 
ChIP using neonatal mouse brains and identified the putatively imprinted Dlx5/6 locus 
(Horike et al., 2005). Additionally, this study suggested that imprinting was lost in Mecp2-




conformation capture analysis (Horike et al., 2005). The findings of this study have since 
been refuted (Schule et al., 2007) and indeed this locus has not been identified in expression 
studies using Mecp2-null mice. Analysis of binding targets in immature mice or neuronal 
cultures may not give a clear picture of its true function, due to the late onset of the MeCP2 
associated phenotypes and the developmental increase in expression. 
 
Suggestions that MeCP2 does not specifically bind methylated DNA and may actually act as 
an transcriptional activator (Chahrour et al., 2008; Georgel et al., 2003; Nikitina et al., 2006) 
have received some support from ChIP-microarray experiments using the neuronal cultured 
cell line SH-SY5Y (Yasui et al., 2007). The report claimed that MeCP2 does not selectively 
bind methylated promoters, but instead is bound predominately at nonmethylated promoters 
and has a similar binding pattern to RNA polymerase II (Yasui et al., 2007). The validity of 
this study is questioned by evidence that the MeCP2 antibody used in the ChIP analysis 
displayed only two-fold greater enrichment in wildtype brain than in the Mecp2-null brain 
(Yasui et al., 2007). 
 
Overall, the understanding of the MeCP2 binding pattern in mature mouse brain is poorly 
understood. The observation that in the mature neurons, MeCP2 is theoretically abundant 
enough to coat the genome needs to be considered in the light of published ChIP data. To 
this end a ChIP assay using mature mouse brain was developed to identify the MeCP2 
distribution across the genome. 
 
4.2 Development of a ChIP assay 
To allow high resolution mapping of binding sites, chromatin is fragmented prior to 
immunoprecipitation. This is typically achieved through the either sonication or micrococcal 
nuclease (MNase) digestion. Due to the putative binding of MeCP2 to the linker DNA 
(Chandler et al., 1999; Nikitina et al., 2007), extensive MNase treatment could therefore 
result in the selective degradation of MeCP2 binding sites. As a result, sonication of 
crosslinked brain material was initially attempted (Figure 4.1A). Despite extensive 
sonication, which is associated with heating of the sample, a significant fraction of chromatin 
remained refractory to fragmentation. Approximately 40% of the DNA by weight was shown 
to be greater than 1 kb in size by sucrose gradient centrifugation (data not shown). 
Accordingly, the fragmentation obtained by sonication alone was not deemed sufficient for 




likely that chromatin fragmentation would be easier in the absence of crosslinks, but it was 
thought to limit future experiments, as only stably bound proteins could be studied. 
Consequently, limited MNase digestion was used to ‘loosen’ the chromatin prior to 
sonication (Figure 4.1B). Using a combination of the two, sufficient fragmentation was 
obtained without extensive digestion of the linker DNA, as indicated by the absence of clear 
nucleosomal laddering. Figure 4.1C shows typical inputs for wildtype and Mecp2-null used 
in the subsequent ChIP experiments. Due to relatively precise amount of MNase activity 
required to sufficiently digest without excessive laddering, there is typically some variation 
associated with the degree of fragmentation between experiments. However, there is no clear 
















Figure 4.1 – Optimisation of chromatin fragmentation for use in ChIP. Mouse brain tissue was 
crosslinked using 1% formaldehyde and then subjected to (A) sonication alone; (B) a combination of 
limited MNase digestion followed by sonication. (C) Represents typical inputs used in ChIP analysis. 
Samples were taken at the indicated timepoints, after the crosslinks were reversed the DNA was 
isolated and subjected to gel electrophoresis. The smear of high molecular weight DNA that is 
refractory to sonication is indicated by a bracket. The positions of molecular weight markers (kb) are 
indicated. 
 
Relatively standard crosslinking conditions were used (1% formaldehyde for 10 min at room 
temperature) with no specific optimisation of these conditions. For a discussion on how this 
might have affected the results, see section 4.7. 
 









































Given the poor efficiency of FACS purification of neuronal nuclei and concerns that length 
of protocol for nuclear isolation in combination with the FACS protocol, it was conceivable 
that this could lead to artefacts. It was decided therefore to use whole brain for ChIP 
analysis. Given that ~89% of brain MeCP2 is derived from the neuronal nuclei, the resulting 
pattern will be dominated by the neuronal population. It is important that the specificity of 
the antibody is verified, especially in the light of the recent publication suggesting the 
distribution of MeCP2 correlates with the RNA PolII occupancy (Yasui et al., 2007). The 
specificity of the 674 MeCP2 antibody (Nan et al., 1998) was tested by using the 234 bp 
major satellite repeat as a probe, as it is the only clear MeCP2 binding target ((Nan et al., 
1996); for discussion see section 3.3). Despite the MeCP2 antibody displaying relatively low 
efficiency (1.7% IP/Input), it was highly specific, exhibiting a 130-fold enrichment in 
wildtype compared to Mecp2-null mouse brain (Figure 4.2). It is possible that the low the 
immunoprecipitation efficiency is a result of the formaldehyde crosslinking leading to the 
epitope becoming inaccessible; for a discussion of the possible effects of over-crosslinking 
see section 4.7. As a result, it was concluded that this high degree of specificity was 










Figure 4.2 – Verification of the MeCP2 antibody for use in ChIP analysis. MeCP2 ChIP for the mouse 
major satellite repeat shows 130-fold enrichment in wildtype brain compared to Mecp2-null brain, 
indicating that the antibody is highly specific. Whole mouse brain was dissected and ChIP performed 
using an antibody against MeCP2. Immunoprecipitated DNA was analysed by real time PCR using 
primers specific for the major satellite repeat. (A) ChIP data is represented as % IP/Input. Error bars 
indicate mean ± SEM. For a schematic of the major satellite repeat see figure 3.5. (B) A schematic of 
the 234 bp mouse major satellite repeat is indicated: the blue vertical lines mark the position of CpG 
































4.3 MeCP2 shows widespread binding across gene loci in 
mature mouse brain tracking the meCpG density 
Previous reports using cultured immature neurons have suggested that MeCP2 binds to a 
discrete site within the Bdnf locus corresponding to exon 4 (Chen et al., 2003b; Martinowich 
et al., 2003). As a result, initially MeCP2 binding to the Bdnf locus was investigated. The 
mouse Bdnf locus has eight alternative first exons, most of which are located in two large 
CGIs, with a large intervening exon. A panel of 22 ChIP primers was designed across the a 
39 kb region spanning the CGIs and the MeCP2 binding profile was determined in mature 
mouse brain using ChIP and quantitative PCR (ChIP-qPCR; Figure 4.3A; blue line). 
Significant enrichment across the entire region was observed when compared with the 
Mecp2-null brain (Figure 4.3A; red line), suggesting that MeCP2 is broadly distributed at the 
locus, in line with the almost-saturating abundance of MeCP2 in the mature brain (see 
section 3.4). Interestingly, MeCP2 binding over the Bdnf CGIs is depleted relative to the 
surrounding regions, raising the possibility that these active promoters fail to attract 
significant amounts of MeCP2 due to their lack of DNA methylation. The intervening 
regions are CpG deficient by comparison with the CGIs, and as part of the bulk genome 
would be expected to be largely methylated. To confirm that the methylation status follows 
these predictions, bisulphite DNA sequencing of a limited number of regions was attempted 
focusing around the first CGI. Despite, all bisulphite PCR primers giving successful 
amplification, not all the amplicons were possible to clone even though multiple strategies 
were attempted. However, the data indicates that the flanking portions are predominantly 
methylated (Figure 4.3B). The methylation status of the CGIs could not adequately be 
determined by bisulphite sequencing (Figure 4.3B), but CXXC-affinity chromatography has 
confirmed that they are largely nonmethylated (personal communication from R. 
Illingworth). 
 
MeCP2 ChIP over the same region in wildtype liver gave a profile indistinguishable from the 
Mecp2-null brain, suggesting that the wildtype brain profile is a result of the high abundance 
in neurons (Figure 4.3A). The failure to detect signal for MeCP2 binding across the Bdnf 
locus in liver compared to null brain could be the result of lack of binding or reflect the limit 
of sensitivity of the experiment. Further work would be required to investigate this, such as 
confirmation of MeCP2 binding to sites such as the major satellite repeat in liver. It is 
possible that the MeCP2 binding pattern in the whole brain is an aggregate of a large number 
of distinct patterns from individual regions and neuronal subtypes. To address this, the ChIP 




restricted set of neuronal subtypes. The resulting MeCP2 binding profile was very similar to 
that of the wildtype whole brain, with MeCP2 bound over the entire locus but reduced over 
the CGIs (Figure 4.3A). This finding makes it likely that the ChIP results represent a 


















Figure 4.3 - MeCP2 shows widespread binding across 39 kb of the mouse Bdnf locus in mature brain. 
Mouse tissues (brain, hippocampus, liver) were dissected and ChIP performed using an antibody 
against MeCP2. (A) Immunoprecipitated DNA was analysed by real time PCR using a panel of primers 
and ChIP signal plotted as % IP/Input. Error bars indicate mean ± SEM from the replicates of the real 
time PCR analysis. Multiple biological replicates were performed, with this representing a typical result 
obtained. ChIP was performed on various tissues as indicated. The blue vertical lines below the graph 
indicate CpG sites, with CGIs shaded in light grey. The gene goes left to right; with alternative Bdnf first 
exons 1-7 indicated with dark grey rectangles, arrows indicate the transcriptional start sites. Bisulphite 
PCR amplicons are indicated with black bars. The asterisk marks the discreet binding site identified 
using cultured embryonic cortical neurons (Chen et al., 2003b). The region shown corresponds to 
chromosome 2: 109505000 – 109544220; NCBI build NCBIM37 (B) Total brain genomic DNA was 
subjected to bisulfite sequencing at specific sites as indicated above by black bars. Each row 
represents a single clone. Open and filled circles indicate nonmethylated and methylated CpG sites, 
respectively. Gaps indicate uncharacterised CpG sites. Due to unforeseen difficulties in cloning the 
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A similar approach was used to examine MeCP2 occupancy over two housekeeping genes, 
c-Myc and Actb, which have nonmethylated CGIs that is are flanked by comparatively CpG 
deficient DNA, but which is methylated. ChIP across the c-Myc locus revealed MeCP2 
bound to the methylated regions flanking the large CGI, but, as in the case of the Bdnf locus, 
MeCP2 binding was depleted across the CGI (Figure 4.4A). Analysis of 9.5 kb surrounding 
the Actb locus, showed a similar pattern with higher MeCP2 occupancy across the flanks, but 
depleted binding over the CGI (Figure 4.4B). In order to relate this result to methyl-CpG 
density, bisulphite sequencing was performed to unambiguously determine modification of 
all 262 CpG sites across the Actb region (Figure 4.4B). The results confirm that the CGI is 
DNA methylation-free, whereas the flanking region is predominantly methylated. Due to the 
variable CpG density, the methylation level varies dramatically across the locus. 
Significantly, the MeCP2 binding profile mirrors the methylation density throughout the 
region. A complete methylation density map could not be produced for either Bdnf or c-Myc 
due to the abundance of repetitive elements within these loci. Limited bisulphite analysis at 
the Bdnf locus and CXXC-affinity purification (personal communication with R. Illingworth) 
confirm that as expected these CGIs are non-methylated whereas the flanks are largely 
methylated. Overall, this analysis is compatible with the conclusion that MeCP2 shows 
widespread binding tracking the meCpG density. The observation of ‘residual’ binding 






























Figure 4.4 – MeCP2 binding is reduced over nonmethylated CGIs of housekeeping genes. Mouse 
brains were dissected and ChIP performed using an antibody against MeCP2. Immunoprecipitated 
DNA was analysed by real time PCR using a panel of primers across the (A) c-Myc locus and (B) the 
Actb locus. The blue vertical lines below the graph indicate CpG sites, with CGIs shaded in light grey. 
Exonic structure is indicated with dark grey rectangles. Total brain genomic DNA was subjected to 
bisulfite sequencing for a continuous run of 262 CpG sites across ~9 kb of the Actb locus. From this 
bisulphite analysis, the % methylation of each CpG site was calculated. The methylation density is 
plotted based on a window size of 650 bp and step of 50 bp with the cumulative % methylation of the 
CpG sites within each window calculated. Error bars indicate mean +/- SEM 
 
4.4 MeCP2 specifically binds methylated DNA 
Taken together, the results of the above ChIP experiments with the abundance measurements 
are consistent with the hypothesis that MeCP2 binds globally and the tracks the methyl-CpG 
density of the neuronal genome. To test whether MeCP2 specifically binds methylated DNA 
in neurons or binds regardless of the methylation status, as proposed by in vitro chromatin 
assembly experiments (Georgel et al., 2003; Nikitina et al., 2006) and other ChIP studies 
(Chahrour et al., 2008), genomic regions were selected that occur in both methylated and 
nonmethylated states within each cell. First, MeCP2 binding over 12 kb of the X-linked Xist 
locus was characterised, comparing male to female mouse brains (Figure 4.5A). In male 
mice there is a single methylated copy of the Xist gene, whereas in females there are two 
copies, one methylated and one nonmethylated (Hendrich et al., 1993). In the male brain, 
MeCP2 occupies the entire region, peaking over the densely methylated CGI. The finding 
that MeCP2 occupancy drops over non-methylated CGIs (Figure 4.3 and 4.4), but peaks over 
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In females, MeCP2 occupancy flanking the Xist CGI is indistinguishable from the male 
profile. As part of the bulk genome, it is likely that these flanking regions are methylated on 
both the Xa and Xi, however, this has not formally been shown. Over the Xist CGI, however, 
MeCP2 binding in female brain is reduced by half relative to the male brain (Figure 4.5A). 
This result is consistent with the notion that MeCP2 is only bound to one of the two Xist CGI 
alleles in the female. To test this more rigorously, the ChIP protocol was combined with 
bisulphite sequencing to determine the methylation status of the immunoprecipitated DNA. 
Input DNA from female brain gave approximately equal numbers of nonmethylated and 
methylated clones, as expected, confirming unbiased PCR amplification (Figure 4.5B). As a 
control, bisulphite sequencing of Xist DNA immunoprecipitated by an antibody against 
acetylated histone H3 was performed. This histone mark is specific for the active Xist allele 
and duly recovered the nonmethylated allele in 97% of clones (n=39 clones). Following 
ChIP with anti-MeCP2 antibody, however, 88% of the recovered clones were methylated 
(n=58 clones). 
 
A similar result was obtained by analysing 9 kb of the imprinted Snrpn locus, which has a 
paternal nonmethylated allele and a maternal methylated allele (Sutcliffe et al., 1994). 
MeCP2 is bound through the entire region, peaking over the imprinted CGI (Figure 4.5C). 
Using the ChIP-bisulfite protocol, the input DNA gave approximately equal numbers of non-
methylated and methylated clones (Figure 4.5D). As before, acetylated histone H3 ChIP 
recovered 100% non-methylated clones (n=23), whereas 89% of the clones obtained by 
MeCP2 ChIP were methylated (n=19). The conclusion is that MeCP2 preferentially binds to 
































Figure 4.5 – Brain MeCP2 binds selectively to methylated DNA in vivo. Whole mouse brains were 
dissected and ChIP performed using antibodies against MeCP2 and acetylated histone H3. Input DNA 
and immunoprecipitated DNA were analysed by real time PCR and subjected to bisulfite sequencing. 
(A) MeCP2 binding profile across 12 kb of the Xist locus in wildtype male brain (blue), wildtype female 
brain (pink) and Mecp2-null brain (grey). The blue vertical lines below the graph indicate CpG sites, 
with the CGI shaded in light grey. The transcription start site is indicated with an arrow. The horizontal 
black line marks the region amplified for bisulfite sequencing. (B) ChIP was performed on the wildtype 
female brain for MeCP2 and histone H3 acetylation. Recovered DNA was used for bisulfite sequencing 
of a region of the Xist promoter. A representative number of clones chosen at random are indicated 
(see main text for details of total numbers of clones); each line represents a single clone. Open and 
filled circles indicate non-methylated and methylated CpG sites, respectively. Crosses indicate 
uncharacterised CpG sites. (C) MeCP2 ChIP profile across 9 kb of the imprinted Snrpn locus in 
wildtype brain. (D) ChIP was performed on the wildtype brain for MeCP2 and histone H3 acetylation. 
The resulting DNA was used for bisulfite sequencing of a region of the Snrpn promoter. Error bars 
indicate mean +/- SEM. 
 
4.5 MeCP2 ChIP-seq analysis of global distribution 
Analysis of candidate loci across ~150 kb of the mouse brain genome suggests that MeCP2 
is widely distributed. To view MeCP2 occupancy genome-wide, high-throughput DNA 
sequencing of total MeCP2-bound chromatin using Illumina Solexa sequencing (ChIP-seq) 
was performed. In all, 2.9 x 10
9
 bases were sequenced, of which 1.3 x 10
9
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mappable. Despite relatively extensive sequencing, clear peaks corresponding to discrete 
MeCP2 binding sites were not identified, even with a total of seven lanes of sequencing. For 
comparison, a typical transcription factor usually requires one lane. Instead, sequencing 
reads were dispersed throughout the genome, covering 56% of the mappable mouse genome 
(the haploid mouse genome is 2.5 x 10
9
 bp, of which 1.8 x 10
9
 bp is not removed by repeat 
masking). This lack of clear binding sites fits with our analysis of candidate regions by 
ChIP-PCR. Since MeCP2 binding is genome-wide, it would be necessary to sequence the 
entire genome several-fold to obtain a comprehensive high-resolution profile. Due to the lack 
of depth of sequencing, it was generally not possible to directly compare the sequencing data 
with the results obtained by ChIP across candidate regions (ChIP-qPCR; see section 4.3 and 
4.4). However, it is clear that for c-Myc, the sequencing data correlates with the previous 












Figure 4.6 – Comparison of the brain MeCP2 ChIP-qPCR with the brain MeCP2 ChIP-seq data across 
the c-Myc locus verifies the high-throughput sequencing data. MeCP2 ChIP was performed using 
whole mouse brain, and immunoprecipitated DNA was end-repaired and linkers ligated for Illumina 
Solexa sequencing. Prior to sequencing, a standard PCR using the linkers as primers was performed 
to confirm successful ligation of the linkers (data not shown). Libraries were sequenced on the Solexa 
Genome Analyzer to generate 37 bp reads. Single-end sequence reads were mapped to the mouse 
genome. (A) MeCP2 ChIP-qPCR analysis (see section 4.3) aligned with the (B) ChIP-seq data across 
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Figure 4.7 - Comparison of MeCP2 ChIP-qPCR data with the b MeCP2 ChIP-seq data across (A) Bdnf 
(B) Actb (C) Snrpn and (D) Xist loci. MeCP2 ChIP was performed using whole mouse brain, and 
immunoprecipitated DNA was sequenced on a Solexa Genome Analyzer to generate 37 bp reads. 
Single-end sequence reads were mapped to the mouse genome. For each loci, the upper panel 
indicates the MeCP2 occupancy determined by ChIP-qPCR (vertical axis represents ChIP signal 
plotted as % IP/Input), whilst the lower panel indicates the binding pattern determined by ChIP-seq 
(vertical axis represents reads per base). Co-ordinates of loci are indicated according to genome build 
NCBIM37. 
 
Despite the inability to clearly look at individual loci, we were able to robustly test for a 
relationship with DNA methylation by comparing the profile of the CpG density in a sliding 
5 kb window with that of MeCP2 bound chromatin. CGIs only represent ~2% of the mouse 
genome and typically have an approximate length of 1 kb, whilst the remaining ~98% is 
predominantly methylated (Ehrlich et al., 1982). Therefore, by using a 5 kb window size this 
primarily looks for fluctuations in CpG density within the bulk genome. The match between 
MeCP2 ChIP-seq and CpG density was striking (Figure 4.8), suggesting that MeCP2 binding 
coincides with the CpG dinucleotide sequence. As a more direct test of the methyl-
dependence of the distribution of MeCP2, the distribution of meCpG was determined by 
fractionating whole brain genomic DNA based on its affinity for an immobilized methyl-
CpG binding domain (Cross et al., 1994; Illingworth et al., 2008). Retained sequences were 
analyzed by high-throughput sequencing (MBD-seq; this data was kindly provided by R. 
Illingworth). Despite an apparent circularity in comparing the binding specificity of a MBD-
tagged protein in vitro and the distribution of a MBD protein in vivo, an earlier comparison 
between this method of meCpG mapping and use of an anti-meC antibody (MeDIP) 
indicated that both are equally effective at measuring meCpG density (Zhang et al., 2006). 
Comparison of MeCP2-bound chromatin and MBD-seq revealed that in vivo bound MeCP2 
mirrors meCpG over long regions of chromosomal DNA (Figure 4.8), consistent with the 






















Figure 4.8 – High throughput sequencing of immunoprecipitated chromatin shows MeCP2 globally 
distributed and tracking the meCpG density. Profiles of MeCP2-bound sequences (blue), CpG density 
(red) and sequencing from methyl-CpG-rich sequences (green) were analysed using a sliding window 
(5 kb window; 1 kb step). A 52 Mb region of chromosome 5 is shown. The vertical axis represents 
sequencing hits or number of CpGs per window. MBD-seq data was provided by R. Illingworth. 
Bioinformatic support was gratefully received from R. Illingworth, S. Webb and A. Kerr. 
 
ChIP-qPCR analysis indicated that MeCP2 binding was reduced over the nonmethylated 
CGIs associated with the c-Myc, Actb and Bdnf loci. To determine if this applied genome-
wide, the mappable mouse genome sequence was binned according to CpG density in 500 bp 
windows and the level of MeCP2 binding in each bin determined (Figure 4.9A). The results 
show that MeCP2 binding initially increases with CpG composition as predicted by Figure 
4.7, as these sequences are part of the largely methylated bulk genome. However, MeCP2 
occupancy drops at densities above 25 CpGs per 500 bp. This density predominantly reflects 




































Figure 4.9 – MeCP2 occupancy increases with CpG density within the bulk genome, but is depleted 
over CGIs. (A) The genome was scanned using a 500 bp window (100 bp step) and the number of 
MeCP2 hits per window plotted against the number of CpGs per window. Boxplots are shown with the 
horizontal line indicating the median and the surrounding box showing the interquartile range. The 
width of the box is proportional to the fraction of the genome that corresponds with that CpG density. 
(B) Boxplot showing the number of CpGs per 100 bp calculated using the NCBI strict algorithm for 
CGIs. (www.ncbi.nlm.nih.gov/mapview/static/humansearch.html#cpg). The majority of CGIs contain 
greater than 5 CpG sites/100 bp as indicated by red line (A), whereas the bulk genome has a lower 
CpG density. 
 
Furthermore, ChIP-qPCR indicated increased MeCP2 occupancy over the methylated CGIs 
of the Xist and Snrpn genes (Figure 4.5). The genome-wide binding to methylated CGIs, as 
identified by MBD-seq, was therefore determined. The results reveal a peak of MeCP2 
binding centred over the methylated CGIs, further confirming the role of DNA methylation 
in targeting MeCP2 (Figure 4.10). This observation of increased binding over methylated 
G/C rich sequences confirms that the depleted binding observed over the largely 
nonmethylated G/C rich sequences (Figure 4.9) is not the result of bias against G/C rich 
DNA in the sequencing reaction. This bias has previously been suggested at extreme G/C 
contents, (Hillier et al., 2008). However, this observed bias is outside the typical G/C content 











































































Figure 4.10 – MeCP2 ChIP-seq identifies increased occupancy over methylated CGIs. Methylated 
CGIs (n = 1273) were indentified by methyl-CpG affinity chromatography (data kindly donated by R. 
Illingworth). The surrounding 5 kb of genomic DNA was analyzed for MeCP2 binding using a 500 bp 
window (100 bp step). Data presented as the number of MeCP2 hits per window plotted against the 
number of CpGs per window. Boxplots are shown with the horizontal line indicating the median and the 
surrounding box showing the interquartile range 
 
Overall, this first genome-wide analysis of the distribution of MeCP2 in mouse brain 
suggests that MeCP2 binds globally, consistent with its near-histone octamer abundance, 
tracking the meCpG density of the genome. The inability to robustly look at individual gene 
loci, as indicated by some inconsistency between the ChIP-qPCR and the ChIP-seq results 
(figures 4.6 and 4.7), would hopefully be improved by an increased depth of sequencing. 
 
4.6 Are there high and low affinity binding sites? 
A previous in vitro study used methyl-SELEX in order to determine any additional sequence 
requirements for the binding of MeCP2 and identified the frequent presence of an A/T run of 
four or more bases close to the methylated CpG site (Klose et al., 2005). Alignment of the 
selected sequences identified the consensus sequence, with the A/T run motif appearing in 
two vertical stripes, as indicated in Figure 4.11A. The relevance of this consensus for the 
targeting of MeCP2 was not robustly tested in vivo (Klose et al., 2005), but the preferential 
binding site in the Bdnf locus in cultured neurons was noted to contain this A/T run (Chen et 
al., 2003b; Ho et al., 2008). This suggests that there may be additional levels of targeting, 
despite the data presented here indicating that the distribution of MeCP2 is simply defined 
by the meCpG density (Figure 4.9). To determine if the presence of an A/T run impacted the 
probability of MeCP2 occupancy, isolated CpG sites, with no other CpG site within 40 bp 
0 1 2-1-2
























either side were identified within the genome. This criterion for identifying isolated CpG 
sites excludes CGIs and focuses on the largely methylated bulk genome. Isolated CpG sites 
were scored for the presence or absence of this A/T run motif (Figure 4.11A; (Klose et al., 
2005)) and then the binding of MeCP2 within this region quantified as determined by ChIP-
seq. No preference was observed for CpG sites associated with this motif, questioning the 





















Figure 4.11 – MeCP2 ChIP-seq indicates no clear preference for an A/T run adjacent to the CpG site in 
vivo. (A) methyl-SELEX identified a broad consensus motif that contained an A/T run in two alternative 
positions after the CpG dinucleotide as indicated in red and green. Due to the palindromic nature of 
CpG, it is also possible for the A/T run to be situated in front of the CpG site (these possible consensus 
sequences are not shown). A or T is represented as W; any base is represented as N. (B) Isolated 
CpG sites within the bulk genome were identified as containing no other CpG site within 40 bp either 
side. Subsequently, these sites were scored for the presence or absence of the above consensus motif 
and MeCP2 binding was then assigned within this window using the ChIP-seq data. Data presented as 
boxplots for log2(MeCP2 hits per 80 bp window); outliers have been removed. 
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Increasing salt concentration can be used to selectively solubilise nuclear proteins. An early 
studying characterising the properties of MeCP2 monitored its release from rat brain nuclei 
with increasing salt concentrations (Meehan et al., 1992). This indicated that MeCP2 was 
released over a broad salt range. However, with careful quantification, it was noted that the 
release of MeCP2 appears to follow a biphasic pattern in comparison with the release of 
histone H1, suggesting the possibility of high and low affinity binding sites for MeCP2 
(Figure 4.12A; (Meehan et al., 1992)). To investigate the possibility of differential binding of 
MeCP2, the ChIP protocol was combined with an initial 300 mM salt-wash to remove this 
putative low affinity bound component. This necessitated using isolated nuclei for the ChIP 
analysis. Preliminary analysis indicated that 60 minute incubation with 300 mM NaCl 
released 75% of the nuclear MeCP2, whereas only 25% of MeCP2 was released with 150 
mM NaCl, which is approximately physiological (Figure 4.12B). ChIP analysis was 
performed across the mouse Bdnf locus in salt treated brain nuclei (Figure 4.12C). For some 
unknown reason the use of isolated nuclei led to a minor alteration of the MeCP2 binding 
pattern as observed in whole brain, perhaps suggesting that the time lag between nuclei 
preparation and crosslinking can induce artefacts. Despite these concerns, the binding pattern 
observed between the 150 mM-washed sample and 300 mM-washed sample appears largely 
the same, with on average 60% of the occupancy in the 300 mM sample compared to the 150 
mM sample, consistent with the western blot analysis. To test if there are any key differences 
in the binding pattern between these samples, the signal for each primer pair was normalised 
to the average of that ChIP sample, thereby setting the average of each sample to 1 (Figure 
4.12D). This analysis indicates that there are no clear differences, thereby providing no 








































Figure 4.12 – Partial salt-dependent release of MeCP2 indicates no differential binding across the Bdnf 
locus. (A) Salt extraction of proteins from rat brain nuclei indicated a biphasic release of MeCP2 (blue 
line) compared to histone H1 (red line), proposing putative high and low affinity bound populations of 
MeCP2 (figure adapted from (Meehan et al., 1992)). (B) Isolated mouse brain nuclei were incubated 
with extraction buffer supplemented with either 150 mM or 300 mM NaCl for the indicated time. 
Western blot analysis of the salt-washed pelleted nuclei was performed for MeCP2 and histone H3 (as 
a loading control) before and after the incubation. Densitometry was used to quantify the western blot, 
data was normalised to histone H3. (C) Isolated mouse brain nuclei were incubated with extraction 
buffer supplemented with either 150 mM or 300 mM NaCl for 20 min. Salt-washed nuclei were then 
crosslinked and used for MeCP2 ChIP analysis across the Bdnf locus. ChIP signal plotted as % 
IP/Input. (D) The ChIP results were normalised to the average of each sample, therefore averaging 
each dataset to 1. The blue vertical lines below the graph indicate CpG sites, with CGIs shaded in light 
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This data provides clear evidence for methylation dependent binding in neurons, contrary to 
the reports of focusing on methylation independent binding in vitro (Georgel et al., 2003; 
Nikitina et al., 2006) and in vivo (Chahrour et al., 2008). Early quantitative in vitro analysis 
for the methyl-specific affinity suggested that methylation independent binding may be as 
little as 10-fold less (Nan et al., 1993). However, measurements from in vitro studies are 
likely to be highly dependent on the experimental conditions. It is conceivable that a highly 
basic protein, such as MeCP2 which binds to a short dinucleotide consensus sequence, will 
also exhibit some non-specific binding to the negatively charged DNA. The ChIP analysis 
presented here may suggest that there is a component of non-specific binding. Firstly, it is 
clear that the MeCP2 ChIP signal for wildtype brain is never as low as the level observed in 
Mecp2-null brain, even at the Actb CGI where the methylation level was determined to be 
zero, suggesting that MeCP2 is bound. This could be due to immunoprecipitation of flanking 
methylated regions and therefore represents the resolution restraints of the ChIP analysis. 
However, the c-Myc CGI is very large, almost 3 kb, and therefore the residual MeCP2 ChIP 
signal is larger than would be reasonably expected from this flanking contamination. 
Secondly, the ChIP-bisulphite analysis for the Xist locus reproducibly identified only 88% of 
clones as methylated, even though the ChIP signal in wildtype female mice was ~150-fold 
greater than the Mecp2-null, consistent with a non-specific binding component. 
Serendipitously, the binding across the Dlx5/6 locus had been examined, as previous reports 
indicated a discrete binding pattern of MeCP2 in 1-day old mice (Horike et al., 2005). 
Despite the relatively high CpG density across the 40 kb region examined, with 1 CpG per 
45 bp compared to a genome average of 1 CpG per ~100 bp, the MeCP2 ChIP signal was 
surprisingly low (Figure 4.13A and B) with no correlation with CpG density as previously 
indicated (Figure 4.9). Limited bisulphite sequencing indicated that for the most part the 
DNA was nonmethylated, with only the peak of MeCP2 binding associating with methylated 


































Figure 4.13 – MeCP2 shows a background level of non-specific DNA binding. (A) Mouse brains were 
dissected and ChIP performed using an antibody against MeCP2. Immunoprecipitated DNA was 
analysed by real time PCR using a panel of primers across 40 kb of the Dlx5/6 locus. The blue vertical 
lines below the graph indicate CpG sites, with nonmethylated CGIs shaded in light grey as determined 
by CXXC affinity chromatography (data not shown; R Illingoworth). Exonic structure is indicated with 
dark grey rectangles. (B) CpG density across the locus was calculated using a 200 bp window; 10 bp 
step, plotted as number of CpGs per 100 bp (blue line). Typical density of mouse CGIs is indicated by 
a red line; typical density of the bulk genome is indicated by a blue line. (C) Total brain genomic DNA 
was subjected to bisulfite sequencing at specific sites as indicated above by black bars. Each line 
represents a single clone. Open and filled circles indicate nonmethylated and methylated CpG sites, 
respectively. Gaps indicate uncharacterised CpG sites. 
 
Despite the lack of DNA methylation, there is again residual MeCP2 binding. This residual 
binding is significantly above the signal observed from the Mecp2-null brain, suggesting that 





















































however, be artefact due to over-crosslinking with formaldehyde (for discussion see section 
4.7). Despite questions surrounding the crosslinking producing aretfacts, interestingly, this 
non-methyl dependent association showed no correlation with CpG density. Speculatively 
suggesting that this non-sequence dependent binding may be the result of non-specific 
interactions between the negatively charged sugar-phosphate DNA backbone and some part 




Previous studies have focused on the concept of MeCP2 binding to discrete sites, perhaps 
due to the historical model of MeCP2 functioning as a methyl-dependent transcriptional 
repressor for discrete target genes. However, the finding that MeCP2 is almost as abundant 
as the histone octamer in the neurons of the mature brain suggests that this discrete binding 
pattern cannot be true. Indeed, the above ChIP analysis has confirmed that in neurons, 
MeCP2 binds globally tracking the meCpG density of the neuronal genome. 
 
Indeed, a re-evaluation of the literature supports this view. Early experiments indicated the 
particularly high abundance of MeCP2 within the brain (Lewis et al., 1992; Meehan et al., 
1992; Nan et al., 1997). Despite this high abundance, the release of the majority of MeCP2 
has repeatedly been shown to require high salt extraction even in the brain (Klose and Bird, 
2004; Meehan et al., 1992; Nan et al., 1997). Therefore, suggesting that there is no clear 
unbound fraction of MeCP2 within the nucleus (Nan et al., 1997). The distribution of 
MeCP2 within the genome has also been examined by immunofluorescence. The use of 
mouse cells for studying MeCP2 localisation is dominated by the punctate staining to the 
pericentromeric heterochromatin (Lewis et al., 1992). However, rat nuclei exhibit a more 
even DNA distribution as indicated by staining for DNA with agents such as Hoescht 33258 
(Lewis et al., 1992). Immunofluorescence of MeCP2 localisation in rat liver fibroblasts 
implied a global distribution along the length of the chromosomes (Lewis et al., 1992). This 
global distribution in rat cells has been more recently confirmed and extended with the 
analysis of monkey kidney COS7 cells and human cells (Nan et al., 1997). Therefore, despite 
our initial surprise as to the global binding pattern observed in neurons, where there is huge 
abundance of MeCP2, there is precedent for these findings within the literature. Furthermore, 
the conclusion that the majority of MeCP2 resides within the bulk genome is perhaps 




work at the low methylation density observed within the bulk genome (Nan et al., 1997). 
Also, despite the identification of a consensus binding site containing an A/T run being 
originally thought to target MeCP2 to specific site (Klose et al., 2005), this may actually 
reflect the fact that MeCP2 has evolved to bind to the bulk genome, where CpGs containing 
this motif are common, rather than in the rare methylated CGIs. However, MeCP2 ChIP-seq 
provided no support to the role of the A/T run in defining MeCP2 distribution in vivo. This 
difference may be due to a number of reasons. Firstly, this extra specificity in targeting 
provided by a relatively weak consensus may be lost in neurons, where the abundance is so 
high that almost all meCpG sites are occupied. Secondly, this could be the result of an in 
vitro artefact, for example, A/T runs are known to induce a bend in the DNA, similarly to 
wrapping of the DNA around a nucleosome. Therefore, the identification of an A/T run may 
have simply been a reflection of the fact that the true binding target of MeCP2 is meCpG 
within the context of chromatin (for a discussion of MeCP2 binding to chromatin see section 
5.2). More work is required to formally disprove the role of an A/T run in the targeting of 
MeCP2, for example, analysing the ChIP-seq data for regions that show higher than expected 
MeCP2 occupancy given the CpG density and determining if these regions contain CpGs 
with A/T runs, or indeed other elements. This analysis would rely on the assumption that the 
bulk genome is entirely methylated, or may indeed require bisulphite sequencing of the brain 
genomic DNA. This study has elucidated the genome-wide binding of MeCP2 and is 
suggestive of a global function of MeCP2, it does not however, preclude the possibility that 
MeCP2 also has some site specific roles. Evidence for site specific roles could be found from 
the analysis of the ChIP-seq data for sites that are more enriched than would be predicted for 
the DNA methylation density. 
 
As discussed there have been various reports proposing that MeCP2 binds independent of 
methylation (Chahrour et al., 2008; Georgel et al., 2003; Harikrishnan et al.; Kernohan et 
al.). The genome-wide ChIP data presented here reveals that MeCP2 occupancy is primarily 
determined by DNA methylation. The observation that there is some residual methylation-
independent binding may be due to the almost-saturating levels of MeCP2 within neurons, as 
suggested by the failure to observe increased binding to the A/T run consensus motif. This 
hypothesis could be followed up by repeating the ChIP-bisulphite analysis in tissues 
expressing moderate levels of MeCP2, such as kidney, and low levels, such as liver, and 
monitoring any changes in the methylation status of the recovered clones. Previous work 
from this laboratory has shown that transient interactions are not efficiently crosslinked and 




B). Despite this study showing that wildtype MeCP2 is efficiently crosslinked; it perhaps 
raises the possibility that the residual signal in ChIP analysis could be the result of 
artefactual non-crosslinked interactions occurring after cell lysis. The mixing of crosslinked 
wildtype female extracts with crosslinked Mecp2-null male extracts and with the subsequent 
ChIP analysis for MeCP2 occupancy on the Y chromosome would confirm whether indeed 
there is some non-crosslinked reshuffling of the MeCP2 binding pattern. However, even if 
this was true, it would not fully explain the lack of methyl-dependence of such spurious 
interactions. It is also possible that the formaldehyde crosslinking conditions used (1% 
formaldehyde for 10 min at room temperature) could have ‘over-crosslinked’, whereby 
neighbouring DNA that was not specifically bound by MeCP2 became crosslinked and 
therefore was interpreted as being bound by MeCP2. In light of this possibility it would be 
appropriate for further work to vary the crosslinking conditions used and investigate whether 
this ‘background’ binding to non-methylated DNA is reduced, as would be predicted if this 
was an effect of over-crosslinking. 
 
These considerations withstanding, it seems most likely that there is some weak non-specific 
DNA binding activity, as suggested from a solution structure of MBD of MeCP2 (Wakefield 
et al., 1999). Previous analysis of the localisation of MeCP2 in mouse cells indicated that the 
punctate staining observed was largely dependent on the presence of an intact MBD, 
identifying the importance of methylation in binding (Nan et al., 1993). However, it was 
noted in a minority of cases (~20%), that cells expressing a truncated form of MeCP2 
lacking the MBD, retained punctate staining (Nan et al., 1993). It has been hypothesised that 
this residual binding may reside with the AT-hook present in MeCP2 (Nan et al., 1993). 
Therefore, the non-specific binding observed in ChIP analysis presented here, may be a 
result of this alternative weaker binding activity and therefore there is scope for a role of 
MeCP2 in binding to nonmethylated sequences as indicated by various studies (Chahrour et 
al., 2008; Georgel et al., 2003; Harikrishnan et al.; Kernohan et al.). However, as the 
majority of missense mutations causing Rett syndrome are within the MBD domain (Figure 
1.6) and the fact that methylation is the primary determinant for this observed binding 
pattern, then the methyl-CpG binding activity is likely to be key to its function. Also, the 
ChIP analysis perfomed to indicate binding to non-methylated target sites was very limited, 
with only a single primer pair used to analyse the binding (Chahrour et al., 2008; Georgel et 
al., 2003; Harikrishnan et al., 2010; Kernohan et al., 2010), raising questions as to the 





Chapter 5 Impact of Global MeCP2 Binding 
5.1 Global changes in chromatin modifications 
Analysis of the effect of MeCP2 has typically been performed on an individual locus basis, 
in line with previous thinking that MeCP2 functioned as a classical transcription factor. 
Consistent with earlier transfection experiments indentifying the role of HDACs in MeCP2 
transcriptional repression (Nan et al., 1998), elevated levels of histone acetylation have been 
observed at the promoter of the human multidrug resistance gene (MDR1) upon the loss of 
MeCP2 due to 5-azadeoxcytidine treatment in cancer cells (El-Osta et al., 2002). Elevated 
histone acetylation has also been observed at the p16 tumour suppressor gene promoter in 
the absence of MeCP2 binding in cancer cells (Nguyen et al., 2001). However, the role of 
MeCP2 in regulating these specific genes has not been confirmed in expression studies using 
the various Mecp2 mouse models (Jordan et al., 2007; Nuber et al., 2005; Tudor et al., 2002; 
Urdinguio et al., 2008). These findings question the relevance of these genes in the aetiology 
of Rett syndrome. This inconsistency may be a reflection of the atypical methylation patterns 
observed in immortalised cell lines (Antequera et al., 1990). Despite questions over the 
significance of these genes, elevated histone acetylation in the absence of MeCP2 binding is 
consistent with a mouse model expressing a truncated version of MeCP2 lacking the TRD, 
where moderately increased histone H3 acetylation (H3Ac) was observed (Shahbazian et al., 
2002a). As these mice exhibit a Rett-like phenotype similar to the Mecp2-null animals 
(Shahbazian et al., 2002a), it suggests that this ability to recruit HDAC complexes may be 
imperative to the function of MeCP2. 
 
The effect of MeCP2 has to be re-evaluated in light of the findings that in neuronal nuclei 
MeCP2 is expressed at near-nucleosomal levels and binds across the entire genome. These 
considerations raise the possibility that MeCP2 may globally influence the chromatin state. 
As approximately 89% of MeCP2 is within neurons, any global changes in histone 
acetylation between wildtype and Mecp2-null brain would likely be restricted to the neurons, 
but be absent in glia. To test this, H3Ac levels were quantified by western blotting in 
unsorted nuclei, FACS-purified neuronal and glial nuclei from both wildtype and Mecp2-null 
brain (Figure 5.1). Unsorted Mecp2-null brain nuclei displayed a 1.5-fold increase in H3Ac 
compared to wildtype. This difference increased significantly to 2.6-fold in sorted neuronal 
nuclei (Kolmogorov-Smirnov [KS] test p≤0.01), whereas glial nuclei consistently showed no 













Figure 5.1 – MeCP2-deficiency affects the global chromatin state by elevating levels of histone H3 
acetylation (H3Ac). H3Ac levels were determined by western blotting of unsorted brain nuclei and 
FACS purified nuclei from both wildtype and Mecp2-null brain, the antibody specifically recognises 
H3K9AcK14Ac. The western blot shows H3Ac levels and NeuN (as a loading control) in the purified 
neuronal nuclei. The graph indicates densitometric analysis of H3Ac levels in the different nuclei 
populations, normalised for differences in loading. The horizontal line represents no change between 
wildtype and Mecp2-null. Error bars indicate mean ± SEM from at least two biological samples; the KS 
test was used to determine statistical significance. 
 
As might be predicted this suggests that the small increase in H3Ac observed in whole brain 
is entirely due to the effect in neurons, where MeCP2 is highly abundant. This finding does 
not corroborate a recently published study indicating that H3Ac levels were increased in 
Mecp2-null in vitro cultured glial cells (Ballas et al., 2009). Additionally, the initial study 
showing elevated H3Ac levels in the truncated Mecp2-null mouse, suggesting that the effect 
was, surprisingly, largest in the spleen, which only expresses moderate levels of MeCP2 
((Shahbazian et al., 2002a); see also Figure 1.5B). This result may reflect the limited western 
blotting analysis performed in this by a non-quantitative technique. 
 
The widespread chromosome binding by MeCP2 observed in neurons might be expected to 
modulate chromatin structure globally rather than at specific sites. ChIP using an anti-acetyl 
H3 antibody was used to detect alterations across specific chromatin domains in the MeCP2-
deficient brain. Due to low recovery of neuronal nuclei via FACS (see section 3.5 for 
discussion), whole brain was used, although this probably leads to an under-estimate of 
changes in neuronal chromatin. Across the 39 kb Bdnf region, as expected H3Ac levels 
peaked over the active promoter CGI regions in both wildtype and null (Figure 5.2A), but 
were low in the flanking regions. Comparing wildtype and mutant brain, levels of anti-H3Ac 
immunoprecipitated DNA in the mutant were elevated by ~2-fold relative to input 









































the pattern of MeCP2 binding (Figure 5.2B), being lowest where MeCP2 binds least (the 
CGIs), but highest where MeCP2 is relatively concentrated in the bulk genome. This is 
consistent with a simple causal relationship between binding of MeCP2 and the recruitment 
of HDAC complexes, as suggested from earlier immunoprecipitation experiments (Nan et 
al., 1998). A 1.4-fold elevation in histone acetylation was also seen in regions of the male 
Xist locus flanking the CGI (Figure 5.2C; KS-test p=0.03). This difference was notably 
absent over the heavily methylated Xist CGI itself, implying that repression of histone 
acetylation at this DNA promoter sequence is not solely dependent on MeCP2. Altogether 
100 loci were examined covering 90 kb of genomic DNA by quantitative PCR and with an 
average of 1.4-fold elevation in H3Ac (Figure 5.2D; KS-test: p<0.002), comparable to the 
1.5-fold increase observed by western blotting for unsorted brain nuclei (Figure 5.1).  
 
These data indicate that the global chromosomal association of MeCP2 imposes a reduction 
in histone acetylation levels across the genome. This increase appears to be primarily in the 
bulk chromatin as opposed to CGIs, both nonmethylated CGIs, such as Bdnf, and methylated 
CGIs, such as Xist, which are likely to have redundant control mechanisms. However, H3Ac 
is predominantly associated with CGIs, as shown for the Bdnf locus and other regions (data 
not shown) and confirmed by western blotting analysis of CGI chromatin ((Thomson et al., 
2010); see Appendix B). Therefore, the relatively modest 2.6-fold difference in H3Ac levels 
between wildtype and null neurons (Figure 5.1) is likely to be diluted by this effect, as 
confirmed by the ChIP analysis (Figure 5.2B). This could be further verified by the use of 
methyl-sensitive restriction enzymes to selectively remove nonmethylated CGI chromatin 









































Figure 5.2 – MeCP2 deficiency results in elevated histone H3 acetylation primarily within the bulk 
genome. Mouse brains were dissected and ChIP performed using an antibody against H3Ac. 
Immunoprecipitated DNA was analysed by real time PCR using a panel of primers and ChIP signal 
plotted as % IP/Input. (A) H3Ac profile across 39 kb of the Bdnf locus in wildtype (blue line) and 
Mecp2-null (red line) brains. (B) The H3Ac fold difference (null divided by wildtype) across the Bdnf 
locus between wildtype and Mecp2-null brain (black line); the MeCP2 ChIP profile is also shown (grey 
line). (C) . H3Ac ChIP profile across the promoter region of Xist showing wildtype brain (blue) and 
Mecp2-null brain (red). The blue vertical lines below the graphs indicate CpG sites, with CGIs shaded 
in light grey. Gene structure of Bdnf is indicated with dark grey rectangles; transcription start site of Xist 
is indicated by an arrow. Error bars indicate mean +/- SEM and the KS test was used to determine 
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A preliminary analysis of the impact of MeCP2 on other histone modifications has also been 
performed. A previous study suggested that MeCP2 can also associate with a histone H3 
methyltransferase activity specific for lysine 9, with H3K9 methylation considered as a 
repressive mark (Fuks et al., 2003). Therefore, as when investigating the effect of loss of 
MeCP2 on H3Ac levels, H3K9me3 levels were determined in FACS-purified neuronal 
nuclei by western blotting (Figure 5.3). However, this analysis did not suggest a significant 
change. This may question the relevance of this interaction in the brain, or alternatively, the 
lack of a global effect may suggest that MeCP2 only recruits a H3K9-methyltransferase to 
specific targets and therefore global effects are not observed, in contrast to H3Ac where the 









Figure 5.3 – Preliminary analysis indicates no detectable change in the global levels of H3K9me3 in 
Mecp2-null brain. H3K9me3 levels were determined by western blotting of FACS-purified neuronal 
nuclei from both wildtype and Mecp2-null brain; histone H3 was used as a loading control. 
 
Additionally, changes in the level of histone H4 acetylation (H4Ac) have been investigated. 
Preliminary quantitative western blotting using unsorted nuclei suggested a modest 1.3-fold 
increase in the Mecp2-null brain (Figure 5.4A). However, preliminary ChIP analysis across 
the Bdnf locus failed to indentify any increase in H4Ac (Figure 5.4B). More work would be 



























Figure 5.4 – Preliminary analysis of H4Ac levels in wildtype and Mecp2-null brain. Mouse brains were 
dissected and homogenised. (A) Quantitative western blotting was used to determine the level of H4Ac 
in wildtype and Mecp2-null brain homogenate; NeuN was used as a loading control. The positions of 
molecular weight markers (kDa) are indicated. The graph to the right depicts densitometry analysis, 
normalised for NeuN loading, using Licor Odyssey imaging software. (B) The homogenate was 
crosslinked using formaldehyde and ChIP performed using an antibody against H4Ac. 
Immunoprecipitated DNA was analysed by real time PCR using a panel of primers across 39 kb of the 
Bdnf locus in wildtype (blue line) and Mecp2-null (red line) brains. 
 
5.2 Global changes in chromatin composition 
Histone H1 is present in most cell types at an approximate stoichiometry of one molecule per 
nucleosome (Woodcock et al., 2006), but uniquely in neurons this is reduced to one molecule 
every two nucleosomes, with no comparable reduction in glia (Allan et al., 1984; Pearson et 
al., 1984). Chromatin reconstitution experiments showed that MeCP2 can compete with 
histone H1 for binding to methylated chromatin and may function as a substitute linker 
histone (Nan et al., 1997). Subsequently, various reports have investigated the mode of 
MeCP2 binding to chromatin. Using the 5S rRNA nucleosomal positioning sequence, 
MeCP2 was shown to bind to meCpG groups exposed in the major groove on the surface of 
the nucleosome, as determined by DNase1 footprinting, therefore binding in a manner 
distinct from histone H1 (Chandler et al., 1999). A more recent study, again based on the 5S 
rRNA sequence, used positioned meCpG sites along the length of the exposed linker DNA 
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a manner more similar to histone H1 (Ishibashi et al., 2008). This study noted that the DNA 
at the entry and exit sites forms a structure similar to cruciform DNA, which MeCP2 has also 
been shown to bind (Galvao and Thomas, 2005). A study using the 601 nucleosomal 
positioning sequence suggested that MeCP2 bound to the nucleosome asymmetrically, 
specifically protecting only one side of the linker DNA, in contrast to the observed 
symmetrical binding of histone H1 (Nikitina et al., 2007). However, this study failed to 
consider that the distribution of meCpG sites within the linker DNA is highly asymmetrical 
and this therefore may have influenced the asymmetrical binding of MeCP2. Overall, these 
various in vitro studies may suggest that there are various modes of MeCP2 binding to 
nucleosomes and that this may depend upon the sequence context, as has also been observed 
for histone H1 (Travers, 1999). 
 
Given that MeCP2 can function as a putative linker histone and occurs at approximately one 
molecule per two nucleosomes in neurons, where earlier reports have shown histone H1 is 
specifically depleted (Allan et al., 1984; Pearson et al., 1984), this provides tantalising 
evidence for a functional relationship between these two proteins. Therefore, whether the 
abundance of histone H1 is affected by MeCP2 depletion was investigated. Using FACS 
purified neuronal nuclei, histone H1 was found to be elevated ~2-fold in the Mecp2-null 
compared to the wildtype (Figure 5.5A; KS-test p<0.05). No difference was seen in unsorted 
nuclei from wildtype and mutant whole brain, suggesting that this effect is specific to 
neurons where MeCP2 is highly abundant. The absence of an observed difference in the 
unsorted population is consistent with the studies reporting histone H1 is enriched in the glial 
nuclei (Allan et al., 1984; Pearson et al., 1984). As further confirmation for an increase in 
histone H1 in the Mecp2-null brain, the levels of histone H1 mRNA were investigated. There 
are currently six known somatic isoforms of histone H1. Isoforms H1.1 through H1.5 are 
highly homologous and expressed in a wide variety of tissues, whereas histone H1.0 shows 
greater sequence diversity and is predominantly expressed in terminally differentiated cells 
(Sancho et al., 2008). Expression analysis for H1.0 (Figure 5.5B) and H1.1-H1.5 (Figure 
5.5C; differences in the individual isoforms could not be easily determined due to the high 
degree of sequence identity) was consistent with an increase in the Mecp2-null brain. 
However, expression analysis indicated only a mild 1.2-fold upregulation. This may be the 
result of having to use whole brain for expression analysis due to the limitations of FACS 
sorting of isolated nuclei, or indeed implicates the role of post-transcriptional mechanisms in 
the control of histone H1 levels. Overall, the level of histone H1 present in MeCP2-deficient 




suggesting that the reduced level in neurons may reflect substitution of histone H1 by 
MeCP2. It should be noted that it is not clear which H1 isoforms this antibody recognises in 
western blot analysis (see Table 2.1); personal communication with Abcam suggests that all 
H1 isoforms should be recognised. It will be important, however, that future work addresses 



















Figure 5.5 – Histone H1 levels are doubled in Mecp2-null neurons compared to wildtype neurons.  
(A) Quantitative western blotting for histone H1 and NeuN (as a loading control) using FACS-purified 
neuronal nuclei from wildtype and Mecp2-null mice. The graph indicates densitometric analysis of  
H1 levels in the different nuclei populations. RNA was extracted from whole mouse brain and cDNA 
prepared, with and without reverse transcriptase. Quantitative PCR was used to determine levels of 
expression of (B) Histone H1.0 and (C) variants Histone H1.1 through H1.5. The data was normalised 
and shown as % relative to GAPDH. Error bars indicate mean +/- SEM. 
 
Eukaryotes exhibit a wide range of nucleosomal repeat lengths, with a robust positive 
correlation between histone H1 content and repeat length being observed (for review see 
(Woodcock et al., 2006)). Interestingly, glia cells display a nucleosomal repeat length of 200 
bp in line with their H1 content, whilst neurons have been shown to exhibit a shorter 
nucleosomal repeat length of ~165-168 bp which is shorter than predicted by their H1 


























































































structure typical of H1-containing chromatin (Allan et al., 1984; Pearson et al., 1984). 
Limited MNase digestion was used to compare the nucleosomal laddering pattern from 
wildtype and Mecp2-null brains. Initially, FACS-purified neuronal nuclei were used to avoid 
any diluting effects of the glial nuclei. However, preliminary analysis indicated that the 
laddering pattern observed was too diffuse to allow accurate comparison between the 
samples (data not shown). Therefore, in order to isolate a pure population of neurons from an 
intact brain, the striatum granulosum of the dentate gyrus was dissected from both wildtype 
and Mecp2-null mice (assistance in the dissection was gratefully received from Dr S. Cobb). 
Limited MNase digestion did not indicate any clear difference in the laddering pattern 
obtained (Figure 5.6). However, as the bands are not particularly sharp it is possible that this 
reflects heterogeneity within the repeat length. This may be overcome by future work 
looking at discrete loci by southern blot. For example, the tandemly arrayed major satellite 
repeat may be more likely to have phased nucleosomes that would produce sharper bands 
and therefore allow a more precise comparison between wildtype and Mecp2-null neurons. 
Currently, however, the in vivo role of MeCP2 functioning as a linker histone remains 
enigmatic. More precise measurements of nucleosomal repeat length would be required to 














Figure 5.6 – There is no difference in the nucleosomal laddering pattern observed between the striatum 
granulosum of the dentate gyrus between wildtype and Mecp2-null mice. Nuclei from the striatum 
granulosum were prepared using a hypotonic buffer and then subjected to limited MNase digestion. 
Subsequently, the DNA was extracted and end labelled with γ 
32
P-ATP and resolved by agarose gel 



















5.3 Transcriptional noise 
Previous gene expression studies using microarrays have failed to identify clear MeCP2-
gene targets. However, this study indicates that MeCP2 functions as a global regulator of 
chromatin structure, thereby questioning the concept of MeCP2 gene targets. Histone 
deacetylation is thought to aid the formation of repressive chromatin, in part through the 
formation of higher order structures (Shogren-Knaak et al., 2006). Linker histones have been 
shown to specifically repress non-promoter driven transcription, with limited impact in 
authentic promoter-driven transcription (Laybourn and Kadonaga, 1991). Therefore, through 
the methyl-dependent binding of MeCP2 throughout the genome and the recruitment of 
HDAC complexes coupled with the putative role as a linker histone, MeCP2 may act to 
create a transcriptionally inert environment primarily within the bulk neuronal genome. This 
is consistent with previous models suggesting a role of low density DNA methylation as a 
mechanism for suppression of spurious transcription ((Bird and Tweedie, 1995; Boyes and 
Bird, 1992); see section 1.4.3 for discussion). To test this possibility, the expression of L1 
retrotransposons, intracisternal A particles (IAP) and the tandem repetitive units of the 





































Figure 5.7 – Repetitive elements are distributed throughout the genome and are largely methylated and 
bound by MeCP2. MeCP2 ChIP followed by quantitative PCR using wildtype mouse brain shows 
significant binding to 3 classes of repeats as indicated. MeCP2-null brain was used as a negative 
control. Bisulphite sequencing of mouse genomic DNA indicates that these repeats are largely 
methylated. Each line represents a single clone. Open and filled circles indicate nonmethylated and 
methylated CpG sites, respectively. Crosses indicate uncharacterised CpG sites. A schematic of the 
region is indicated: the blue vertical lines mark the position of CpG sites; black arrows mark the 
position of the primers used for real-time PCR analysis; the red bar indicates the bisulphite PCR 
amplicon; a scale bar is indicated. It should be noted that these repetitive elements are distributed 
throughout the genome and it is possible that there is some variation in the level of methylation that is 
not fully represented by this limited number of clones. 
 
RNA was extracted from whole brain and used to measure the expression levels of these 
repeats. No significant difference was observed, however, between wildtype and Mecp2-null 

























































































Figure 5.8 – Using RNA extracted from a whole brain there is no difference in the expression of 
repetitive elements between wildtype and Mecp2-null mice. RNA was extracted from whole mouse 
brain and cDNA prepared, with and without reverse transcriptase. Quantitative PCR was used to 
determine levels of expression of repetitive regions and gene regions. The data was normalised to 
Gapdh and shown as a ratio between Mecp2-null and wildtype mice. The horizontal line marks no 
change between wildtype and Mecp2-null mice. Error bars indicate SEM +/- mean. 
 
It is possible that spurious transcripts might be degraded by the exosome and therefore not 
survive as stable components of cytoplasmic RNA. To reduce the opportunities for transcript 
degradation, RNA was extracted directly from isolated nuclei and analysed by RT-PCR. The 
same repetitive regions now showed significantly increased levels of expression in the 
Mecp2-null brain compared to the wildtype. In contrast, no differences in the expression 
levels of Actb, c-Myc or tyrosine hydroxylase mRNAs were observed (Figure 5.9A). On 
average, repetitive regions showed 1.6-fold overexpression in the MeCP2-null brain (4 
biological replicates; KS-test p<0.0002), whereas the expression of these bona fide genes 
was unaffected (Figure 5.9B). This effect was not seen in embryonic brains from E18.5 mice 
(Figure 5.9C), suggesting that increased transcriptional noise is confined to the mature brain 



























































Figure 5.9 – MeCP2 suppresses transcription from repetitive elements distributed throughout the 
genome. Nuclei were isolated from wildtype and Mecp2-null brains. RNA was extracted and cDNA was 
prepared, with and without reverse transcriptase. (A) Quantitative PCR was used to determine the 
expression levels of repetitive regions and genic regions in the brains of mature mice. The data was 
normalised to Gapdh and shown as a ratio between Mecp2-null and wildtype nuclei. The horizontal line 
represents no change between wildtype and Mecp2-null mice. (B) Shows the pooled data from (A), 
grouping repetitive regions and genic regions. (C) Elevated expression of repetitive elements is only 
apparent in mature mice, where MeCP2 is highly abundant. Nuclei were prepared from wildtype and 
Mecp2-null E18.5 embryonic brains. Data presented as for (B). Error bars indicate SEM +/- mean. The 
KS test was used to determine statistical significance. 
 
5.4 Discussion 
In line with the global distribution of MeCP2 within mature neurons, there are global 
changes in histone modifications and chromatin composition. Elevated histone acetylation in 
MeCP2-deficient whole brain samples has been reported previously (Shahbazian et al., 
2002a). By sorting neuronal from glial nuclei, this difference is shown to be entirely due to a 
large change in neurons, consistent with the fact that 89% of MeCP2 is expressed within 






















































































than at distinct sites. Early evidence suggested that MeCP2 can recruit the HDAC-containing 
complexes (Nan et al., 1998). A plausible hypothesis is therefore that MeCP2 attracts co-
repressors throughout the neuronal genome, which depress histone acetylation according to 
the local density of meCpG sites. The finding that the ratio of mutant to wildtype H3 
acetylation matches the density profile of MeCP2 provides support for this model (Figure 
5.2B). Previous findings have indicated that histone H1 is surprisingly depleted within 
neuronal nuclei (Allan et al., 1984; Pearson et al., 1984). The data presented here shows that 
in the absence of MeCP2, neuronal histone H1 approximately doubles, with no comparable 
effect in whole brain and therefore presumably the glia level of H1. Previous studies have 
suggested a putative linker histone function for MeCP2, by virtue of its ability to compete 
with histone H1 binding to chromatin (Nan et al., 1997) and in its mode of binding to 
nucleosomes (Chandler et al., 1999; Ishibashi et al., 2008; Nikitina et al., 2007). It is 
tempting to propose that competition for chromatin binding sites between neuronal MeCP2 
and H1 displaces the linker histone from half of its potential sites, leading to a reduction in 
the requirement for H1. In the Mecp2-null brain, where this competition does not occur, H1 
is apparently restored to its conventional nucleosomal stoichiometry of 1:1 and may 
functionally compensate in part for MeCP2-deficiency. Further work is needed to clarify the 
role of MeCP2 as a putative alternative linker histone. However, it is possible that the TSA-
independent transcriptional repression imposed by MeCP2 in targeted transfection studies 
could be due to its action as a linker histone (Nan et al., 1998). 
 
Through the use of FACS purified nuclei, it has been possible to propose that global effects 
of MeCP2-deficiency on both H1 abundance and histone acetylation are seen exclusively in 
neurons because only in these cells is MeCP2 sufficiently abundant to coat the genome. In 
other cell types, the low density of MeCP2 occupancy is insufficient to impact bulk 
chromatin. However, given the duration of the FACS protocol and inherent RNA instability, 
it is not possible to determine if the observed increase in transcriptional noise is only within 
neurons. The observation that nuclei from embryonic brains do not show this effect, coupled 
with the developmental increase in MeCP2 expression, suggests that this increased 
transcriptional noise will also be specific to neurons. Currently, the analysis on the effect of 
transcriptional noise has been limited to repetitive regions. Despite this limited analysis, it 
seems feasible that as MeCP2 is bound globally, repetitive regions are no more silenced by 
MeCP2 than other methylated unique sites throughout the bulk genome. However, there is 
currently no evidence for increased transcriptional noise from single copy sites. As the effect 




removing the cytoplasmic component of the exosome, it is possible that the nuclear exosome 
is still suppressing the scale of this effect. Therefore by visualising nascent RNA directly 
through transcription run-on assays it may be possible to increase the sensitivity of this assay 




Chapter 6 Conclusions 
6.1 Global roles of MeCP2 
The identification of MeCP2 as a transcriptional repressor led to the prevailing hypothesis 
that Rett syndrome was the result of failure to regulate specific gene targets. However, both 
mouse models and human diseases indicate that the precise abundance of MeCP2 is 
imperative to its correct function, as both deficiency and mild two-fold overexpression result 
in a neurological phenotype (Amir et al., 1999; Chen et al., 2001; Collins et al., 2004; Guy et 
al., 2001; Lubs et al., 1999; Luikenhuis et al., 2004). It is unlikely that such moderate 
overexpression of a canonical transcription factor, which binds to discrete targets, would 
lead to a phenotype similar to the loss of the factor. The observation that MeCP2 is almost as 
abundant as the histone octamer and through genome-wide methylation dependent binding it 
globally effects chromatin modifications and composition may explain why the abundance of 
MeCP2 is crucial. It is conceivable that even two-fold overexpression of global regulator, 
such as MeCP2, could have severe consequences, as implicated by the precise regulation of 
histone H1 stoichiometry (Woodcock et al., 2006). 
 
The requirement for DNA methylation in the binding of MeCP2 has been of somewhat 
contentious over recent years. Various studies have observed methyl-specific binding of 
MeCP2 (El-Osta et al., 2002; Lorincz et al., 2001; Nan et al., 1996; Nguyen et al., 2001), 
whereas other publications reported binding to nonmethylated DNA (Chahrour et al., 2008; 
Georgel et al., 2003; Harikrishnan et al., 2010; Kernohan et al., 2010; Nikitina et al., 2006; 
Yasui et al., 2007). Using ChIP-seq with a highly specific antibody in a biologically relevant 
model system, we have shown that the global binding pattern of MeCP2 is determined by the 
meCpG density of the underlying DNA. This methylation-dependent binding may account 
for the remarkable reversibility of severe neurological symptoms in mice when MeCP2 is 
restored following development under MeCP2-deficient conditions (Guy et al., 2007). If, as 
seems likely, DNA methylation patterns are laid down normally in the absence of MeCP2, 
then the restored protein is expected to distribute correctly according to these genomic marks 
and take up its usual function. 
 
The global distribution of MeCP2 casts new light on gene expression studies which have 
been performed in order to identify gene targets. These studies initially detected few 




Nuber et al., 2005; Tudor et al., 2002). But with the development of more sensitive 
microarray-based technologies, large numbers of subtle alterations have been observed upon 
the loss of MeCP2, comprising both of increases and decreases in gene expression (Ben-
Shachar et al., 2009; Chahrour et al., 2008). These studies have suggested the surprising 
conclusion that MeCP2 is primarily a transcriptional activator, in part through interaction 
with CREB. These studies however focused on the idea that MeCP2 binds to discrete sites, 
with the view that when a transcriptional regulator affects a restricted number of genes, 
coherent expression changes at those genes are expected when the protein is deficient. If, 
however, a large proportion of all genes are affected due to the loss of a genome-wide factor, 
it is more difficult to predict how deficiency will impact expression. The histone deacetylase 
inhibitor trichostatin A, for example, causes dramatic hyperacetylation of histones, but, 
despite the clear association between histone hyperacetylation and transcriptional activity, 
the drug usually causes equal numbers of genes to be up- and down-regulated (Peart et al., 
2005). A potential explanation is that the nucleus contains limiting supplies of transcriptional 
machinery, so that increased expression at some loci must be matched by decreases at others, 
even if all genes are potentially activated by hyper-acetylation. By analogy, the high 
abundance of MeCP2 may mean that many genes are potentially affected, but analysis of 
stable gene expression patterns following long term absence of MeCP2 may not accurately 
reflect these effects. 
 
These findings question the concept of a MeCP2-target gene. The global distribution and 
effects of MeCP2 do not preclude the possibility that some genes are specifically regulated 
by MeCP2. However, the failure to identify a consistent list of genes showing altered 
expression in the Mecp2-null brain (Chahrour et al., 2008; Jordan et al., 2007; Nuber et al., 
2005; Tudor et al., 2002), coupled with the observation that histone acetylation is primarily 
elevated outside of the CGIs, suggests that aetiology of Rett syndrome is not the result of 
misregulation of a limited number of genes. In line with a global role of MeCP2, this work 
has shown elevated transcriptional noise from repetitive elements distributed throughout the 
genome. This role of genome wide suppression of transcription is consistent with the earlier 
in vitro characterisation of MeCP2, where the repressive activity of MeCP2 was shown to be 
tailored to the density of the bulk genome (Nan et al., 1997). Furthermore, MeCP2 was 
shown to be able to repress transcription from distance of a least 2 kb (Nan et al., 1997), 
suggesting that MeCP2 has evolved to repress domains rather than discrete sites. This 
property would be consistent with the heterogeneous nature of the maintenance of domains 




(Bird, 2002)). Additionally, this work has provided preliminary suggestions that MeCP2 may 
act as a linker histone, as suggested from previous in vitro studies (see section 5.2 for 
discussion). It is premature to suggest that MeCP2 may function in a manner analogous to 
histone H1, but it is interesting that histone H1 is not primarily involved in the repression of 
promoter-driven transcription, but in the suppression spurious transcriptional initiation 
(Laybourn and Kadonaga, 1991). Further work will be required to fully evaluate the extent 
of genome-wide transcriptional noise in the absence of MeCP2, as indicated from this 
limited analysis of repetitive sequences. This does not preclude the possibility that MeCP2 is 
also involved in the regulation of specific genes, in line with the concept of ‘MeCP2 target 
genes.’ Given the importance of the precise high level of MeCP2 expression, however, it is 
likely that the genome-wide binding is most relevant to the aetiology. For example, this 
analysis has shown that MeCP2 is enriched at methylated CGIs, however, it is likely that 
there are redundant levels of control at these highly regulated genes. Indeed, MeCP2 has 
been shown to not be required for the silencing of Xist, at least in mouse tail fibroblasts (Barr 
et al., 2007). 
 
6.2 Rett syndrome: failure of the quiescent or active state? 
The near-nucleosomal abundance of MeCP2 in neurons raises questions as to why these cells 
have evolved a requirement for a genome-wide methyl-dependent transcriptional repressor, 
whereas other somatic cell types have not. One possibility is that the neurons are particularly 
sensitive to the levels of transcriptional noise from the bulk genome and therefore have a 
special need for MeCP2 to quench this. To my mind, a more likely explanation is that 
neuronal plasticity and homeostasis may depend upon the specific ability of the neuronal 
nucleus to allow gross changes in its genome metabolism in response to activity. Neuronal 
firing leads to a burst of synaptic protein synthesis, nuclear transcription and chromatin 
modification, which is required for development of synaptic systems (Bading, 2000; Gupta 
et al., 2010). MeCP2 undergoes site-specific phosphorylation at serine 421 following 
synaptic firing, which is reported to alter its affinity for DNA and its nuclear distribution 
(Chen et al., 2003b; Zhou et al., 2006). A further report indicates that post-translational 
modification of MeCP2 also occurs in the quiescent state, including phosphorylation of 
serine 80 (Tao et al., 2009), raising the possibility that MeCP2 is a signalling hub within 
neurons and as such may play a crucial role in neuronal maintenance. The functional role of 
these modifications is yet to be fully elucidated. It should however be noted that a knock-in 




phenotype than the null mouse, suggesting that other factors must contribute to the Rett 
phenotype (Tao et al., 2009). These neuronal specific effects on chromatin structure indicate 
that it is imperative that MeCP2 is investigated within this context, as opposed to a large 
number studies which have used cell lines. Additionally, the effect of neuronal stimulation 
needs to be considered, with an analysis of changes in MeCP2 distribution/modification, 
transcriptional activity and chromatin modification. Given the genome-wide distribution of 
MeCP2, it is likely that these analysis need to be performed on a global scale, rather than 
focusing on gene loci. These analyses will provide evidence as the role of MeCP2 in both the 
active and quiescent states of the brain. 
 
6.3 The CpG dinucleotide as a signalling module 
The mammalian genome exhibits a dimorphic distribution of CpG and meCpG 
dinucleotides, with CpG islands being conspicuous by their high density of CpG sites and 
being primarily nonmethylated, whilst the bulk genome shows CpG suppression and is 
largely methylated. It is clear that both genomic compartments have specific roles to play, as 
indicated by existence of proteins that can interpret these signals in vivo: MBD proteins 
binding to meCpG sites and CXXC proteins binding to nonmethylated CpG sites. This study 
has provided evidence that, specifically in neurons, MeCP2 is sufficiently abundant to bind 
almost every meCpG dinucleotide within the genome and in turn regulates the chromatin 
state. How meCpG sites are interpreted within other tissues and whether a transient sub-
stoichiometric interaction with MeCP2 or the other MBD proteins is sufficient is currently 
unknown. Nonmethylated CGIs, of which 80% are potentially associated with a promoter (R. 
Illingworth; manuscript in preparation), are specifically bound by Cfp1 by virtue of the 
underlying DNA sequence, through which histone H3K4 becomes trimethylated ((Thomson 
et al., 2010); Appendix B). Overall, both meCpG and nonmethylated CpG sites recruit 
factors which specifically modify the chromatin state to create a transcriptionally inert or 
permissive state respectively. In this way, the global distribution of these marks may be 
crucial in determining the transcriptional capacity of the genome. DNA methylation has 
historically been considered as an additional level of silencing with a rather static role, rather 
than being strategic in the initiation of silencing, in part through the assignment of 
maintenance methylation to DNMT1 (see sections 1.3 and 1.4). It is however now clear that 
DNA methylation perhaps is more dynamic than initially thought, with the observation that 
in transformed cells, multiple signalling and transcriptional factors are required for the 




dinucleotide as a signalling module and how it impacts the transcriptional landscape is likely 




Appendix A: List of Primers 
 
Primers were resuspended in water at a concentration of 100 µM and stored at -20 °C. 
 
Primers for real time PCR analysis   
    
Locus Amplicon name Forward Primer Reverse Primer 
Major 
satellite 
Maj Sat GGCGAGAAAACTGAAAATCACG AGGTCCTTCAGTGTGCATTTC 
    
Bdnf -3 GGAACATCTCCACAGTAATTTGC CCTAGAGGTTAAACAACTTCAGC 
 -1 GGAGTCAGCCAGAGTTACCC CACCACTTTTCTGCCTCATCCA 
 0 GCAGCTGTGAAATCTTCCCTC CCATGGAGTATGGAACTAGAGC 
 1 GCTGACTAGAGTTGTGTGAGG CCTGGTTCATTATCAGCTTTCC 
 1.2 CGCAACACTGGATTTACTGCT GCTGTGTTTGAAGGGAATTCG 
 3 CGTTGAGAAAGCTGCTTCAGG CCTTCGCAATATCCGCAAAGC 
 4.2 CCTTTCTATCATCCCTCCCCG GGCTCTTCGATCTAGAAAGGAC 
 5 CGTCATCCTCTTACACCCAAG GGTTAAATGTCTCTCTCTCTCC 
 6 CCAACACTGTAAAAAGAATCCTG CAGACCGTCCACTGTGGTATG 
 7 GTGTCTTGTTCTTATAAATAATGC GCAGGGAATGGCTTGCAGTC 
 8 GCAAATACTACTGGGTAAGATCC GCCTTTTACACACTGTGTAGCT 
 9 CCAGAAATAAATATCTAACCCCAC GGAAAGGCAAACTTATGAAATGG 
 10 CACATGTTGAGTGTAGGACTTC CCAGCCTTACTGAAGATGAAGG 
 11 GCCTAGGCAGGACCAGGTC CCATGTTTTAATGTGTGATAGTCG 
 12 GTGGTAGAGAAAACATTGGCATC GTGTCACTATTTAGCTCAAACTC 
 13 CCACTCTGGTGACAACAGACA GGCATATGTGACTCAGAAAGG 
 14 CCACAGAACTTGGGTGCTGG GCTGCTTAAACCCAAAGCTCTG 
 15 GGTCCAAGGTCAACGTTTAAC CATCCCTGGAAATCAAAACTAGC 
 16 CCATTATTGGAATTCCAGAATCAT GCACAACAGTCTTGTTTATCTGG 
 17 GGAATCAGAAGAGAGTTTTGCAG GCATTACTCCATACTAGACAGAA 
 19 CCTAGACCAAAGGCTCCAAGG CCACACACAGAAGTTAATTACAC 
 20 CCTTAAACTAGAAGCCATGTAAG CAGGAATATAGGCTTTGATCTTTG 
    
c-Myc 1 CCAGAAGCTTTCCCAGCAAGC CAGCTCAGCCTTGCTTGCTC 
 2 GCATGCCATGGCTAGCTTGG GAGAAGCAGGAGACCCTAAGG 
 3 AGTGACTGAATGAATGCTGACC TCTCATACTAACAGTCATGATGC 
 4 GTGATGTCATCAGGCTGGGG CACCAACAGATATGACAGTGGG 
 5 AGGCAATAATAAGCTAATGCTCC GTGAAGGAGATCTAACAGAAACG 
 6 TGGTTAATAAGCTAGATTATCGTG CCTTCGTATGTGTGTGTTAAGC 
 7 CCTAGATAACTCATTCGTTCGTC CCCTGCGTATATCAGTCACCG 
 7.1 GACTCGCTGTAGTAATTCCAGC GCAAAGCCCCTCTCACTCCA 
 8 GCTGTTTGAAGGCTGGATTTCC CAACTACTCTTGAGAAAAGTGTC 
 9 CAGTGCTGAATCGCTGCAGG CCGATTGCTGACTTGGAGGAG 
 9.1 GCTCTTAGCAGACTGTATTCCC GTCGGACTAGCAGCTGCTCC 




 10.1 CCAGAGCTTCATCTGCGATCC TCAGGCTGGTGCTGTCTTTGC 
 11 GGCTTATCTTTCAGCTCCATCC TGGGTCTTAGACAAACGTATCC 
 12 GACACACAACGTCTTGGAACG GTGAGCTTGTGCTCGTCTGC 
 13 CTCAACCCAAGGACTCTGCC CCAGGATCAACTTAGCAGTGG 
 14 GCCTCTGAAAAGCCACAATCC GAATGATGGTGAATTAAAGTCCC 
 15 CTGGGATGGTGCTCTTCAGG CTACATACGTGTTCAAGCTTTGG 
 16 GGTCTATATGGCTAGGAAAGAG GCTTATGTGACTTCAGGCCAG 
 17 GGTTTCTCTGTGTCTGAGAACC GTGGTAGGTAGTAAGTGTATCG 
    
Actb -1 CCATTTGACCTTCTTGTGTTGC CCAGATCTTCCTTCATGGAACC 
 -1.1 GATCCAGTGACCTGAAAAGACC CCACTCTTGATTCTTTGCTTTCC 
 0 CCAGTTTGCCTGCTGGACCC CCATTTGAGAAATGGACACACC 
 1 CCAAGCTAACCTCAGCCTTGC CCAGTATCACTGTACATTGAGCA 
 1.1 CCAGTTATGCAGATGGAGGC CCTTGCTGATGGTATCTAGTGG 
 1.2 CAGTACATAATTTACACAGAAGC CCAAGTATCCATGAAATAAGTGG 
 1.3 AAGCCATGCCAATGTTGTCTC AGCAGATGTGGATCAGCAAGC 
 2.1 TGAAGCTGTAGCCACGCTCG CTGTCCCTGTATGCCTCTGG 
 3 GCAGAAACTGCAAAGATCCAAG CCACACCTTCTACAATGAGCTG 
 3.1 CCAAAGTAACAGGTCACTTACC GTGTCTTGATAGTTCGCCATGG 
 4 CCTAATACGGCTTTTAACACCC CCTGAGGATCACTCAGAACGG 
 4.2 CGAGCACTTAAGTGGATGAGG GCTTTCCGGCTATTGCTAGC 
 5 CCTTGTCTGGAAGAGGTGACC CTGAGCAACTGAGAAATACAAGG 
 6 CCTAAGCTGCACATTTTCAAGTG GCATTATGGCTGGATCTTAAAGC 
    
Xist -3 GACAGCCTTATCCAGTGTCC GAACAGCGTAAAACTGTAATGG 
 -2 GTGGTCTCATTGGTTGGCAC GGAACATTTTATGTGGATAATCC 
 1.21 GTCTTGAGGAGAATCTAGATGC TTCTATACCAGTTCAGGCTTTGC 
 2 GAATTCAACAAGTAAGCAAATCG GCCAGAGTCATAGTGGATCAC 
 2.1 GCACTGTAAGAGACTATGAACG CGCATGCTTGCAATTCTAACAC 
 3 CCTGTACGACCTAAATGTCC GTATTAGTGTGCGGTGTTGC 
 3.1 CTCAGTTTAAGAGCAAAGTCGT GCTTGGTGGATGGAAATATGG 
 4 CAAAAAGTATGGAGGACATGTC CGTGCAACGGCTTGCTCCAG 
 4.1 AGGTCACACACCTGTCTATGC CCAAGGAGCCATTTTGTGAGG 
 5 GTCTCGTTGATTCACGCTGAC GTTTATTCAGTCTGTGTGCATC 
 7 GCTACTGCTCATAGGTAGGC CATGATCTTTGGTAGATTGATTTC 
    
Snrpn -3 TCAGTCTAGGCTAAATGAATCC GTTTTGTGGAGCAGGTTCTCTC 
 -2 CATGTTAGGAACTGCAGAAACC CAACTGTTAACTGGTCAGGTGC 
 -1 AGGAGAAAGCCTCATCAAAGAG CACACTGCAATTGCCAGACTTC 
 1 CAGTCTTAAATCATGTACAATCG CAGGACCTATTATTGGTGATGG 
 3 GGACACACAATCACTTCTCTG CTCTGTTGCTGCTTCATGTGG 
 4 CACAGTAACAGTTACAAAATCCC TGGAAGTCAGAGCTGTGTTGC 
 5 CCTCAGAACCAAGCGTCTGG TGCATTGCGGCAAAAATGTGC 
 6 TCCTGATTCCTAATTCTACATTC CCCTGTCTCTAAAACCAACAAC 









Dlx 5/6 -2 TCCATGATCTCCTAGGTATTCC TGAAAGCTATTCAAATGAATGTGC 
 -1 GCACAAGGCAGCTGGTGAGC GGCTCACGTGAATACTCTTGC 
 0 TAGGTTCTGTCTGCAACCACC TAGGATGGTAGACTGCTTGTCC 
 1 CCTACCATGAAATTTACTTCCAC AGGGTGCCAAGGTTCACTGG 
 2 CGCTAACACCTATTTCACAACC CCCTCTCCTTGAAAATCTTCCA 
 3 CAAAGATGACACAGTCAAATGC CTCACTCCTTTCCACCTCTGG 
 4 CAGGTACCTATTCTTGGAAACC CTCTAGCAATAAAACTGCAAAGC 
 6 GGTTCTACCACCTGGATGTGC CTCTAATTATACACCAGTGTCGC 
 7 GAGCTAAGGTGGCTGCAAAGG GGATTTGGACGAGTCCTGGC 
 8 CTTACAGCGCCACGGACTTC GCTATACCACTGTGGGCACG 
 9 GTAATGCTACATTGTAGGTTTCC CTACCTCCTATGTTGCTTAAGC 
 11 CGATCAGTCTTGTCATTTTCTAGC CCCAATGTCTGCTTCAAATTGG 
 12 GAGACTACAGCTCTATGCAAGG GCAGTCAGCTATGGGGATGG 
 13 GCTCTACTGCGTCCTAGAGG CGAATTGTGACATAGAAGCAACC 
 14 GGTCAAAAATGTGCAAGGTCTG CTCCACTCTCAAGCACCTTCC 
 16 GCATAGGCTAGATATCTACATGC CTCTTTCAGGATCTCCTGTGC 
 18 CCATCCTCAGATCATACATGGA GAAACACACAAGGTGAATACAGG 
 19 GTGCTGTCCTGTTTGCAGTCC CCCCTACCACCAGTACGGC 
 21 CCTGAAGTGCTGAAAGACTGG ACTCGAGGCTGTCTATAGTGG 
 22 GGTCATGCGTTCTGTGAAGGC CCATAGAACTGCAGTCACATGG 





   
Primers for bisulphite sequencing   
































 BDNF Bis H GGTTGGAATAGATTTTTGGTAAGT
TT 
CAAAAAAATTAAACTTCCTCCACC 

















    








 Act Bis F4R4 TGTTGGAGTTTGGTTTTGAATAGT TAACAAAAACCCAAATAACACAAA
C 
















 Act Bis F9R9 TTAGTAATGTTTGGGTATATGGTG
GTAT 
CATCCTCTTCCTCCCTAAAAAAA 























































 Act Bis F23R23 TTTTAGTTTTGGGATTGGTTAAGG AAAAACCACTATTTCAAACAAAAA
AAC 
 Act Bis F24R24 TGTTTTTTTTGTTTTAGTTTTTTGT
GT 
AACCAACTTCACTTCCTCTACCTT 




































































    
Xist Xist BS 5/6 TGTAARTTTTGTGGTTATTTTTTTT ATATTCCCCCAAAACTCCTTAAAT
A 
    






   











 Dlx Bis 3F3R TTTTAGGGGTGGAAAAATATTTTA
A 
CCCAAACTTTAATTTAACTAACC 





































   
Primers for expression analysis   
Histone H1 H1.0 ATGACCGAGAACTCCACCTC CGATCATGTCTGAATACTTG 
 H1.2-H1.5 CGGTGTCCGAGCTCATCACC GCTGTTGTTCTTCTCCACATCG 
    
L1 retro-
transposons 
L1R1 CAATCGCGTGGAACTTGAGAC GACTCAGCTGGCAAGGTAGC 
Major 
satellite 
Maj Sat GGCGAGAAAACTGAAAATCACG AGGTCCTTCAGTGTGCATTTC 
Intracisternal 
A particles 
IAP 1 GCTTTCGTTTTTGGGGCTTGG CTTACTCCGCGTTCTCACGAC 
    
Tyrosine 
hydroxylase 
Tyrhy Ex2 GCAGAGTCTCATCGAGGATG CTCAAACACTTTCAAAGCCC 
c-Myc c-Myc 10.1 CCAGAGCTTCATCTGCGATCC TCAGGCTGGTGCTGTCTTTGC 
Gapdh Gapdh P3P4 TACCCCCAATGTGTCCGTCG CCTGCTTCACCACCTTCTTG 
Actb Actb 2.1 TGAAGCTGTAGCCACGCTCG CTGTCCCTGTATGCCTCTGG 
 
 
   
Primers for 
colony PCR 
   





Appendix B: Publications 
 
1) CpG islands influence chromatin structure via the CpG-binding protein Cfp1 
 
2) Neuronal MeCP2 Is Expressed at Near Histone-Octamer Levels and  
Globally Alters the Chromatin State 
 
3) A Temporal Threshold for Formaldehyde Crosslinking and Fixation 
 
CpG islands influence chromatin structure via the CpG-





Neuronal MeCP2 is expressed at near histone-octamer levels 
and globally alters the chromatin state 
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